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ABSTRACT 
 
 Metabolic inflexibility is an emerging physiological marker indicative of metabolic dysfunction 
and associated with type 2 diabetes (T2D) and obesity.  Exercise is a potent stimulus to improve 
metabolic health, however, not much is known about the acute effects of exercise on metabolic flexibility 
(METFLEX).  The purpose of this dissertation was study the time-course of diet and exercise and its 
effects on METFLEX.  Three studies were conducted to investigate molecular and clinical aspects of diet 
and exercise and how these stimuli may alter the metabolic response to fuel.  
 The first study was conducted on obesity-prone, Osborne-Mendel (OM) and obesity-resistant 
S5B/Pl (S5B) rats. This experiment investigated inherent differences in EE, metabolic rate, METFLEX 
and skeletal muscle markers of metabolism, lipid storage and lipid oxidation between OM and S5B, as 
well as HFD-induced strain differences in these parameters.  The consumption of a HFD in S5B rats 
increased metabolic rate and EE and decreased metabolic rate and EE in OM rats. These strain differences 
were not due to the differences in activity or food intake.  These results suggest that HFD-induced 
differences in metabolic rate and EE may be mediated by HFD-induced differences in pAMPK and 
PPARγ expression and lipid accumulation in the gastrocnemius muscle of OM and S5B rats. 
 The second study was designed to investigate the effect of acute aerobic exercise at an intensity 
that maximizes the rate of fat oxidation (FATMAX) on glucose tolerance, insulin action, and METFLEX 
compared to acute aerobic exercise at lactate threshold (OBLA) resulting in greater carbohydrate (CHO) 
oxidation. OBLA exercise appears to have deleterious effects on oral glucose tolerance and metabolic 
flexibility acutely, however, FM exercise does not confer improved METFLEX. These results suggest 
that predominate substrate utilization does not promote improved glucose tolerance and metabolic 
flexibility in young overweight men. The third and final study of this dissertation was designed to 
	 vi	
investigate the immediate and extended of a single bout of high intensity interval exercise (HIIE) on 
METFLEX and mitochondrial function. Participants were recruited with a family history (FmHx) of T2D 
(n=8) and without a family history of T2D (n=8).  The extended effects (48 hours) work via the reduction 
fat oxidation by increasing resting fat oxidation rate and improving the suppression of fat oxidation in 
response to a mixed meal.   
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CHAPTER 1. INTRODUCTION 
 
 Metabolic flexibility (METFLEX) and metabolic inflexibility (MI) are biomarkers for metabolic 
health and dysfunction respectively.  Kelley and colleagues (1999) first noted a profound lack of plasticity 
in obese skeletal muscle to reduce fat oxidation and increase carbohydrate oxidation in the presence of 
insulin 1. In this seminal work, the authors define METFLEX as “a high capacity to modulate rates of 
energy production, blood flow, and substrate utilization”.  Since that time, METFLEX is more often 
described as the body’s ability to match fuel oxidation to fuel availability.  Interestingly, MI is not only a 
characteristic of T2D and obese patients, but also those with a family history (FmHx) of T2D and is 
linked to mitochondrial dysfunction 2-6.  
 Exercise interventions (6-12 weeks) have been shown to improve insulin sensitivity and 
metabolic flexibility in obese and type 2 diabetic patients, with greater improvements demonstrated with 
higher intensities 7,8. Recent research suggests that 2-6 weeks of high intensity interval training (HIIT) 
improves insulin sensitivity and skeletal muscle oxidative capacity 9,10. Interestingly, the time course of 
glucose tolerance and insulin action in response to a single bout of exercise reveals periods of increased 
insulin sensitivity (immediately post exercise to 3 days) and resistance (5 to 7 days’ post exercise) 11,12. 
Moreover, improvements found in insulin sensitivity due to exercise training often do not coincide with 
improvements in METFLEX, suggesting MI does not simply occur secondarily to insulin resistance or 
obesity 13,14.  
The purpose of this dissertation was study the time-course of diet and exercise and its effects on 
METFLEX. Three studies were conducted to investigate molecular and clinical aspects of diet and 
exercise and how these stimuli may alter the metabolic response to fuel. These include work using both 
animal models and human participants. The first study was conducted on obesity-prone, Osborne-Mendel 
(OM) and obesity-resistant S5B/Pl (S5B) rats. This experiment investigated inherent differences in energy 
expenditure (EE),   
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metabolic rate, METFLEX and skeletal muscle markers of metabolism, lipid storage and lipid oxidation 
between OM and S5B, as well as HFD-induced strain differences in these parameters.  The consumption 
of a HFD in S5B rats increased metabolic rate and EE and decreased metabolic rate and EE in OM rats. 
These strain differences were not due to the differences in activity or food intake.  These results suggest 
that HFD-induced differences in metabolic rate and EE may be mediated by HFD-induced differences in 
pAMPK and PPARγ expression and lipid accumulation in the gastrocnemius muscle of OM and S5B rats. 
 The second study was designed to investigate the effect of acute aerobic exercise at an intensity 
that maximizes the rate of fat oxidation (FM) on glucose tolerance, insulin action, and metabolic 
flexibility (METFLEX) compared to acute aerobic exercise at lactate threshold (OBLA) resulting in 
greater carbohydrate (CHO) oxidation. OBLA exercise appears to have deleterious effects on oral glucose 
tolerance and metabolic flexibility acutely, however, FM exercise does not confer improved METFLEX. 
These results suggest that predominate substrate utilization does not promote improved glucose tolerance 
and metabolic flexibility in young overweight men. 
 The third and final study of this dissertation was designed to investigate the immediate and 
extended of a single bout of high intensity interval exercise (HIIE) on METFLEX and mitochondrial 
function. In study 3, participants were recruited with a family history (FmHx) of T2D (n=8) and without a 
family history of T2D (n=8).  Participants completed baseline (no previous exercise) mixed tolerance tests 
(MMTT) to assess METFLEX. On a separate week participants completed a single bout of HIIE follow 
by an immediate (1 hour later) MMTT and follow-up MMTT (48 hours later) MMTT. The immediate 
effects (1 hour) of HIIE on METFLEX are primarily directed on the increase in carbohydrate oxidation 
and blood flow in response to a mixed meal.  The extended effects (48 hours) work via the reduction fat 
oxidation by increasing resting fat oxidation rate and improving the suppression of fat oxidation in 
response to a mixed meal.   
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CHAPTER 2. HIGH FAT DIET DIFFERENTIALLY REGULATES METABOLIC 
PARAMETERS IN OBESITY-RESISTANT S5B/Pl RATS AND OBESITY-PRONE 
OSBORNE-MENDEL RATS 
 
2.1 Introduction 
The current prevalence of obesity has been linked to a number of health consequences. 
1,2. Differences in the susceptibility to becoming obese exists and a subset of individuals gain 
weight and become obese on high-fat/energy dense diets, while others resist weight gain on the 
same diet 3-7. Studies indicate that the susceptibility to develop obesity is due to several central 
and peripheral factors. These factors may include an inability to adapt to the consumption of an 
energy dense diet by the obesity-prone individuals 8-10. Inherent differences in metabolic 
parameters and a differential response to the consumption of an energy dense diet on energy 
expenditure (EE) may influence the susceptibility to develop obesity.  
Energy expenditure and carbohydrate and fat metabolism is regulated by skeletal muscle 
and alterations in the regulation of EE, metabolic rate and skeletal markers of glucose and fatty 
acid metabolism may affect the susceptibility to developing obesity 11-18.  Studies have 
demonstrated that respiratory exchange ratios (RER) measured in isolated muscle tissue during 
fasting in obese people and those with type 2 diabetes are elevated and do not respond to insulin 
stimulation 19-21.  An increased susceptibility to obesity has been linked to metabolic inflexibility, 
which may be due to alterations in the transport and oxidation of fatty acids and glucose in 
skeletal muscle 18,20,22.  The fatty acid receptor, CD36, and the glucose transporter, GLUT4, are 
important regulators of fatty acid and glucose uptake in skeletal muscle and are regulated by the 
phosphorylated state of AMP-activated protein kinase (AMPK) 23.  Defects in peroxisome 
proliferator-activated receptor-gamma (PPARγ), a regulator of fatty acid storage and glucose 
metabolism, are also associated with increased susceptibility to developing obesity 24. Obesity-
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prone and obesity-resistant rodent models and obese and lean humans demonstrate differential 
expression of skeletal muscle proteins induced by a high fat diet (HFD) 14 suggesting that 
dysregulation of one or more of these skeletal muscle markers may affect the susceptibility to 
becoming obese. 
 Obesity-prone, Osborne-Mendel (OM) and obesity-resistant S5B/Pl (S5B) rats are 
animal models used to assess the mechanisms underlying HFD intake and obesity 3-5,8,25-31. OM 
rats are susceptible to diet-induced obesity and gain more weight and adiposity when eating a 
HFD, than S5B rats, which are resistant to obesity, when consuming the same diet. The current 
experiment tested the hypothesis that consumption of a HFD would differentially affect 
metabolic parameters and skeletal muscle markers of metabolism in obesity-prone, OM and 
obesity-resistant, S5B rats. This experiment investigated inherent differences in EE, metabolic 
rate and skeletal muscle markers of metabolism, lipid storage and lipid oxidation between OM 
and S5B, as well as HFD-induced strain differences in these parameters.  Assessment of 
metabolic rate, EE, glucose and carbohydrate metabolism, and lipid oxidation and storage in 
skeletal muscle will provide insight into mechanisms which alter the susceptibility to developing 
obesity.  
2.2 Methods 
2.2.1 Animals: 
 Male obesity-prone Osborne-Mendel (OM; n=8/diet) and obesity-resistant S5B/Pl (S5B; 
n=8/diet) rats (8-9 weeks old) used in these studies were bred in the Association for Assessment 
and Accreditation of Laboratory Animal Care (AAALAC)-approved Pennington Biomedical 
Research Center vivarium. Rats were individually housed on a 12/12 h light/dark cycle (lights on 
at 0700) with food and water available ad libitum. Animals were given access to a pelleted high 
fat diet (HFD, 60% kcal from fat, Research Diets, New Brunwick, NJ) or a pelleted  low fat diet 
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(LFD,  10% from fat, Research Diets).  All procedures were approved by the Pennington 
Biomedical Research Center Institutional Animal care and Use Committee.  
2.2.2 Fasting Glucose: 
Following 2 weeks access to HFD and LFD, OM and S5B rats underwent an overnight 
fast (16 hours) and glucose levels were measured. For the determination of circulating glucose 
level, blood was taken from the tail and glucose was measured using a glucometer (Contour 
blood glucose monitoring system, Bayer Health Care, Mishawaka, IN). 
2.2.3 Body Composition: 
OM and S5B rat were fed the HFD or the LFD for 2 weeks prior to assessment of 
metabolic parameters. Immediately prior to placement in the metabolic chambers, rats were 
weighed and body composition was determined using nuclear magnetic resonance imaging 
(NMR, MiniSpec Plus, Bruker Corp.).  Percent body fat was determined for each rat ((fat mass 
(g)/body weight (g))*100) and percent lean mass for each rat was calculated ((lean mass 
(LBM)(g)/body weight (g))*100).    
2.2.4 Effect of HFD consumption on metabolic parameters in OM and S5B: 
For metabolic testing, OM-LFD (n=6), OM-HFD (n=6), S5B-LFD (n=6) and S5B-HFD 
(n=6) rats were individually housed in metabolic chambers (PhenoMaster System,TSE Lab 
Master System, Homburg, Germany),  which performed continuous metabolic measurements for 
5 days (1 day of habituation and 4 days of data collection). The PhenoMaster System at PBRC 
contains 24 metabolic cages. All rats were placed in the metabolic chambers at the same time 
and measurements for all rats were collected concurrently. Rats were weighed immediately prior 
to being placed in the metabolic chambers.  Throughout metabolic assessment, rats continued to  
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receive ad libitum access to HFD or LFD. Data from the metabolic chambers were 
assessed, calculated and analyzed using the TSE Systems LabMaster software (v.1.5).  
Respiratory exchange ratio (RER), EE (kcal/h/LBM), metabolic rate (VO2/kg LBM), food intake 
(g), and activity (beam breaks) were assessed every 40 min throughout the experiment by the 
TSE system.  EE and VO2 were calculated based on lean body mass (kg) as determined by 
NMR. Food intake was converted to kilocalories. For each day, the data point for an individual 
rat was averaged across the light and the dark cycle. Total daily food intake and activity values 
were obtained by combining the average data from the light cycle and the dark cycle for each rat. 
The values for each day were combined and used to provide an average value for the light cycle, 
the dark cycle, and the total daily value. To determine the shift in substrate utilization (RER) 
between the light and dark phase, the RER value during the light phase was subtracted from the 
RER value from the dark phase. 
2.2.5 Protein Expression in Skeletal Muscle: 
OM and S5B rats fed HFD or LFD diet (n=6/strain/diet) were used to assess protein 
expression of skeletal muscle markers of glucose and lipid metabolism. At the time of sacrifice 
(0900-1100), the gastrocnemius muscle was dissected and a 100mg sample was collected, frozen 
in liquid nitrogen and stored at -80°C until further processing. Rats were not fasted prior to 
sacrifice. Protein was isolated and Western Blot analyses were conducted as previously 
described 8. For protein isolation, samples were incubated on ice in RIPA buffer (Sigma-Aldrich, 
St. Louis, MO) containing 1:100 protease inhibitor (Sigma-Aldrich), and 1:100 phosphatase 
inhibitor (Sigma-Aldrich) and then homogenized for 30 seconds or until a smooth suspension 
resulted.  Homogenized samples were centrifuged for 10min at 16,874 x g at 4⁰ C.  Supernatant 
was collected and measured for protein concentrations using a BCA protein assay kit 
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(Pierce/Thermo Fisher Scientific, Rockford, IL). For Western Blot, equal amounts of protein (30 
µg) were separated on a 10% Tris-Hepes-SDS premade gel (Pierce/Thermo Fisher Scientific) 
and transferred to a PVDF membrane (Amersham, Amersham, UK) as indicated by the 
manufacturer.  The membrane was then blocked in TBS (20 mM Tris-Base, 150 mM NaCl, pH 
7.6) containing 5% nonfat dry milk overnight at 4⁰ C.  On Day 2, the membrane was incubated 
for 1h with primary antibody for CD36 (1:500; Novus Biologicals, Littleton, CO), GLUT4 
(1:1000; Abcam, Cambridge, MA), PPARγ (1:1000; Abcam), pAMPK (1:2000; Cell Signaling, 
Danvers, MA), total AMPK (AMPK-α; 1:1000; Cell Signaling) or alpha-tubulin (1:500; Abcam) 
against rabbit in TBS containing 5% nonfat dry milk.  Following several washes the membrane 
was incubated for 45min with horseradish peroxidase-conjugated anti-rabbit antiserum 
(1:10,000, Abcam). Immunoreactivity was visualized using ECL Western blotting detection 
reagents (Amersham).  Images were obtained using exposure to chemiluminescence film 
(Amersham).  Bands were quantified using ImageJ for densitometry and values were normalized 
to alpha-tubulin. pAMPK was also normalized to total AMPK. For quantification in Image J, 
films were scanned and saved as jpeg files. Images were cropped to contain the appropriately 
sized band. Using Image J, a box was drawn around the band for each sample. This same box 
was used for each sample on each image. Image J provided graphical information on the relative 
density of each band, which reflected the portion of the drawn box that contained the band. This 
allowed for a more precise measurement of densitometry of the actual band and not the 
surrounding image. 
 
 
	 10	
2.2.6 Histological Analysis of gastrocnemius muscle in OM and S5B (Succinate 
Dehydrogenase and Oil Red O): 
Fat and connective tissue were dissected from gastrocnemius muscle, frozen in 
isopentane, and stored at -80°C until histological processing.  At the time of processing, sections 
(10µm) were cut using a cryostat (Shandon Cryotome, Thermo Scientific) at -20°C and mounted 
on slides. Slides with cross sections of the gastrocnemius muscle were incubated with succinate 
dehydrogenase (SDH) to evaluate the presence of oxidative enzymes or Oil Red O to detect the 
presence of intramuscular lipids. Images were captured via light microscope (Nikon Eclipse 80i) 
with a connected digital camera under a 10x objective. Within the cross section, quantitative 
image analysis was conducted using the Image J Software on a minimum of 75 fibers. Image J 
provided a numerical value for the density of staining for each fiber. The oxidative capacity of 
the muscle was determined by the intensity of SDH staining according to validated methods 32. 
With this method, there is a positive linear correlation between color and oxidative potential. 
Type I fibers (slow twitch, oxidative) stain darkest and Type II fibers (fast twitch, glycolytic) 
stain lighter. Oil Red O staining was quantified according to the area occupied by the lipid 
staining within individual muscle fibers 33. 		
2.2.7 Statistical Analysis: 
Data is presented as mean + SEM. Two way ANOVAs were used to determine if 
significant differences between groups (strain vs. diet).  If an overall ANOVA demonstrated 
significant differences, post hoc comparisons were performed using a Bonferroni t-test.  
Differences were considered significant if p < 0.05. Statistical analyses were performed using 
SPSS.  
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2.3 Results 
2.3.1 Fasting Glucose:  
Fasting glucose levels were significantly affected by diet and strain (F=6.03, p<0.05; 
Figure 2.1A). Consumption of HFD increased fasting glucose levels in the OM, but not the S5B 
rats.  
2.3.2 Body Composition: 
 OM rats weighed more than S5B rats fed either the HFD or the LFD (F=10.6, p<.01; 
Figure 2.1B). Body weight was increased by the consumption of a HFD in OM and S5B rats, 
with a greater increase in body weight in the obesity-prone OM rats, compared to the obesity-
resistant S5B rats (58.3 g vs. 15.3 g, respectively). Body composition was assessed by NMR and 
a higher percentage of body fat was detected in OM rats, compared to S5B rats (F=5.9, p<.05; 
Figure 2.1C). HFD intake increased the percentage of body fat in OM rats only. The percentage 
of LBM was not altered by strain or diet (Figure 2.1D).  
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Figure 2. 1: A. Fasting glucose levels were elevated in OM rats consuming the HFD. 
B. OM rats weighed more than S5B rats. HFD intake increased body weight in both strains. OM 
rats consuming a HFD weighed more than S5B rats consuming a HFD. C. Consumption of a 
HFD increased the percentage of body fat in OM rats. D. The percentage of LBM was not altered 
by HFD consumption. Data is shown as mean + SEM, p<.05, # diet differences, *strain 
differences. 
 
2.3.3 Effect of HFD consumption on metabolic parameters in OM and S5B: 
Rats were placed in the metabolic chambers for 5 days (1d habituation, 4d data collection), 
during which food intake, RER, activity, metabolic rate (VO2) and EE were measured. Data 
collected during the dark phase and the light phase was analyzed, as well as over the total 24h 
period (for food intake and activity).  Rats consuming the HFD exhibited a significantly lower 
RER value than rats consuming the LFD during the light phase (F=4552.8, p<.001; Figure 2A, 
2B) and an interaction between strain and diet was detected during the dark phase (F=22.0, 
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p<.001). During the light phase, S5B rats fed the LFD were able to shift their substrate utilization 
toward fat oxidation, compared to the OM rats (difference in light to dark: OM-LFD 0.020 + 
.007 vs. S5B-LFD 0.074 + .008, p<.001).  
 
 
Figure 2.2: A. RER time course over 4 days of measurements in metabolic chambers. B. RER 
was lower in rats consuming HFD, reflecting the predominance of fat utilization. During the dark 
cycle, OM rats consuming LFD exhibited a higher RER than S5B rats consuming a LFD. C. OM 
rats consumed more LFD and HFD during the light cycle. During the dark cycle, OM rats 
reduced their consumption of LFD. OM rats consumed more HFD over the 24h period than S5B 
rats. Black bars indicate dark period. Data is shown as mean + SEM, p<.05, # diet differences, 
*strain differences. 
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Differences in HFD and LFD intake were seen across the light and dark cycles. During 
the light cycle, OM rats consumed more HFD and LFD than S5B rats and more LFD, than HFD 
(F=15.2, p<.001; See Figure 2C). During the dark cycle, OM rats consumed less LFD than the 
S5B rats and similar amounts of HFD (F=15.7, p<.001). Total daily HFD intake was higher in 
the OM rats (F=7.9, p<.001). OM rats were more active in the metabolic cages than S5B rats 
during the light cycle (F=6.9, p<.01; Figure 2D) and HFD fed OM rats were more active than 
S5B rats during the dark cycle (F=27.5, p<.001). Total daily activity was highest in OM rats 
consuming the HFD (F=4.2, p<.05). 
Metabolic rate (VO2 based on kg LBM) was differentially affected by diet in the OM and 
S5B rats during the light (F=20.6, p<.001) and dark phase (F=27.8, p<.001; Figures 2.3A, 2.3B). 
In both the light and the dark phase, HFD consumption increased metabolic rate in the obesity-
resistant S5B rats and decreased metabolic rate in the obesity-prone OM rats. Estimated hourly 
EE was calculated by the TSE software and based on kg LBM. Estimated EE was differentially 
affected by diet in the OM and S5B rats during the light (F=20.5, p<001) and dark (F=27.1, 
p<.001) cycles (Figures 2.3C, 2.3D). Estimated hourly EE was increased by HFD consumption 
in the S5B rats and decreased by HFD intake in the OM rats.  
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Figure 2.3: A. Time course of metabolic rate (VO2 (kg LBM). B. HFD intake differentially 
affected VO2 level in OM and S5B rats. HFD intake increased metabolic rate in obesity-resistant 
S5B rats and decreased metabolic rate in obesity-prone OM rats. C. Time course of estimated EE 
over 4 days of measurements in the metabolic chambers. D.  HFD consumption increased EE in 
S5B rats and decreased EE in OM rats. Black bars indicate dark period. Data is shown as mean + 
SEM, p<.05, # diet differences, *strain differences. 
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2.3.4 Skeletal Muscle CD36, GLUT4, pAMPK and PPARγ protein expression: 
Protein expression of skeletal muscle markers of fat and carbohydrate metabolism were 
assessed by Western blot. There were no inherent strain differences or HFD-induced alterations 
in the expression of CD36 (Figure 2.4A). GLUT 4 expression was elevated in OM rats (F=5.6, 
p<.05; Figure 2.4B). A differential response to HFD consumption was detected for pAMPK/total 
AMPK (F=12.2, p<.01, Figure 2.4C) and PPARγ (F=4.8, p<.05; Figure 2.4D) between OM and 
S5B rats. Consumption of HFD decreased pAMPK and PPARγ in the obesity-prone OM rats. In 
LFD fed rats, PPARγ expression was higher in OM rats, compared to S5B rats. 
 
Figure 2.4: Western Blots were used to assess protein expression of skeletal muscle markers of 
metabolism in OM and S5B rats fed LFD or HFD. A. CD36 protein levels were not altered by 
strain or diet. B. GLUT4 protein expression in the gastrocnemius muscle was increased in 
OMrats OM rats. C. pAMPK levels in the gastrocnemius muscle were decreased by HFD in OM 
rats. D. PPARɣ protein expression was decreased in OM rats consuming a HFD. Data is shown 
as mean + SEM, p<.05, # diet differences, *strain differences. 
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2.3.5 Histological Analysis of gastrocnemius muscle in OM and S5B (Succinate 
Dehydrogenase (SDH) and Oil Red O: 
 
Assessment of inherent and HFD-induced differences in oxidative activity of the 
gastrocnemius muscle, as measured by SDH activity, indicated that HFD consumption increased 
the oxidative capacity of the skeletal muscle in both strains (F=172.9, p<.01, Figure 2.5). SDH 
activity indicates a greater number of Type I, slow twitch fibers following HFD consumption. 
HFD consumption increased intra-muscular lipid droplets, as measured by Oil Red O, in both 
OM and S5B rats (F=178.4, p<.001, Figure 2.6). The intensity of Oil Red O staining was higher 
in the OM rats fed the HFD, than the S5B rats fed the HFD.  
 
Figure 2.5: SDH assay was used to determine oxidative capacity of the gastrocnemius muscle in 
OM and S5B rats fed LFD or HFD. The consumption of a HFD increased SDH staining in OM 
and S5B rats, suggesting an enhanced oxidative capacity. OM rats fed LFD had greater SDH 
staining than S5B rats fed LFD.  
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Figure 2.6: Oil Red O was used to determine lipid deposition in the gastrocnemius muscle S5B 
and OM rats fed LFD or HFD. An increase in density of Oil Red O stain is reflective of an 
increase in lipid deposition. The consumption of a HFD increased Oil Red O staining in OM and 
S5B rats. Lipid deposition in HFD fed was markedly enhanced in OM rats, compare to S5B rats.  
Data is shown as mean + SEM, p<.05, # diet differences, *strain differences. 
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2.4 Discussion 
OM rats are susceptible to diet-induced obesity and gain more weight and body fat when 
eating a HFD, than obesity-resistant S5B rats. The current experiment investigated inherent 
strain differences and HFD-induced differences in metabolic parameters (e.g. metabolic rate) and 
skeletal muscle markers of metabolism, lipid storage, lipid oxidation and muscle fiber type in 
these animal models. It was hypothesized that the consumption of HFD would differentially 
affect metabolic parameters and skeletal muscle markers of metabolism in the obesity-prone, 
OM and the obesity-resistant, S5B rats. The results from this experiment elucidate HFD-induced 
changes in the metabolic phenotype of these two strains, which may contribute to the 
susceptibility to develop diet-induced obesity. 
The animals models used in the current study have been studied for a number of years to 
assess physiological and pharmacological differences that would alter the susceptibility to 
developing diet-induced obesity. Multiple studies have demonstrated innate strain differences as 
well as strain differences in response to HFD consumption 3-5,8,25-31. However, metabolic 
parameters have not been assessed in these models and these strains may differ from other 
models of diet-induced obesity on these parameters. Previous studies using other models of 
obesity have examined differences in metabolism and activity as potential mechanisms to 
account for the susceptibility to obesity.  A recent study by Azzout-Marniche and colleagues 34 
failed to demonstrate differences in EE, or substrate utilization in fat-resistant and fat-sensitive 
Wistar rats fed a HFD, though fat-sensitive rats were more active. Jackman and colleagues 9 
reported a sex difference in the response to dietary fat in obesity-prone and obesity-resistant rats, 
indicating that their male rats demonstrated minor increases in EE, compared to female rats. 
Their study concentrated on the switch from a LFD to a HFD, and reported a lack of difference 
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in activity levels.  Reported differences in activity have also been suggested as a method by 
which obesity-resistant rats are able to resist obesity. Specifically, high levels of spontaneous 
physical activity (SPA, very low-intensity physical activity) were associated with obesity 
resistance in selectively-bred obesity resistant Sprague-Dawley rats. 6,35-37. In these studies, 
obesity-resistant rats spent more time being ambulatory than Sprague-Dawley rats, and exhibited 
decreased body weight, fat mass and food intake, suggesting that EE generated from SPA 
accounts for the difference between obesity resistance and propensity in this model. 
In the current experiment, HFD consumption increased fasting glucose levels in the 
obesity-prone OM rats, but not the obesity-resistant, S5B rats. These data are in congruence with 
previous reports suggesting that OM rats have higher circulating insulin and leptin levels 26,28, in 
response to a HFD.  OM and S5B rats gained weight on the HFD and OM rats consuming the 
HFD weighed considerably more than the OM rats consuming the LFD (approximately 58g). A 
HFD-induced increase in the percentage of body fat was only seen in the OM rats and there were 
no differences in percentage of LBM between the strains, regardless of diet. Similar percentages 
of LBM in these strains suggest that differences in metabolic parameters and skeletal muscle 
markers are not due to HFD-induced muscle degradation. As expected, daily food intake was 
highest in the OM rats consuming the HFD. This increase in total HFD intake by the OM rats 
appears to be driven by an increase in HFD consumption during the light phase. An increase in 
activity levels during the light phase was also seen in the OM rats, suggesting that these rats were 
awake, active and eating. This increase in LFD consumption and increase in activity, compared 
to the S5B rats, may account for the lack of “flexibility” in RER of the OM rats during the light 
phase. Multiple studies have suggested that obese individuals are metabolically inflexible, 
suggesting that these individuals are not able to adequately shift from carbohydrate to fat 
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oxidation during times of fasting (e.g. sleep) 18,20,22.  In the current study, the rats fed the HFD 
exhibited a RER that reflected fat oxidation. Since this diet contains 60% of its kilocalories from 
fat (20% from carbohydrates), this was expected. Metabolic inflexibility was not able to be 
assessed in the HFD groups, since the RER did not fluctuate between the light and dark cycle. 
Energy expenditure and metabolic rate were assessed in the OM and S5B rats fed the 
HFD and LFD. The consumption of the HFD increased metabolic rate (VO2) and estimated EE 
in the obesity-resistant S5B rats during the light cycle and the dark cycle. This was not due to an 
increase in activity level, since S5B rats fed the HFD were not more active than those fed the 
LFD. This was also not due to an increase in HFD intake, since the S5B consumed the same 
number of kilocalories regardless of diet. Conversely, consumption of HFD decreased metabolic 
rate and estimated hourly EE in the obesity-prone OM rats. These decreases were not due to a 
decrease in HFD intake, since OM rats consumed more HFD than LFD and they were not due to 
a decrease in activity level, since OM rats consuming the HFD were more active than those 
consuming the LFD. These data suggest that there is an alternate mechanism regulating the 
HFD-induced alterations in metabolic rate and EE in the OM and S5B rats. Previous studies have 
investigated altered sympathetic output, as measured by peripheral norepinephrine, in these 
strains and have shown higher concentration of norepinephrine in brown adipose tissue following 
HFD intake in S5B, compared to OM rats, supporting decreased EE in OM rats consuming HFD 
38.  
Skeletal muscle is a major component of glucose utilization and metabolic rate, and is 
predicted to be a major factor in the resistance to developing obesity. Therefore, the current 
study assessed skeletal muscle markers of carbohydrate and lipid metabolism, as well as lipid 
oxidation and storage. Expression of the fatty acid receptor, CD36, did not differ between OM 
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and S5B rats and was not affected by HFD consumption. GLUT 4 expression was higher in OM 
rats. Inherent strain differences in pAMPK and PPARγ expression were not detected, however, 
HFD consumption decreased pAMPK (pAMPK/total AMPK) and PPARγ expression in obesity-
prone OM rats, but not in obesity-resistant S5B rats. AMPK serves as a key protein kinase that 
integrates nutrient and hormonal signals to regulate whole-body metabolism by stimulating 
glucose uptake and partitioning fatty acids toward oxidation 23,39-42. Investigations linking obesity 
with impaired skeletal muscle AMPK have provided largely inconsistent findings.  In several 
genetic models of obesity, AMPK levels in skeletal muscle were altered 16,43,44, however, other 
studies assessing AMPK levels in obese and insulin resistant models did not indicate differences 
45-50. In the current experiment, pAMPK expression was decreased by HFD consumption in OM 
rats. Due to the role of AMPK as an energy sensor and a regulator of fat oxidation, these data 
suggest that HFD-induced decreases in AMPK phosphorylation in the skeletal muscle of OM 
rats may be a mechanism by which OM rats decrease their metabolic rate and EE in response to a 
HFD. Previous research has implicated defects in PPARγ , a regulator of fatty acid storage and 
glucose metabolism, as a mediator of the susceptibility to developing obesity 24, which supports 
data from the current study. 
 Inherent and HFD-induced alterations in lipid accumulation in the skeletal muscle of 
OM and S5B rats were measured by Oil Red O. HFD intake increased lipid accumulation in both 
strains, but to a greater extent in the OM rats. Oxidative capacity of the skeletal muscle was 
assessed by an SDH assay and these data suggest that the gastrocnemius muscle of OM rats have 
a greater oxidative capacity (more Type I fibers).  HFD consumption increased the oxidative 
capacity of the muscle in both strains.  Lipid accumulation in skeletal muscle, in most cases, is 
indicative of the cellular energy status, which favors storage rather than oxidation, and is 
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associated with obesity and type 2 diabetes 51. Previous studies have demonstrated excessive fat 
transport and β-oxidation in skeletal muscle following HFD intake 52, which rendered rats 
incapable of switching to carbohydrate oxidation in the postprandial state, and therefore inhibited 
metabolic flexibility. The accumulation of intramuscular triglycerides and the intermediaries of 
incomplete fat oxidation (DAG, ceramides) have been shown to alter the insertion of GLUT4 in 
the plasma membrane 53-55. Excessive, but incomplete fat oxidation leading to an accumulation 
of lipids in skeletal muscle has been seen in rats fed a HFD 52 and is similar to the pattern seen in 
the current study, in which HFD intake increased fat oxidation and lipid accumulation in OM 
rats. Incomplete fat oxidation and excessive lipid accumulation may explain, in part, the 
increased susceptibility to developing obesity in the OM rats.  
The current experiment tested the hypothesis that there were inherent differences and 
HFD-induced alterations in metabolic parameters, skeletal muscle markers of carbohydrate and 
fat metabolism, and oxidation and lipid accumulation in skeletal muscle of obesity-prone and 
obesity-resistant rats. Obesity-prone OM rats gained more weight and body fat on a HFD and 
consume more HFD, than obesity-resistant S5B rats. HFD consumption also increased fasting 
glucose levels in the OM rats, suggesting glucose intolerance.  No inherent strain differences 
were detected in metabolic rate and estimated EE.  However, the consumption of a HFD in S5B 
rats increased metabolic rate and EE and decreased metabolic rate and EE in OM rats. These 
strain differences were not due to the differences in activity or food intake. HFD-induced 
differences in metabolic rate and EE may be mediated by HFD-induced differences in pAMPK 
and PPARγ expression and lipid accumulation in the gastrocnemius muscle of OM and S5B rats. 
HFD intake decreases in pAMPK and PPARγ expression in OM rats predict a decrease in EE 
and an increase in lipid accumulation. Taken together these data suggest that the susceptibility to 
	 24	
developing HFD-induced obesity, in these two strains, may be mediated by differential rates of 
EE, which are mediated by AMPK and PPARγ and by lipid accumulation in skeletal muscle.  
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CHAPTER 3. DIFFERENTIAL EFFECTS OF FATMAX VS. HIGH CARBOHDRATE 
OXIDATION (OBLA) EXERCISE ON ORAL GLUCOSE TOLERANCE AND 
METABOLIC FLEXIBILITY 
 
3.1 Introduction 
Exercise is an important lifestyle intervention used to prevent, delay, or treat the 
development of metabolic disorders such as obesity and type 2 diabetes 1.  However, there is a 
need to develop more effective exercise strategies to account for the large variability in the 
response to exercise in people with metabolic disorders 2.  For example, an acute bout of exercise 
has been shown to improve insulin sensitivity for up to 24 hours, in some, 3-5,but not all studies 
6,7. This discrepancy is due to numerous factors including exercise intensity 8-10 , glycemic status 
of subjects 11,  dietary behavior 12,13, or timing of the post-exercise measurement of insulin 
sensitivity 14. The total dose of exercise at differing intensity is also a consideration that might 
explain the variability in post exercise insulin sensitivity.  
The improvements in glucose tolerance with aerobic exercise may be the result of 1) 
increased glucose uptake to support glycogen synthesis 3 or 2) more complete oxidation of 
intramuscular triglycerides (IMTG), and lipid species 15.  Previous research suggests that a single 
bout of aerobic exercise at a higher intensity (as a percentage of maximal cardiorespiratory 
fitness; VO2max) improves glucose tolerance to a greater extent 16.  However, this result may be 
partially due to a lower variability in individual responses regarding fuel utilization as high rates 
of carbohydrate oxidation are common at higher exercise intensities.  At lower exercise 
intensities, physiologic, nutritional, and genetic factors lead to an increase in the variability in 
fuel selection potentially obscuring the benefits of increased fat oxidation during acute exercise 
17,18.  Aerobic exercise can also be prescribed at an intensity (FATMAX) eliciting a maximal fat 
oxidation rate (MFO; g/min).  The FATMAX varies between individuals, but is easily 
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determined by a standard graded exercise test to exhaustion (VO2max) 19.  To our knowledge, only 
one study has examined the effect of aerobic training at FATMAX 20.  In this study, insulin 
sensitivity improved after only 4 weeks of aerobic training at FATMAX compared to 4 weeks of 
aerobic interval training of equal caloric dose. The effect of acute exercise at FATMAX on 
glucose tolerance is unknown.  Additionally, no research exists comparing a single bout of 
aerobic exercise at FATMAX to a higher intensity exercise in which the primary fuel source is 
carbohydrate (i.e onset of blood lactate accumulation).  Determining the intensity of aerobic 
exercise that has the greatest impact on glucose tolerance has practical applications and could 
potentially offer options for individuals looking to start exercise programs, especially sedentary 
individuals at risk for diabetes.  Likewise, a lower intensity exercise may also promote greater 
adherence through improved affective (feeling and arousal) responses during exercise. 
The purpose of this study is to investigate the effect of acute aerobic exercise at an 
intensity that maximizes the rate of fat oxidation (FATMAX) on glucose tolerance compared to 
acute aerobic exercise at a higher intensity resulting in greater carbohydrate oxidation (OBLA).  
We hypothesize that glucose tolerance will improve acutely post FATMAX and OBLA exercise. 
Additionally, we expect that affective responses will be stable and more positive during the 
FATMAX trial compared with the OBLA trial.  
3.2 Methods 
 3.2.1 Participants 
Eight apparently healthy, sedentary, overweight/obese college-aged men gave written 
informed consent to participate in this study. Individuals who presented with any known 
cardiovascular disease, type 2 diabetes, resting blood pressure ³140/90mmHg, and/or body mass 
index ³35kg/m2 were excluded. Baseline participant characteristics are provided in table 1.  The 
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participants enrolled were all college aged, sedendtary, and overweight. All participants had 
fasting plasma glucose levels below the threshold criteria (³126 mg/dl) and 120-minute threshold 
of ³200 mg/dl.  All participants were physically inactive, nonsmokers, presently not taking any 
medications, and had physician approval to participate. This study was approved by the 
Institutional Review Board at Louisiana State University.  
Table 3.1. Baseline Characteristics 
Age (y) 20.5 ± 1.5 
Height (m) 1.81 ± 0.04 
Weight (kg) 95.9 ± 13.8 
BMI (kg/m2) 29.5 ± 4.7 
VO2peak (ml•kg-1•min-1) 33.2 ± 6.8 
Fasting plasma glucose (mg/dl) 93.9 ± 10.6 
120 min plasma glucose (mg/dl) 93.2 ± 12.2 
Fasting RER 0.80 ±0.05 
VO2peak maximal aerobic capacity; BMI body mass index; 
Respirator Exchange Ratio (VCO2/VO2) ±SD 
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3.2.2. Experimental Protocol 
 
Participants underwent a maximal cardiorespiratory fitness test (VO2max) with 
electrocardiogram (ECG) on a cycle ergometer (Velotron, Racermate, Inc., Seattle, WA).  
Participants started at an initial workload of 25 Watts for 4 minutes.  The workload was 
increased by 25 Watts every 4 minutes until respiratory exchange ratio reached 1.05 after which 
the workload increased by 25 Watts every 2 minutes until volitional exhaustion.  Throughout the 
test, respiratory gases were analyzed using a metabolic cart (ParvoMedics Inc., Sandy, UT) and 
fat oxidation rates were determined using stoichiometric equations21.  FATMAX was determined 
using a 3-parameter logistic line of best fit calculated from the fat oxidation vs. exercise intensity 
(%VO2max) graph (figure 3.2) 19.  During the VO2max test, we also obtained finger stick blood 
lactate concentrations (Lactate Plus,Waltham,MA), at the end of each interval for the 
determination of onset of blood lactate accumulation (OBLA; 4 mM lactate).  The exercise ECG 
was reviewed by a cardiologist for final study approval.   
The baseline OGTTs occurred ~1 week after the screening visit and VO2max test.  Prior to 
the baseline visit participants recorded all food and beverages ingested for the 24-hour period 
prior to the baseline OGTT. Participants were required to abstain from exercise 48 hours prior to 
the visit. Participants then completed, in random order separated by ~1 week,  two bouts of 
Figure 1. Visit Schedule.  *After confirmation of non-diabetic status, participants undergo 2 acute aerobic 
exercise sessions in random order.  The intensity of the acute exercise sessions will be 1) FatMax or 2) high 
carbohydrate oxidation.  24-hour diet records will be kept prior to the baseline OGTT and replicated between 
the acute exercise sessions and the OGTTs.
0
Visit Schedule (days)
7 14
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OGTT,
Randomization*
Acute
Exercise 1
15
OGTT, Resting
Metabolism
24-hour Diet24-hour Diet
6 21
Acute
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22
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isocaloric (400 kcal) exercise at either FATMAX or OBLA.   Additional OGTTs were conducted 
24 hours after the 2 acute exercise sessions separated by ~1 week.  Prior to the post-exercise 
OGTTs, participants replicated the 24-hour food and beverage diary recorded prior to the 
baseline OGTT. All OGTTs and exercise sessions were conducted in the morning hours after a 
10-hour fast. 
The acute aerobic exercise sessions occurred ~1 week after the screening visit and 
VO2max test and were performed on a cycle ergometer at intensities eliciting 1) FATMAX and 2) 
high carbohydrate oxidation (lactate threshold).  All participants underwent the acute aerobic 
exercise sessions in a random, counter-balanced order.  The targeted total dose of exercise was 
400 kcal for both exercise sessions. Caloric expenditure rates were monitored periodically 
throughout exercise.  The time to finish the 400 kcal exercise dose was accurately determined by 
extrapolating the kcal expenditure rate (from the metabolic cart) at each time point to the final 
caloric dose.  We estimated that a 100 kg male (VO2peak=35 ml×kg-1×min-1) will finish the 
FATMAX session in ~50 minutes and the OBLA session in ~30 minutes 22. 
3.2.3 Experimental Measures 
3.2.3.1 Exercise Prescription 
 FATMAX was determined using a 3-parameter logistic line of best fit calculated from the 
fat oxidation vs. exercise intensity (%VO2max) graph 23 (figure 3.2). According to this method, we 
required >3 valid fat oxidation points with 2 valid inflection points. Once MFO was identified 
FATMAX intensity could be determined by using the corresponding power generation (watts) 
performed during the GXT (Figure 2). FATMAX calculated for each individual participant. 
Lactate was measured at the end of each stage during the GXT.  OBLA was considered the onset 
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of blood lactate (4mM).  The corresponding intensity was determined by the inspection method 
24. 
 
 3.2.3.2 Exercise Sessions 
 During both exercise sessions, respiratory gases were measured at 5-min intervals prior to 
25%, 50%, 75% and 100% of the exercise bout, equivalent to 100, 200, 300, and 400kcal, 
respectively, and the time to complete the exercise bout was adjusted accordingly. Any excessive 
energy expenditure achieved during the first of the randomized sessions was accounted for in the 
subsequent session to match energy expenditure. 
 Affective responses were measured from the perspective of the circumflex model of 
affect. Affect is defined by the orthogonal and bipolar dimensions of affective valence (pleasure-
displeasure) and perceived activation (low-high). To capture these dimensions, two single-item 
measures were used. The Feeling Scale is an 11-point measure of affective valence. The scale 
ranges from -5 to +5. Anchors are provided at zero (“Neutral”) and at all odd integers, ranging 
Figure 3.2 Example of FATMAX analysis. FatMax and MFO calculated by MatLab (.exe) from
VO2max test. Fat oxidation (FAOx) by Jeukendrup and Walis equation (2005). Required 3 PL
regression with ≥ 3 valid FAOx points with 2 valid inflection points. Lower Bound = 0%; forced
equation through origin (0,0). Upper Bound (UB) ≤ 100% and LB < FatMax < UB. 
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from “Very Bad” (-5) to “Very Good” (+5). The Felt Arousal Scale 25 is a 6-point measure of 
perceived activation. The scale ranges from 1 to 6, with anchors at 1 (“Low Arousal”) and 6 
(“High Arousal”). Affective responses were measured pre- and post-exercise in all 3 trials as 
well as at each minute during the initial VO2max test and at regular intervals (e.g., ~25%, 50%, 
75%, and 100% of the 400 kcal exercise dose) during the experimental conditions. Additionally, 
rating of perceived exertion (RPE) was recorded at the same intervals as other affective 
responses.  
 3.3.3.3 Oral Glucose Tolerance Test (OGTT) 
 The baseline OGTT occurred ~1 week after the screening visit and VO2max test.  .  The 
baseline OGTT completed the exclusion criteria for high fasting glucose (> 125 mg/dL) and 
abnormal 2-hour glucose (> 200 mg/dL).  Additional OGTTs was conducted 24 hours after the 2 
acute exercise sessions and was separated by ~1 week.  Prior to the post-exercise OGTTs, 
participants were asked to replicate the 24-hour food and beverage diary recorded prior to the 
baseline OGTT.  Glucose area under the curve was measured by the trapezoidal method 26. 
Indirect calorimetry was performed prior to and during each OGTT.  Resting energy 
expenditure and substrate utilization were assessed using the ParvoMedics, TruOne 2400 
metabolic cart (Sandy, UT) calibrated with standard gas mixtures .  A transparent plastic hood 
connected to the metabolic cart was placed over the participant’s head and calculations of energy 
expenditure and carbohydrate and fat oxidation rates were made from expiratory gases diluted in 
a constant air flow (~40 L/min).  Resting metabolic measurements were assessed before the 
OGTT (0 min) and at 60 and 120 minutes after ingestion of the glucose drink.  The average of 
the last 20 minutes of the 30 minute measurement was used to calculate resting metabolic rate 
and substrate oxidation using the equations of Jequier et al 27.  Participants remained motionless 
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and awake during these periods. Metabolic flexibility was measured at 60 minutes (RER 60-0 
min) and at 120 minutes (120-0 minutes).  
3.2.4 Statistical Analysis 
 All statistics were performed using JMP statistical software (SAS Institute Inc., Cary, 
NC).  Data analysis generally followed CONSORT recommendations using General Linear 
Models and repeated measures analysis of variance (RM-ANOVA) co-varied as needed 
depending on normality distributions at baseline and order of intervention trials.  In addition, 
two-way RM-ANOVA (exercise session x time point) were used to determine differences in 
responses in both the primary and secondary outcome variables. Primary outcomes included 
AUC plasma glucose and change in metabolic flexibility (shift in RER pre to post oral glucose). 
Baseline (non-exercise) and exercise (FATMAX and OBLA combined) comparisons were 
evaluated using contrast statements with the one-way RM-ANOVAs. Significant effects were 
further evaluated using student’s t-test post-hoc analyses were appropriate.  Data will be reported 
as mean±SD and differences declared at P<0.05.  
3.3 Results 
3.3.1 Substrate Oxidation During Fat Max and OBLA Exercise 
The percent VO2max at FATMAX (41±12%) and OBLA (68±10%) differed significantly 
(p<0.001). Substrate oxidation for fat (figure 3.3A) and carbohydrate (figure 3.3B) was measured 
during FATMAX and OBLA exercise. Total energy expenditure was 416.1 ± 11.4kcal for 
FATMAX  and 422.1 ± 10.4kcal for OBLA exercise. FATMAX exercise elicited greater average 
fat utilization (18.6 ± 12.1g) than OBLA (10.1 ± 20.3g; p=0.03) exercise (figure 3.4).  
Accordingly, OBLA (82.8 ± 12.1g) exercise elicited greater carbohydrate utilization than 
FATMAX (62.4 ± 20.3g; p<0.05) exercise. As expected, the average time to complete the OBLA 
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exercise was less (40.0± 10.9 min) compared to the FATMAX exercise trial (62.9± 21.9 min; 
p=0.01). 
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3.3.2 Affective Response 
 Participants completing the FATMAX exercise session reported lower RPE (Figure 7a) at all time 
points (25%, 50%, 75%,100%) compared to OBLA (average RPE FATMAX 10.1±2.1vs. OBLA 
13.9±2.4; pvalue).  Participants completing the FATMAX trial also reported significantly lower Felt 
Arousal (FA)(Figure 7b) (p<0.05) and Feeling Score (FS) (Figure 7c) (p<0.05) at the 25 (FATMX 
1.6±1.7 vs. OBLA 2.5±1.5)  and 50% (FATMAX 1.7±1.1 vs. OBLA 3.0±1.2)  time points and 75 
(FATMAX 2.5±2.7 vs. OBLA 0.05 ±3.0) and 100% (FATMAX 2.1±3.1  vs. OBLA -0.05±3.3) 
respectively.  
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3.3.4 Oral Glucose Tolerance  
No significant differences were detected for fasting glucose at baseline or before the 
FATMAX or OBLA exercise conditions (84.2 ±17.0 and 90.0 ± 19.9 mg/dl respectively).  Total 
AUC for glucose (figure 3.6) was higher for OBLA (15126.2±1351.1) exercise than baseline 
condition (13143.9±909.5; p<0.05).  There were no significant differences between AUC for 
glucose after FATMAX (13411±1721) compared to baseline conditions (p=.58).  Additionally, 
peak plasma glucose did not differ between trials (Baseline=128.8±15.4, FATMAX= 
142.2±24.4, and OBLA=148.8±17.1)).  
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Figure 3.5. A) RPE, B) Feeling Score (FS), and C) Felt Arousal (FA) during FM 
and LT exercise. *P<0.05 , #P<0.001. + SEM 
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 3.3.5 Metabolic Flexibility 
 No significant differences were detected between the FATMAX (0.089 ± 0.032) and baseline 
measurements (0.11± 0.04; p<0.005) for the metabolic flexibility (DRER 120-0) (figure 3.7). There was 
however, a lower DRER (0.051 ± 0.032) 24-hr post OBLA exercise at the 60-minute time point compared 
to baseline (values; p<0.05).  There were no significant differences between any condition at 120 minutes.  
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 3.4 Discussion  
The purpose of this study was to investigate the effect of acute isocaloric aerobic exercise 
at FATMAX and OBLA on the glucose tolerance and metabolic flexibility of young overweight 
males. Previous work suggests that acute exercise increases insulin sensitivity for up to 24 hrs. 
post-exercise 7,10,28,29.  However, within these studies there appears to be differential effects of 
exercise due to intensity, type, meal timing, measurement timing, and diabetic status. Energy 
expenditure (total kcal) is a modifiable facet of exercise that is a potential source variability that 
may explain the response to exercise.  In the current study, we found that OBLA exercise acutely 
lowers glucose tolerance and metabolic flexibility  under well-controlled exercise conditions.  
This suggests that the acute period (24 hours) is characterized by delayed glucose disposal and 
oxidation.  
Substrate utilization during exercise is dictated primarily by the intensity of exercise 23,30.  
Duration of exercise also affects carbohydrate and fat oxidation especially when comparing 
trained versus untrained individuals.  Klein et al (1990), demonstrated that fat oxidation was 
higher in trained volunteers (vs. untrained) during 4 hours of treadmill running at a low intensity 
(~20 ml/kg-1/min-1), despite similar rates of lipolysis and fatty acid uptakes 31.  Fat oxidation is 
also impacted by carbohydrate availability and the production of lactate 30,32,33. However, these 
factors have been demonstrated under long duration (2.5-4 hours) exercise, which may not be 
clinically applicable.  
Fat oxidation can be challenging to measure, in part, to the different sources (adipose and 
IMTG) of FFA available to the skeletal muscle during exercise.  Evidence suggests that IMTG 
are a major source of FFA during exercise at low to moderate intensity 34,35. Experimental 
inhibition of adipose lipolysis does appear to increase IMTG oxidation in healthy and T2D 
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patients, which suggests IMTG does account for some percentage, albeit varying, amount of fat 
oxidation 36,37.  As exercise intensity exceeds ~55% of VO2max there appears to be a decrease in 
fat oxidation rate, especially IMTG oxidation 23,35.  In our study, FATMAX exercise trials were 
completed at individually calculated FATMAX thresholds (41.1 ± 12% VO2max).   During 
FATMAX exercise (Fig. 1A and 1B) we demonstrated a consistent level of fat oxidation without 
significant increases in carbohydrate oxidation. This suggest that the dosage of exercise (400 
kcal) may be ideal to observe such effects.  
As expected, as exercise duration increased during the OBLA trial there was an increase 
in fat oxidation and the contribution of FA to overall energy expenditure. However, average 
carbohydrate oxidation (20.8±3.4 g/min) was greater during OBLA exercise suggesting the 
higher exercise intensity promoted preferential utilization of carbohydrates (78.9±5.3% of total 
energy expenditure).  The increased fat oxidation during OBLA exercise can be explained by 
numerous factors. As exercise duration increases, the availability of FA increases as does the 
transport of FA into the contracting skeletal muscle 35,38.  The isocaloric (400 kcal) study design 
was successful in executing exercise trials that promoted preferential substrate oxidation without 
exceeding the physiological threshold that would promote greater carbohydrate oxidation in the 
FATMAX trial and greater fat oxidation in the OBLA trial.  
The accretion of IMTG is thought to be a factor in the development of insulin resistance 
39.  However, this hypothesis is more specifically focused on the lipid intermediaries (ceramides, 
DAG, Faty acyl-CoA) 40.  The accumulation of these by-products of incomplete FA oxidation 
have been shown to interfere with the insulin signaling cascade of the skeletal muscle. The 
oxidation of IMTG and potentially lipid intermediaries could promote increased insulin 
sensitivity 41-43.  In the current study, we were not able to label and track specific sources of FA 
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being oxidized. Therefore, we cannot be certain as to the contribution of IMTG being utilized 
during the FATMAX trial.  Nonetheless, we did not observe a lower glucose AUC 24 hrs post 
FATMAX exercise, which suggests there was no improvement in insulin sensitivity due to acute 
FATMAX exercise. Conversely, there was a significant increase in glucose AUC post OBLA 
exercise. The sympathoadrenal system is stimulated to a greater degree with higher intensity and 
longer duration exercise. The counter regulator hormones that are responsible for fuel 
mobilization (glucagon, epinephrine, norepinephrine, growth hormone, etc.) are activated, which 
increases glycogenolysis and gluconeogenesis 44,45. A similar study comparing a single bout of 
exercise at 50% and 70% VO2max did not detect significant difference in endogenous glucose 
production 30-minutes post exercise, which would suggest that effect does not extend to 24 hrs 
after exercise 7. However, the sedentary and overweight status of our participants, could explain 
the effects of the acute higher intensity OBLA exercise and the duration its metabolic effects.  
Peak metabolic flexibility (∆RER 0.09±0.04) occurred at 120 minutes post oral glucose, 
but was not significantly improved by FATMAX exercise (0.08±0.04) or OBLA exercise 
(0.07±0.04). The shift in RER was significantly (p<0.05) lower at the 60-minute time point for 
OBLA exercise when compared to baseline (0.01±0.05) (Figure 3.7).  Metabolic inflexibility is a 
common feature of obesity, impaired glucose tolerance, and T2D 46-48.  Metabolic inflexibility is 
also a characteristic of the offspring of type 2 diabetics 39,49, who are at a significantly greater 
risk for future develop of T2D 50.  The current study cohort did not have a positive family history 
of T2D and did not demonstrate metabolic inflexibility at baseline. The negative effect of OBLA 
exercise on metabolic flexibility does appear to be related to impairments in glucose tolerance 60 
minutes post oral glucose (Figure 3.6). Higher resolution techniques (i.e hyperinsulinemic clamp 
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and radioactive labeled glucose) would be helpful in elucidating the mechanism behind this 
phenomenon.  
A primary metabolic stimulus for triggering muscle glucose uptake is glycogen depletion 
51.  The post exercise period of glycogen resynthesis is characterized by the rapid resynthesis 
immediately post exercise and the slower insulin mediated resynthesis.  Kelley et al (1988) 
reported that skeletal muscle takes up ~26% of the glucose load after an OGTT and of that 50% 
is oxidized, 35% is stored as muscle glycogen, and the remaining 15% is released as 
gluconeogenic precursors (lactate, pyruvate, alanine)  52. However, after glycogen depleting 
exercise, muscle glycogen storage can account for up to 40% of total oral glucose uptake 53,54.  
These studies were conducted to maximize glycogen breakdown (2 hours of cycling at ~75% 
VO2max).  The amount of time, 40.0±10.9 min for OBLA compared to the FATMAX exercise 
trial 62.9± 21.9 min, and average intensity 41% vs 68% VO2max likely did not reach the same 
level of glycogen depletion.  Additionally, our sample was sedentary overweight young men, a 
group, that compared to well-trained individuals, has reduced glycogen storage capacity 53. 
Nonetheless, exercise has been shown to increase the partitioning of oral glucose to glycogen 
storage even in the untrained.   
OBLA exercise utilized a greater total amount of CHO (82.8 g) vs. FATMAX exercise 
(62.4 g), suggesting a greater potential level of glycogen depletion. The higher glucose AUC 
during the 24-hour post OBLA exercise OGTT, in combination with reduced oxidation of CHO 
(lower RER), suggests that non-oxidative glucose disposal may be impaired in this cohort.  In 
fact, the post-exercise period in which the OGTT was performed (24 hours post FATMAX or 
OBLA exercise) is considered primarily insulin-mediated.  Therefore, it is reasonable to assume 
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the effect exercise at OBLA in this group does not promote insulin sensitivity in the time frame 
we studied. 
Participants reported feeling significantly less stressed and/or feeling better during the 
FATMAX trial compared to OBLA exercise.  Considering the significantly lower intensity level 
(FATMAX 41±12% and OBLA 68±10%) experience during FATMAX exercise this is not 
surprising. However, this does suggest that this FATMAX intensity exercise provides some 
positive feedback to participants and does not acutely negatively affect glucose metabolism. 
These finding may be particularly relevant for certain populations, such as the population in this 
study (overweight sedentary young men) that are at increased risk for the development of 
cardiovascular disease.  
In conclusion, there appears to be differential effects on glucose tolerance and metabolic 
flexibility in response to a single bout of FATMAX and OBLA exercise. The potential benefits 
of exercise may not manifest until sufficient adaptations have occurred. Another potential 
explanation for the differential response to exercise at FATMAX and OBLA intensity is the time 
course for measurement of oral glucose tolerance and metabolic flexibility. The period after 
exercise (immediately post to 24 hours) is characterized by metabolic responses that make the 
interpretation of health-related outcomes troublesome, therefore the measurements of these 
outcome may require a fuller understanding of the impact and lasting effects of a single bouts of 
exercise.  
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CHAPTER 4: THE IMMEDIATE AND EXTENDED EFFECTS OF INTENSE INTERVAL 
EXERCISE ON METABOLIC FLEXIBILITY AND MITOCHONDRIAL FUNCTION 
 
4.1 Introduction  
Metabolic flexibility (METFLEX) is defined as the ability to switch from predominantly lipid 
oxidation and fatty acid uptake in the fasted state to insulin-stimulated suppression of lipid oxidation and 
high rates of muscle glucose uptake and glycogen synthesis that occurs in the postprandial state 1.  The 
inability to “shift” (Δ respiratory exchange ratio (RER)) metabolism from lipid to glucose oxidation, 
termed metabolic inflexibility, is a characteristic of obesity and T2D 2-4 and is implicated in the 
development of insulin resistance 1,5,6. However, metabolic inflexibility is present prior to the 
development of insulin resistance and fasting hyperglycemia in the offspring of T2D individuals 6-8 and 
remains in previously obese individuals after weight loss 4.  
Metabolic inflexibility is associated with impaired fasting lipid oxidation 3,5,9, which suggests that 
metabolic inflexibility is a reflection of the inability of the mitochondria to switch between fuels.2 Since 
lipid oxidation occurs in the mitochondria, it is logical to deduce that impairments in mitochondrial 
function could alter whole-body lipid oxidation.  Adding clarification to this issue, Ukropcova (2007) and 
van de Weijr (2013) have demonstrated that skeletal muscle mitochondrial function is reduced in 
metabolically inflexible individuals 8,10.  Recent evidence also suggests that the offspring of type 2 
diabetics have impaired METFLEX without the presence of other metabolic risk factors 7.  Moreover, 
individuals with a biological mother that has T2D are at greater risk of developing T2D, when compared 
with a father with a positive history 11,12.  
Continuous moderate to high intensity exercise training (6-12 weeks) has been shown to improve 
insulin sensitivity and metabolic flexibility in obese and type 2 diabetic patients, with greater 
improvements demonstrated with higher intensities 13,14. Interestingly, the time course of glucose 
tolerance and insulin action in response to a single bout of exercise reveals periods of increased insulin 
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sensitivity (immediately post exercise to 3 days) and potential resistance or no improvement (5 to 7 days 
post exercise) 15,16. However, the data regarding improvements due to a single bout of exercise or exercise 
training is more difficult to interpret in the light of the change in body weight (reduction in whole body 
adiposity)2,17-19.  Favorable changes in body composition have significant impact on insulin action and 
METFLEX 2,20,21, thereby complicating the interpretation of the benefits of exercise in the absence of 
weight loss.  
Recent research suggests that 2-6 weeks of high intensity interval training (HIIT) improves 
insulin sensitivity and skeletal muscle oxidative capacity 22,23. However, data regarding changes in 
METFLEX in response to a single bout of high intensity interval exercise (HIIE) are lacking.  Arad et al 
(2015) did not find any differences in fasted or insulin stimulated change in RER after 14-weeks in 
sedentary, premenopausal, African American women when compared to a non-exercising control group 
24. Careful measures were taken to keep body weight stable during this intervention. The design of the 
study was focused on measuring the chronic adaptations to HIIT and therefore, reassessment of insulin 
sensitivity and METLFEX utilizing the hyperinsulinemic-euglycemic clamp method was completed 72 
hours after the final training session.  This study, and others, suggest that the timing and methodology of 
measuring METFLEX and insulin sensitivity should be carefully considered. While the clamp technique 
is considered the “gold standard” for measuring insulin sensitivity the insulin infusion level likely does 
not reflect the ability of endogenously produced insulin to suppress whole body fat oxidation in the 
postprandial state.  
To date there are no studies investigating the time-course of METLFEX in response to a single 
bout of HIIE. Characterizing the immediate and extended response of a single bout of HIIE could provide 
insight into the therapeutic applications of this exercise approach.   The purpose of this study was to 
determine the immediate and extended (48-hr) effects of a bout of high intensity interval exercise prior to 
a mixed meal on METFLEX in men and women. We sought to test the hypothesis that acute HIIE would 
improve METFLEX in men and women. Additionally, we were interested in whether young men and 
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women with a FmHx of T2D, were metabolically inflexible as has been reported in older adults 8,12,25. We 
also sought to measure in vivo mitochondrial function (OXPHOS) by completing a near-infrared 
spectrophotometry (NIRS) protocol. Several studies demonstrate that the adult children of mothers with 
T2D are more likely to develop metabolic inflexibility and that, in part, may be due to the inherited 
mitochondrial dysfunction passed on through the mother’s mitochondrial DNA 8,25-27.  Finally, we aimed 
to determine the effect of a single bout HIIE on METFLEX in FmHx participants.   
4.2 METHODS 
4.2.1 Participants 
 Sixteen apparently healthy, active, normal weight (BMI = 18 to 25 kg/m2) young (age 19 to 25 y) 
men and women with (n=8) and without (n=8) a positive family history of T2D participated in this study.  
A positive family history (FHx) was defined as having a biological mother with T2D.  The control 
participants were considered to have no FHx if both parents and grandparents were free of T2D.  All 
participants reporting being no more than moderately physically active (3 days week of 30 minutes of 
moderate intensity physical activity) and no participant reported engaging in regular HIIE.  Individuals 
with known cardiovascular, T2D, and/or metabolic disorder were excluded from the study.  This study 
was approved by Louisiana State University’s Institutional Review Board. All participants provided 
written informed consent.  
 4.2.2 Experimental Design  
After an initial screening and confirmation of positive or negative FHx eligible participants were 
scheduled to complete a baseline maximal graded exercise test, near-infrared spectrophotometry (NIRS) 
OXPHOS, and mixed meal tolerance test (MMTT) (Figure 4.1). Results from the maximal graded 
exercise test were used to prescribe a single bout of HIIE performed during a separate week and followed 
by a MMTT 1 hour post HIIE (1hrPE). Finally, a follow-up MMTT was performed 48 hours after the 
HIIE day (48hrPE).  
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4.2.3 Experimental Protocol and Measurements 
4.2.3.1 Maximal Graded Exercise Testing (VO2max) 
If participants meet all inclusion/exclusion criteria during the screening visit, a maximal 
cardiorespiratory test (VO2max) on a cycle ergometer (Velotron, Racermate, Inc., Seattle, WA) was 
completed during the baseline visit.  Participants rode at an initial workload of 25 Watts for 4 minutes.  
The workload increased by 25 Watts every 4 minutes until respiratory exchange ratio reached 1.05 after 
which, the workload increased by 25 Watts every 2 minutes until volitional exhaustion.  Throughout the 
test, respiratory gases were analyzed using a metabolic cart (ParvoMedics Inc., Sandy, UT) and fat 
oxidation rates will be determined using stoichiometric equations28.  The watts achieved at the time of 
volitional exhausting was consider 100% watt max.   
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4.2.3.2 NIRS Protocols to Measure Muscle Metabolism (e.g., NIRS mVO2, blood 
flow, and OXPHOS)   
Study participant arrived at laboratory having refrained from exercise 24 hours prior to the study 
visit and having fated overnight. Measurements of subcutaneous adipose tissue and muscle depth were 
collected for the vastus lateralis and vastus medials via use of B-mode ultrasound (LOGIQ e, GE 
Healthcare, Little Chalfont, UK) Participants were positioned on a table rested in the supine position with 
knees slightly flexed.  The NIRS optodes (Oxymon MKIII, Artinis Medical Sytsems) were placed 
longitudinally on the non-dominant vastus lateralis and vastus medialis just anterior to the iliotibial band 
and ~1/3 the distance between the top of the patella and the greater trochanter of the test leg (Figure 4.2).  
The optodes were secured in place with adhesive tape and Velcro strap.  A blood pressure cuff 
(Hokanson, Bellevue WA) was placed proximal to the optode, and connect the cuff to a rapid cuff 
inflation system (Hokanson E20, Bellevue WA) that was controlled using an external controller and 
Labview Software. NIRS signals for oxygenated (O2Hb) deoxygenated (HHb), and total hemoglobin 
(tHb) were continuously monitored by NIRS.  
Resting muscle blood flow was measured in triplicate using venous occlusions by inflating the 
blood pressure cuff to (50-60 mmHg) for 20 seconds with at least 120 seconds between each 
measurement.  Blood flow was measured by calculating the slope of the linear increase total hemoglobin 
(tHb): BF= (((DtHb x 60)/ ((([Hb] x1000)/4))x1000/10 in ml-1•min•100ml-1. Measurements of resting 
muscle oxygen consumption (mVO2) were made in triplicate using arterial occlusions by inflating the 
blood pressure cuff to (250-300 mmHg) for 20 seconds with at least 120 seconds between each 
measurement and were calculated by measuring the linear decrease in O2Hb by the following formula: 
mVO2=Abs(((DO2Hb x 60)/(10 x 1.04)) x 4) x 22.4/1000) in mlO2•min-1100g-1.  
 For measurement of muscle oxidative capacity (NIRS-OXPHOS), participants completed a 7-
second isometric contraction of the vastus lateralis (by knee extension) immediately followed by a series 
of 15-20 arterial occlusions (250-300 mmHg) to measure the rate of recovery of mVO2. The occlusions 
started with a series of 9 occlusions at 5 seconds on and 5 seconds off followed by a series of 11 
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occlusions 10 seconds on 10 seconds off.  This NIRS-OXPHOS protocol was repeat twice with ~5-10 
min between each trial. Recovery mVO2 was calculated for each occlusion and fit to a monoexponential 
function as follows according to Ryan et al (2014): y=(end – delta) x e-kt where y is the relative mVO2 
during the arterial occlusion, end is the mVO22 immediately following the isometric knee extension, delta 
is the change in mVO2 from rest to knee extension, k is the fitting rate constant and t is time29.   Finally, 
we performed an ischemic calibration procedure and calculate mVO2 corrected for blood volume as 
previously described 30, which includes a 15-20 second isometric contraction of the vastus lateralis (by 
knee extension) immediately followed by ~8-10-minute arterial occlusion (250-300 mmHg). According to 
the methods of Ryan et al (2013) Time constants (Tc) functioned as an index of mitochondrial function 31. 
NIRS data was analyzed via a custom written program in MATLAB (Mathworks, Natick, MA).  Muscle 
blood flow and mVO2 were measured 30 minutes prior to and 30 minutes, 60 minutes, and 120 minutes 
after ingestion of the mixed meal.  
 
 
 
Figure 4.2 A.) Longitudinal placement of NIRS optodes on vastus lateralis (VL) and 
vastus medialis (VM). 
VL
VM
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4.2.3.3 Mixed Meal Tolerance Test (MMTT) 
 Prior to the baseline MMTT visits, participants were asked to refrain from exercise, alcohol, and 
caffeine, for 48 hours and were ask to provide a record of food intake the day preceding the test.  The 
morning of the test, participants arrived fasted and provided the food record. Upon arrival  participants 
started a 30-minute rest period. During this time, the participants were provided with a heart rate monitor 
and NIRS probes were attached, as described previously, for measurements of blood flow -30, +30, +60, 
and +120 post mixed meal ingestion.  
After the 30-minute rest period the -30 minute metabolic rate measurement was taken by placing 
a vented canopy system to measure expired O2 and CO2 (ParvoMedics Inc., Sandy, UT) to measure 
resting energy expenditure (REE; Kcal/day) and calculate carbohydrate and fat oxidation rates using 
stoichiometric equation 32.  Exhaled air was continuously measured for 30 minutes pre-mixed meal (-30 to 
0 minutes,) and post meal (+40 to +70 minutes and 110-140 minutes) while the participate remained still 
and refrained from sleeping. The last ten minutes of each collection period was averaged and used to 
report REE, RER, and substrate oxidation rates.  
After completion of the fasted pre-mixed meal metabolic rate measurement, the mixed meal drink 
(Ensure, Abbott laboratories, Lake Forest, Illinois) was prepared by calculating the average REE 
(kcal/day) of the final 10 minutes of the measurement period and dividing by 3. A member of the study 
staff then prepared the meal by measuring the grams of powder and mixing into ~150-200 ml of water. 
Additionally, blood was drawn through an IV catheter immediately before the ingestion of the mixed 
meal and 5, 10, 15, 20, 30, 60, 90, 120, 150, 180 minutes post meal. All procedures for the MMTT, 
including the energy content (kcal) of the mixed meal, were replicated for the immediate and 48-hour post 
exercise visits. 
4.2.3.4 High Intensity Interval Exercise (HIIE) and 48 hr follow-up visit 
 On a separate week from the baseline measurements, participants arrived fasted overnight having 
replicated the diet 24 hours prior to the baseline MMTT. Participants were also asked to refrain from 
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alcohol, caffeine, and vigorous exercise 48 hours prior to the visit.  Upon arrival participants completed 
30 minutes of rest followed by the baseline REE measurement. Participants then completed a 5-minute 
warm-up on the cycle ergometer (Velotron, Racermate, Inc., Seattle, WA) at 50 watts. Immediately after 
the warm-up participants then completed alternating intervals of watts corresponding to 90% of the watts 
achieved at peak oxygen consumption during the VO2max test for 60 seconds followed by 60 seconds at 
30% of the max watts for a total of 20 minutes.  
After completion of the HIIE intervention (1hrPE) participants returned to the resting laboratory 
to rest for 60 minutes, after which fasted blood samples were drawn, the mixed meal was provided and 
sampling proceeded as detailed previously.  Forty-eight hours after the HIIE visit (48hrPE) participants 
returned to the laboratory to complete the final MMTT of the study. Participants were asked to replicate 
their baseline study diet and refrain from alcohol, caffeine and additional exercise between the HIIE visit 
and 48-hour follow up.  
4.2.3.4 Measurement of Metabolic Flexibility and Calculation of Substrate Oxidation 
Metabolic flexibility (METFLEX) was defined primarily as the difference (D) in RER 60 minutes 
post mixed meal ingestion compared the RER at 0 minutes prior to the mixed meal.  Additionally, we will 
define flexibility at the change in rise rate of carbohydrate oxidation and the decrease in rate of fat 
oxidation (Figure 4.3).  REE, carbohydrate (CHO) and fat oxidation rates were calculated utilizing the 
following equations 32.  
1.) REE= ((3.58 x VO2) + (1.448 x VCO2)-0.002)) x 1440 
2.) CHO Ox= (4.55 x VCO2) – (3.21 x VO2) 
3.) Fat Ox=(1.67 x VO2) – (1.67 x VCO2)  
Additionally, we will classify the different phases of METFLEX as the early or “1st phase” which 
was be measured by subtracting the rate of CHO and fat oxidation (mg/kg/min) at the 60-minute time 
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point by the 0 minute time points. 2nd and 3rd phase will represent the latter phases of METFLEX that 
correspond to (60-120 minute) and (120-0 minute) calculations respectively.  
During the 1st phase of a healthy METFLEX response, insulin should mediate the rapid increase 
in CHO oxidation and suppression of fat oxidation (Figure 4.3).  The 2nd is likely to correspond to a 
lower, but still elevated levels of CHO oxidation, whereas fat oxidation should start to approach near 
fasted levels. The 3rd will represent either the residual CHO oxidation and fasted or higher levels of fat 
oxidation.  
 
4.2.3.5 Plasma and Serum Assays 
 Blood samples were collected in Sodium fluoride/Oxalate EDTA tube and immediately placed on 
ice. An additional set of tubes without anticoagulant was used for the collection for serum. The tubes 
were centrifuged at 2000 rpm for 10 minutes thereafter plasma and/or serum were transferred to a plastic 
microtube and frozen at -80 degrees Celsius.  The glucose oxidase technique was used during the MMTT 
via a bedside glucose measurement system (GL5, Analox Instruments LTD. Lunenburg, MA). The 
measurement of plasma insulin was completed with the use of an enzyme linked immunoabsorbance 
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Figure 4.3. Conceptual model of metabolic flexibility based on the rise in carbohydrate oxidation rate and decrease in fat 
oxidation rate. Outward pointing arrows indicate greater metabolic flexibility. Inward pointing arrows reflect decreased 
metabolic flexibility. 
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assay (ELISA) kit (Sigma Aldrich, St. Louis, MO). Serum non-esterified fatty acids (NEFA) were 
quantified by an in vitro enzymatic colormetric assay (Wako chemical, Richmond, VA).  
 4.2.4 Statistical Analysis 
All statistics were performed using JMP statistical software (SAS Institute Inc., Cary, NC).  Data 
analysis will generally follow CONSORT recommendations using General Linear Models and repeated 
measures analysis of variance (RM-ANOVA), co-varied as needed depending on normality distributions 
at baseline. An unpaired t-test will be used to compare between group baseline characteristics. In addition, 
two way RM-ANOVA (exercise session x time point) were used to determine differences in responses in 
both the primary and secondary outcome variables. Significant effects will be further evaluated using 
student’s t-test post-hoc analyses when appropriate.  Data will be reported as mean±SD and differences 
declared at P<0.05. 
4.3 Results  
 4.3.1 Participants  
A list of participant characteristics is presented in table 4.1. Participants were (n=16, 6 males, 10 
females) young (21.2±1.2 y) with normal body weight (22.6±2.6 m/kg2) and physically active (³30 
minutes of moderate intensity exercise).  All participants had normal fasting plasma glucose levels 
(5.4±0.5 mmol/l). 
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 4.3.2 Baseline Measurements 
 4.3.2.1 Maximal Graded Exercise Test 
 Table 4.2 provides the data acquired from the maximal graded exercise test completed on the cycle 
ergometer. There were significant differences between males and females for VO2max, maximum watts 
achieved during the test (Max Watts), however, when watts were expressed as watts/kg there were no 
significant differences between Max Watts.  The prescribed exercise intensity for HIIE was 90% of the Max 
Watts during the work interval and 30% of Max Watts during the recovery interval. There were significant 
differences according to gender at 90% (men= 187.5 ± 30.7 W vs. women 135 ± 21 W; p=.006 ) and at 30% 
(men= 62.5 ± 10.2 vs. women 45 ± 7.0 W; p=.0063). These differences were not significant in terms of 
watts/kg for the 90% and 30% intervals (p=.674 and p=.1759 respectively).  
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4.3.3.2 NIRS OXPHOS  
Mitochondrial function (OXPHOS) was significantly (p=0.03) lower in FmHx participants 
(46.5±25.6 %/s) compared to control participants (28.4±10.3 %/s) (figure 4.4). There were no significant 
associations between OXPHOS and VO2max.  
 
4.3.3.3 Resting Energy Expenditure and Mixed Meal Composition  
  Individual baseline REE was used to determine the content of the mixed meal (table 4.3). There 
were no significant differences in REE and therefore no differences in meal composition.  The mean 
baseline REE was not significantly different between males (1337±234.9 kcal/d) and females 
(1118.2±198.6 kcal/d). CHO, Pro, and Fat intake were similar across all groups.    
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Figure 4.4 Mitochondrial Function measured in control and FmHx participants during baseline 
assessments. *p<0.05. Data are expressed as mean + SEM
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 4.3.2 Metabolic Response to Mixed Meal and HIIE 
 Resting energy expenditure (Figure 4.5) was not different between visits. REE increased (23.3%) 
between the 0 and 60 minute time points. Baseline REE (1241.1±219.1 kcal/d) increased to 1531.1±327.9 
kcal/d (p<0.0001), but returned to a non-significant (p=0.72) rate at 120 minutes (1488.8±338.6 kcal/d).  
During the 1hrPE REE increased (p<0.0001) in a similar manner from 1305.8±224.9 to 1647.7 kcal/d as 
was the case with the 48hrPE visit as well (1330.9±265.3 to 1539.7±373.0 kcal/d; p<0.001). No 
significant interaction between visit and time point were detected.  
 
Table 4.3 Mixed Meal
REE (kcal/d) 1241.2 ± 219.2 1337.7 ± 234.9 1183.2 ± 198.6
Meal (kcal) 412.2 ± 71.5 445.9 ± 78.3 392.0 ± 62.5
Kcal/kg 6.5 ± 0.8 6.3 ± 1.0 6.7 ± 0.8
CHO (g) 54.4 ± 9.4 58.9 ± 10.3 51.8 ± 8.3
Fat (g) 14.4 ± 2.5 15.6 ± 2.7 13.7 ± 2.2
Pro (g) 14.4 ± 2.5 15.6 ± 2.7 13.7 ± 2.2
CHO(g/kg) 0.9 ± 0.1 0.8 ± 0.1 0.9 ± 0.1
Fat(g/kg) 0.2 ± 0.0 0.8 ± 0.1 0.2 ± 0.0
Protein(g/kg) 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
CHO, carbohydrate; Pro, protein. 
Mean±SD
Males (n=8) Females (n=8)Total (n=16) 
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Figure 4.5 REE across time points (0, 60, 120 min) and visits. *<0.001 (0 min vs. 60 
minute). REE, resting energy expenditure. Data are presented as mean ± SD
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 Analysis of the 1st phase ΔRER (ΔRER60-0min) (Figure 4.6)  METFLEX response did not reveal 
any statistical differences between baseline and 1hrPE (p=0.65) and 48hrPE (p=0.31).  There was no 
significant relationship between any visits and the 2nd or 3rd phase shift in RER. There were no significant 
differences detected between groups for the 1st, 2nd, or 3rd phase shift in CHO oxidation during the mixed 
meal tolerance (baseline vs. 1hrPE p=0.09; baseline vs. 48hrPE, p=0.65; 1hrPE vs. 48hrPE, p=0.88) or fat 
oxidation (baseline vs. 1hrPE p=0.91; baseline vs. 48hrPE, p=0.28; 1hrPE vs. 48hrPE, p=0.40).  
	
 
 Fasted CHO oxidation (1.17 ±0.77 mg/kg/min) was not significantly different between any visits 
(1hrPE 0.97±0.69 and 48hrPE 0.87±0.56) CHO oxidation (mg/kg/min) was increased (p<.0001) within 
the baseline trial when transitioning from fasted CHO oxidation to the measured peak at 60 minutes 
(2.23±0.67) and remained elevated (p=0.04) in the 2nd phase and at 120 minutes (p<0.0001) post mixed 
meal ingestion.  Similar differences (p<0.0001) were detected within the 1hrPE and 48hrPE visits to the 
60 minute time point (2.24±0.92 mg/kg/min and 2.11±0.80 mg/kg/min). CHO oxidation rate was not 
different 1hrPE when comparing the 120 minute time point to the 0 minute (fasted) CHO 
Figure 4.6 Baseline METFLEX measured as the difference between RER at 60 subtracted 
from RER at 0 min. RER, respiratory exchange ration (VCO2/VO2). Data are presented as 
mean ± SD
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oxidation,(1.23±0.58 mg/kg/min), indicating that CHO oxidation levels returned to fasted level more 
quickly than baseline and for the 48hrPE trial (1.39±0.62 mg/kg/min; p<0.0001).  
Fasted fat oxidation rate (figure 4.7) at baseline (0.95±0.32 mg/kg/min) was not significantly 
different when compared to the fasted “0 min” measurement during the 1hrPE (1.1±0.32 mg/kg/min) visit 
prior to the HIIE intervention.  Fasted fat oxidation rate was elevated (p=0.049) at the 48hrPE visit 
suggesting a residual increase in fat oxidation due to the HIIE intervention.  
 
 
 There were no differences (figure 4.8) detected when measuring the transition from fasted to 60 
min for the reduction in fat oxidation during this time period. Fat oxidation decreased from fasted rates to 
0.83±.032 and 0.98±0.35 mg/kg/min for the baseline and 1hrPE visit respectively. However, fat oxidation 
rate decreased significantly (p=0.012) within the trial for 48hrPE falling to a rate of 0.94±0.38 
mg/kg/min. The fat oxidation rate during the 48hrPE at 120 minutes (1.31±0.39) remained elevated above 
fasted level (1.31±0.39), but not significantly (p=0.08). The overall METFLEX response for all visit and 
comparisons to between visits is presented in figure 4.9.  
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Figure 4.7  Fasted oxidation rate prior to mixed meal and or exercise for all 
visits. *p<0.05  baseline vs. 48hrPE. Data are presented as mean ± SD
*
	 70	
 
 
 
 
 
Figure 4.8 Decrease in fat oxidation (1st Phase) in response to the mixed meal. BL, 
baseline, 1hrPE, 1 hour post exercise, 48hrPE, 48 hours post exercise.  *p<0.05 
within visit. Data are presented as mean ± SD
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Figure 4.9 METFLEX response for CHO and Fat oxidation alteration at baseline, basline vs. 
1hrPE, baseline vs. 48hrPE, and 1hrPE vs. 48hrPE. Data are presented as mean ± SD
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4.3.3 Plasma and Serum Analysis 
 Fasting plasma glucose was increased (p=0.043) in the 1hrPE (5.9±1.3 mmol/l) visit when 
compared to the baseline visit (5.3±0.5 mmol/l), but not the 48hrPE visit (5.5±0.7 mmol/l; p=0.45).  
Fasting plasma insulin was not different between baseline (10.7±4.3 uUI/ml) and 1hrPE (9.3±3.3 uUI/ml; 
p=0.68) and the 48hrPE (7.9±3.1 uUI/ml; p=0.25) visits or between 1hrPE and the 48hrPE (p=0.73) visits.  
Fasted serum NEFA levels were significantly greater (p=0.006) 1hrPE (1.2±0.2) when compared to 
baseline (0.76 ±0.2 mmol/l). Fasted NEFA levels returned to near baseline fasted levels at 48hrPE (0.74 
±0.3. The time course of plasma glucose (4.10), plasma insulin (4.11), and serum NEFA (4.12) did reveal 
significanty differences for the calculated total area under the curve (4.13A) and insulin (4.13B) across all 
visits. There was no significant difference between time points.  
  
 
  
Figure 4.10 Plasma glucose response across time points and visits. *p<0.05 baseline 
vs. 1hr post-exercise. Data are presented as mean ± SD
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Figure 4.11 Plasma insulin response across time points and visits. Data are presented as mean ±
SD
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Figure 4.12 Serum NEFA response across time points and visits. Data are 
presented as mean ± SD
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4.3.4 Blood Flow Measurements  
 Blood flow measurements (Figure 4.14) were conducted prior to ingestion of the mixed meal 0 
min, 30 minutes, 60 minutes, and 120 minutes after. Blood flow measurement are expressed in terms of 
fold change. Blood flow did not increase to a significant degree during the baseline visit between 0 and 30 
minutes (p=0.72) and at the 60 minute time point (p=0.20), but did increase at the 120 minute time point 
(p=0.04). During 1hrPE visit blood flow increased (p=0.02) at 30 minutes, 60 minutes (p<0.0005), and 
remained nearly significant (p=0.07) at 120 minute post mixed meal. No differences were detected within 
the 48hrPE trial.  Between group analysis revealed an increased fold change during the 1hrPE visit at the 
60 minutes (1.83±0.8, p=0.03) and 120 minute time point (2.0±1.0; p=0.04)) above the corresponding 
fold change during the baseline visit (1.4±1.01) and 48hrPE visit (1.18±0.5; p=0.004).  
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Figure 4.13  A.) Total glucose area under the curve and B.) total insulin area 
under the curve. Data are presented as mean ± SD
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4.3.5 Comparison of Positive Family History Versus No Family History of T2D 
A comparison of the fold change (figure 4.15) in CHO oxidation and fat oxidation during the 
baseline visit revealed differences in the suppression of fat oxidation (0.99±0.08 fold change) at the 60 
minute time point between the control group (0.76±0.08) and FmHx (p=0.926). These differences did not 
extend past to the 120 minute time point for the fold change in fat oxidation. The increase in CHO 
oxidation at the 60 minute mark did not reach statistical significance (p=0.052) in the FmHx group, 
whereas the control group had significantly (p=0.02) increased CHO oxidation at the 60 minutes.  
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Figure 4.14 Blood flow response reported as fold change from 0 min measurement  across visits 
and time points. *p<0.05 within visit increase in blood flow. α p<0.05 between visits, β p<0.005. 
Data are presented as mean ± SD
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Differences were detected (p=0.043) in the ability to suppress fat oxidation in during the 1hrPE 
visit at the 60 minute time point (figure 4.16).  The ability to increase CHO oxidation was improved 
(p<0.0001) at 60 minutes during the 1hr PE visit, with an approximate 4 fold increase in CHO oxidation 
compared to a 2.5 increase at baseline.  The improvement in CHO oxidation during the 1hrPE visit did 
not extended to the ability to suppression fat oxidation during any of the time points for the FmHx group 
during the 1hrPE visit.  However, this effect also manifested itself in the control, whereby, the increase in 
CHO oxidation significantly increased (p<0.0001) without a significant decrease in fat oxidation (60 
minute, p=0.043; 120 minutes, p=0.09).   
During the 48hrPE visit (figure 4.17)FmHx participants nearly significantly increased CHO 
oxidation at 60 minutes (p=0.053) and to similar fold change measured during the BL visit (BL 2.25 vs. 
48hrPE 2.31). The ability to suppress fat oxidation 48 hours post exercise improved from a fold change 
0.99±0.08 to 0.81±0.07. Comparatively, the control group achieved a suppression fold change of 
0.78±.08, which did not differ significantly between groups.    
 
Figure 4.15 Comparison of the fold change in CHO oxidation and fat 
oxidation between control participants those with FmHx. Data are presented 
as mean ± SD
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Figure 4.16 The comparison between baseline and 1hrPE METFLEX response 
within the FmHx group.* p<0.05.  Data are presented as mean ± SD
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Figure 4.17 The comparison between baseline and 48hrPE METFLEX response within 
the FmHx group. *p<0.05. Data are presented as mean ± SD
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4.4 Discussion 
 The purpose of this study was to determine the effect of HIIE on METFLEX immediately after 
exercise (1hrPE) and to measure any extended effects 48 hours after exercise (48hrPE) on METFLEX.  
To establish baseline METFLEX, we implemented a MMTT that was specifically prescribed for the 
individual participants based on one-third of their measured REE. We assessed METFLEX by measuring 
the difference (1st phase) in RER, CHO oxidation, and fat oxidation from the fasted 0-minute time point 
to 60 minutes.  METFLEX was reassessed at the 1hrPE and 48hrPE visits to determine if HIIE 
intervention promoted greater 1st phase METFLEX response. These measurements were conducted to test 
the hypothesis that acute HIIE would increase the 1st phase response immediately post exercise.   
 We sought to understand some of the potential mechanisms and links to metabolic flexibility, 
measuring plasma glucose, plasma insulin, and NEFA in response to the mixed meal to determine to what 
degree glucose tolerance and insulin sensitivity was affected by HIIE.  Additionally, we were interested in 
whether young men and women with a FmHx of T2D were metabolically inflexible as has been reported 
in older adults 8,12,25 and if HIIE improved metabolic flexibility. The primary findings of this study were 
that METFLEX was differentially improved 1hrPE and 48hrPE via increased CHO oxidation and 
increased suppression of fat oxidation respectively. Additionally, we detected significantly reduced 
mitochondrial function in participants with a FmHx of T2D. We also established improved METFLEX in 
FmHx participants in response to HIIE via similar mechanism demonstrated by control participants as 
previously mentioned.   
Metabolic inflexibility is characterized by the inability to increase RER in response to insulin 
stimulation via either oral glucose administration or hyperinsulemic clamp method 2. However, recent 
work has improved our understanding of METFLEX as the inability to partition fuel once it enters the cell 
33-35. It has been suggested that provision of a single macronutrient (glucose) or stimuli does not challenge 
cells to partition fuel and cannot, therefore, assess METFLEX 33,36. Therefore, we chose to provide a 
mixed meal (~412 kcal, 55g CHO, 14g fat, and 14g Pro) to adequately challenge postprandial metabolism 
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with a mixture of macronutrients.  The MMTT is also considered the gold standard test to measure the 
insulin release, which plays an important role in the postprandial response to METFLEX 37,38.  
The metabolic response (figure 4.5) to a mixed meal in our study was evident in the increase in 
REE at the 60-minute time point. The 23% increase in REE is likely due to a couple of factors. The 
thermic effect of digestion increases metabolic rate typically proportionally to the energy consumed 39,40. 
There are also mechanisms involved in the hypothalamus-pituitary-adrendal axis that work to increase 
gastric motility that influence REE 40.  The response to the meal did not reveal any differences between 
study visits (baseline 23% increase, 1hrPE 26% increase, and 48hrPE 15% increase) suggesting 
differences in RER, CHO ox, and fat ox were likely not due to a simple increase REE.  
 We did not detect a difference in the 1st phase shift in RER between baseline METFLEX and 
1hrPE and or 48hrPE visits. The 2nd phase shift in RER (60min-120min) measures the increase in RER 
from the peak. This phase represents the balance of residual increases in CHO oxidation and or fat 
oxidation suppression. Interestingly, the 2nd phase RER response was significantly elevated at the 1hrPE 
visit.  Parsimonious, analysis suggests that the increase in CHO oxidation is the factor that is driving the 
increase in RER during the phase at the 1hrPE visit. There was an increase, albeit not statistically 
significant (p=0.09), in the 2nd phase response at the 1hrPE visit compared to baseline.  
 Exercise at higher intensity (>75% VO2max), in particular intermittent or interval-based exercise, 
alters the relationship of hepatic glucose output (HGO) and glucose uptake in the muscle 41,42.  Typically, 
during steady state exercise HGO meets the demands of the working skeletal muscle, however, during 
very intense exercise HGO typically exceeds the rate of demand 42.  As exercise ceases, glucagon, 
epinerphrine, and norepiphrine remain elevated, which leads to the increase in HGO and resulting 
hyperglycemia42-44.  Elevated glucose levels in healthy people increase insulin levels in order return to 
euglycemia. Insulin, in this scenario, will promote glucose uptake, oxidation, and storage to varying 
degrees 45.  
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 In the current study, we identified a significant increase in plasma glucose 1 hour post HIIE when 
compared to baseline and 48hrPE visits.  The increase in plasma glucose concentration is a likely 
mechanism to promote the oxidation of glucose in addition to the carbohydrate ingested as a part of the 
mixed meal. The fact that fasted insulin levels were not increased significantly prior to the mixed meal, 
during the 1hrPE visit, may be due to the fact that blood was not taken until immediately before the mixed 
meal was given (60 minutes after HIEE).  This point is supported by a study conducted by Marliss et al 
(2002), whereby insulin levels had returned to fasted levels 60 minutes after a 40-minute bout of 
moderate intensity exercise and return to baseline within 20 minutes after a 15-minute bout of exercise at 
87% VO2max42. 
 Glucose AUC was not different between baseline, 1hrPE, and 48hrPE visits.  Insulin AUC was 
also not affected by the HIIE at 1hrPE or 48hrPE visits. In current, young healthy cohort, reports of a lack 
of improvement in glucose tolerance not entirely surprising. Several studies have indicated with mixed 
meal feeding a lack of effect in terms of glucose tolerance and insulin sensitivity in response to various 
intensities of exercise 46-50.  Potentially, the benefit of utilizing the mixed meal to measure metabolic 
flexibility may not be optimal for testing glucose tolerance and therefore, may indicate the two are not as 
closely related as previously thought 51.  
 An interesting finding of our study was the increase in resting-fasting fat oxidation rate 
(mg/kg/min) at the 48hrPE visit.  Important to note, REE was not elevated at 48hrPE visit.  The lasting 
effect of post-exercise oxygen consumption (EPOC) is due to many factors (fitness level, intensity and 
duration of exercise) 52-55, however, in most cases the effect an exercise bout on has REE has diminished 
within 24 hours.  The specific increase in fat oxidation as a result of HIIE is of interest and coincides with 
existing literature that demonstrates increased skeletal muscle mitochondrial enzyme levels after 2-6 
weeks of HIIE training 23,56.  While there is a paucity of data regarding the effects of a single bout of 
HIIE, a study conducted by Little et al (2011) demonstrated that a single bout of HIIE (4x30s maximum 
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effort or ~500% peak power) increased mitochondrial biogenesis via the increase in the nuclear 
abundance of PGC1-a 57.  
 The HIIE protocol utilized in the aforementioned study by Little et al (2011) was a wingate-based 
model. The demands (specialized equipment, hard to tolerate, unsafe for some individuals) of the 
wingate-based model reduced its practicality and applicability. The HIIE protocol utilized in the current 
study (60s at 90% Wmax followed by 60s at 30%Wmax x 10) was also developed in the lab of Martin 
Gibala and Jonathan Little and is referred to as the “practical model”. Interestingly, similar mitochondrial 
adaptations have been shown using this protocol in 2 weeks of training 22. The results of the current study 
may potentially provide physiological evidence that some mitochondrial adaptations occur within 48 
hours of a single bout practical model HIIE.  
 The increase in fasting fat oxidation rate at 48hrPE also corresponded to a significant suppression 
in fat oxidation rate after ingesting the mixed meal during the 1st phase METFLEX response. An 
important function of insulin is the suppression of lipolysis and fat oxidation in the postprandial period 
36,51,58.  Fat oxidation rate decreased significantly at the 48hrPE visit (~26% reduction), whereas, similar 
levels of suppression were not measured at baseline  (10% reduction) or during 1hrPE visit (~12% 
reduction).  This phenomenon was not robust enough to significantly increase RER during 1st phase 
METFLEX, however, it does emphasis an important component of METFLEX in altering the balance of 
increasing CHO oxidation and decreasing fat oxidation in the postprandial period.    
 The levels of NEFA in the blood stream reflects the balance of lipolysis systemically. 1hrPE 
fasted serum NEFA levels were significantly elevated when compared to baseline and 48hrPE. As was the 
case with HGO, the hormones epinephrine, growth hormone, and hormone sensitive lipase are secreted in 
an intensity-dependent manner 59-61.  Therefore, it is expected that NEFA levels would be elevated after 
one hour HIIE.  Increasing NEFA levels has been experimentally shown to induce metabolic inflexibility 
in lean sedentary individuals and lean endurance trained individuals by reducing CHO oxidation 62. 
However, the lean endurance- trained participants increased non-oxidative glucose disposal (i.e. glycogen 
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storage) in response to the lipid infusion. These results were linked to the superior mitochondrial 
performance measured in the endurance-trained compared to the sedentary participants.  
 In the current study, the increased NEFA levels did not reveal any impairment in the ability to 
increase CHO oxidation. Although we did not purposely maintain elevated NEFA levels, as did the 
previous study, we simply demonstrated an intact mechanism for insulin to reduce lipolysis and lower fat 
oxidation in the postprandial period. An intriguing mechanism that has emerged from these data involves 
increased fasting fat oxidation as an integral component to improve the function of insulin to increase 
CHO oxidation and suppress fat oxidation. This is not a trivial finding,  as elevated NEFA have been 
shown to inhibit insulin action and glucose transport in the skeletal muscle. 58 63 
 Impaired postprandial blood flow is considered a potential factor in the actions of insulin and 
control of glucose levels 64,65. Additionally, metabolic syndrome is often associated with a reduced 
sensitivity to beta-adernergic stimulation thereby reducing blood flow to the skeletal muscle and adipose 
tissue 66. METFLEX is potentially affected by blood flow alterations in the postprandial period 
considering that a large amount of glucose will be oxidized in the skeletal muscle.  Utilizing NIRS (figure 
4.14) we measured the change in blood flow during the MMTT at baseline, 1hrPE, and 48hrPE.  
Significant increases were measured 120 minutes after ingestion of the mixed meal during the baseline 
visit. Blood flow increased 1.3, 1.5, and 1.7-fold 30 minutes, 60 minutes, and 120 minutes post mixed 
meal during the 1hrPE visit. The increases in blood flow were greater than the comparative changes at 60 
minutes during baseline. The changes in blood flow were also evident at 120 minutes 1hrPE when 
compared to 48hrPE.  These finding demonstrate the HIIE is effective at increasing blood flow 
postprandially.  
 A secondary aim of this study was to investigate whether young participants with a FmHx of T2D 
were metabolically inflexible and had reduced mitochondrial function, as has been reported in older 
adults 7,8, and if HIIE improved METFLEX. Baseline mitochondrial function (figure 4.4) was 
significantly lower in FmHx participants when compared to controls. Reduced mitochondrial function is 
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frequently demonstrated as a potential component of metabolic inflexibility and insulin resistance 25,67,68. 
In our study control participants and FmHx particiapants were matched BMI, activity level, and fitness 
(VO2max) all of which may have be closely related to mitochondrial function.  These results indicate that 
mitochondrial dysfunction may play a role in the early manifestation of metabolic inflexibility without the 
presence of insulin resistance or increase adiposity.  
There were no detected interactions between FmHx and the 1st phase RER, CHO oxidation, and 
fat oxidation METFLEX response, however, there were differences within each visit that were not 
detected in our control group.  At baseline FmHx did not significantly reduce fat oxidation (fold change) 
(Figure 4.15) in the 1st phase (60-0 min) and the capacity to increase CHO did not reach statistical 
significance (p=0.052).  1hrPE (Figure 4.16) FmHx significantly increased CHO oxidation during the 1st 
phase, however, fat oxidation suppression was unaltered.  This phenomenon appears to be a uniform 
response across groups. The robust increase in CHO oxidation during the 1hrPE visit suggests the effect 
exercise persists at least 2 hours post-HIIE. Additionally, the reduced suppression in fat oxidation in the 
1st phase during the 1hrPE visit may be due to the increased flux of fatty acids during that time point, and 
under such circumstances would dictate great fat oxidation.   
 During the 48hrPE (Figure 4.17) visit there was a significant improvement in 1st phase fat 
oxidation suppression which was not present during the baseline visit or 1hrPE visit. Importantly, this 
degree of fat oxidation suppression was similar the control group.  There was a difference in the resting 
fat oxidation between controls (1.23±0.3 g/min) and FmHx group (1.8±g/min) at the 48hrPE visit.   The 
relationship may point to a relationship between the actions of insulin and rate of fat oxidation.  
 This study was limited in terms of the ability to determine the rate of HGO as a factor in glucose 
tolerance and or the METFLEX response to exercise. Aside from its role in increasing CHO oxidation, 
glycogen storage, and fat suppression insulin also works to reduce HGO. Understanding the role of the 
liver in METFLEX is a potentially critical component that we were not able to elucidate.  Another 
limitation of this study was the inability to assess the level of glycogen depletion during HIIE and to 
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determine if the METFLEX response was associated with the degree of depletion. The rate of glycogen 
storage is a primary determinant for METFLEX 36,51,62 and insulin sensitivity 69,70.  The determination of 
factors involving the time frame of glycogen resynthesis after exercise and in the day after hold 
considerable potential.  The amount of calories and carbohydrate in the mixed meal may have been 
another potential limitation. It is possible that a greater total amount may have produced a response that 
could be evaluate under the influence of exercise.  
 In conclusion, the immediate effects (1 hour) of HIIE on METFLEX are primarily directed on the 
increase in carbohydrate oxidation and blood flow in response to a mixed meal.  The extended effects (48 
hours) appear to work via fat oxidation or mitochondrial mechanisms by increasing resting fat oxidation 
rate and improving the suppression of fat oxidation in response to a mixed meal.  The lack of difference in 
RER under these conditions demonstrates the need to assess the alteration in fuel oxidation, whereas RER 
does reflect the balance of CHO and fat oxidation it does not identify the influencing factor.  Finally, 
HIIE improved METLFEX in participants with a FmHx of T2D, that demonstrated metabolic inflexibility 
and reduced mitochondrial function, by improving the suppression of fat oxidation in the postprandial 
period.  
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CHAPTER 5. CONCLUSION 
 
The purpose of this dissertation was study the time-course of diet and exercise and its effects on 
METFLEX. Three studies were conducted to investigate molecular and clinical aspects of diet and 
exercise and how these stimuli may alter the metabolic response to fuel. These include work using both 
animal models and human participants. Additionally, we sought to understand the METFLEX response in 
individuals with FmHx of T2D and to determine the effects of exercise in the group. The first study was 
conducted on obesity-prone, Osborne-Mendel (OM) and obesity-resistant S5B/Pl (S5B) rats. This 
experiment investigated inherent differences in energy expenditure (EE), metabolic rate, MF and skeletal 
muscle markers of metabolism, lipid storage and lipid oxidation between OM and S5B, as well as HFD-
induced strain differences in these parameters.  The consumption of a HFD in S5B rats increased 
metabolic rate and EE and decreased metabolic rate and EE in OM rats. These strain differences were not 
due to the differences in activity or food intake.  These results suggest that HFD-induced differences in 
metabolic rate and EE may be mediated by HFD-induced differences in pAMPK and PPARγ expression 
and lipid accumulation in the gastrocnemius muscle of OM and S5B rats. 
 The second study was designed to investigate the effect of acute aerobic exercise at an intensity 
that maximizes the rate of fat oxidation (FATMAX) on glucose tolerance, insulin action, and METFLEX 
compared to acute aerobic exercise at the onset of blood lactate accumulation (OBLA) resulting in greater 
carbohydrate (CHO) oxidation. OBLA exercise appears to have deleterious effects on oral glucose 
tolerance and metabolic flexibility acutely, however, FATMAX exercise does not confer improved MF. 
These results suggest that predominate substrate utilization does not promote improved glucose tolerance 
and metabolic flexibility in young overweight men. 
 The third and final study of this dissertation was designed to investigate the immediate and 
extended of a single bout of high intensity interval exercise (HIIE) on METFLEX and mitochondrial 
function. In study 3, participants were recruited with a family history (FmHx) of T2D (n=8) and without a 
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family history of T2D (n=8).  Participants completed baseline (no previous exercise) mixed tolerance tests 
(MMTT) to assess MF. On a separate week participants completed a single bout of HIIE follow by an 
immediate (1 hour later) MMTT and follow-up MMTT (48 hours later) MMTT. The immediate effects (1 
hour) of HIIE on METFLEX are primarily directed on the increase in carbohydrate oxidation and blood 
flow in response to a mixed meal.  The extended effects (48 hours) work via the reduction fat oxidation 
by increasing resting fat oxidation rate and improving the suppression of fat oxidation in response to a 
mixed meal.  Particiapants with a FmHx of T2D demonstrated reduced mitochondrial function and some 
impairments in metabolic flexibility. HIIE improved METFLEX in a similar time course and mechanism 
as mentioned previously.  
 In summary, the potential benefits of exercise may be contained within a certain time frame after 
the completion of exercise. The degree to which exercise perturbs metabolism often dictates the length of 
the response and therein the benefits of exercise on health. The susceptibility to develop metabolic 
inflexibility appears to be linked to mitochondrial dysfunction. The early manifestation of this 
phenomenon in our cohort demonstrates the important role that mitochondrial metabolism plays in the 
pathogenesis of metabolic inflexibility.  The extend and duration to which exercise improves 
mitochondrial function will be of considerable importance in the future study of metabolic health.  
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Introduction 
 
 Inflammation is a fundamental component of a living organism’s response to noxious or 
infectious stimuli.  The immune system is comprised of specialized organs (thymus, bone marrow, lymph 
nodes, etc.) and cells (T cells, B cells, macrophages) and responds to eliminate an invading parasite, virus, 
or bacteria from the host. In some cases, the host’s initial innate barriers are overwhelmed and infection 
can occur.  In order to defend against these pathogens the host’s immune system works to increase 
inflammation in order to isolate and kill the pathogen by recruiting specific immune cells. If inflammation 
persists, the physiological function of the affected tissue can be destroyed 1 . Chronic inflammation is 
linked to many costly chronic conditions such as obesity, type 2 diabetes (T2D), and cardiovascular 
disease 2-4. In fact, some suggest that chronic inflammation plays a major role in the development of 
obesity and insulin resistance 5,6. 
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 Obesity is a chronic disease characterized by impaired energy balance, which favors the 
accumulation and expansion of adipose tissue during periods sustained energy excess.  The global 
prevalence of obesity has doubled from 1980 to 2008. According to the world health organization (WHO) 
205 million men and 297 million women over the age of 20 are obese (BMI >30 kg/m2) 7.  Obesity is not 
only strongly correlated with T2D, this disease is considered to be a primary driver in the development 
T2D.  T2D is a chronic disease that occurs due to lack of insulin production by the pancreas or the 
inability to utilize the insulin produced in the periphery.  The global prevalence in 2000 was estimated to 
be 2.8% for all age groups 8. The 2030 models predict that 4.4% of global population will have T2D.  
These reports suggest that the T2D epidemic will continue even if obesity levels remain consistent 8-10.  
 Decreasing amounts of physical activity and exercise have coincided with the increasing 
rates of obesity and T2D 11.  Currently, 50% of US adults do not meet the recommended 
guidelines for weekly physical activity and 25% report no regular physical activity 
(cdc.gov/nccdphop/dnpa/physical). The relationship of physical inactivity and increased 
morbidity and mortality rates is indisputable and physical inactivity is a major risk factor for the 
development of a cluster of metabolic disorders (obesity, insulin resistance, dyslipidemia, and 
hypertension) called metabolic syndrome 12-15. Moreover, structured exercise programs can 
significantly slow the development and progression of these diseases 16-18. In this review, I will 
explore the mechanism of chronic inflammation initiated by metabolic dysfunction and how 
skeletal muscle can mediate the anti-inflammatory effects of exercise.  
Obesity and Type 2 Diabetes 
 The expansion of adipose tissue is the defining characteristic of obesity. For many years, 
adipose tissue was thought to be an inert tissue that simply served as storage site for triglycerides 
19. The discovery of leptin, a fat derived hormone, demonstrates that adipose tissue plays a role 
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in systemic metabolism by producing hormones that have downstream effects on the liver and 
skeletal muscle. Serum leptin levels positively correlate with increases in body fat 20 and in vitro 
research demonstrated that leptin plays a direct role in skeletal muscle fatty acid metabolism 9. 
The obesity related reductions in leptin production, are thought to contribute to the development 
of skeletal muscle insulin resistance 10.  
 Skeletal muscle insulin resistance is argued to be the primary defect in T2D 21. In 
humans, under euglycemic hyperinsulinemic conditions approximately 80% of glucose uptake 
occurs in the skeletal muscle 22. In the skeletal muscle of healthy individuals, glucose that enters 
the cell is rapidly converted to glycogen or oxidized into carbon dioxide and water.  The natural 
progression from insulin resistance to frank T2D is characterized by inability to convert glucose 
to glycogen.  Like obesity, there are many contributing factors to the development of insulin 
resistance.  Obesity itself significantly increases the risk of becoming insulin resistant.  However, 
there is a cohort of individuals that are not classified as obese or overweight that demonstrate 
insulin resistance. These lean individuals demonstrate impaired insulin mediated glucose 
disposal in skeletal muscle and are likely to develop T2D if the condition persists23.  
 Histological analysis of obese adipose tissue demonstrates an increase in the presence of 
inflammatory cytokine producing macrophages 2,24.  In the skeletal muscle of type 2 diabetics, 
there is increased concentration of inflammatory cytokines, particularly tumor necrosis factor 
alpha (TNF-α).  Elevated systemic markers of inflammation, such as C-reactive protein (CRP), 
accompany the local inflammation present in adipose and skeletal muscle during metabolic 
dysfunction 1,25-27.  This evidence demonstrates that the metabolic and immune systems are 
closely linked in disease progression.  
	 99 
Exercise and Chronic Inflammation 
 Regular exercise reduces levels of chronic inflammatory markers (1) and also promotes 
both pro and anti-inflammatory responses within the skeletal muscle (8).  The type and intensity 
of exercise appears to modulate the balance between the two responses.  Exercise has been 
shown to be an effective treatment for obesity and T2D 18. In addition exercise also has anti-
inflammatory qualities that promote metabolic health 28-30 
 The mechanism responsible for anti-inflammatory effects of exercise remains 
controversial. On a gross level, exercise induces hormonal fluctuations that have effects on 
immune function (23, 9).  Exercise reduces chronic inflammation, in part, by the production of 
muscular derived IL-6, which then stimulates the release of anti-inflammatory cytokines (IL-1rα 
and IL-10) and a beneficial reduction CRP 31. Additionally, exercise is efficacious at reducing 
chronic inflammation, even without the loss in body fat 32.  However, the mechanisms associated 
with this positive effect are unclear. In this portion of the review, I will provide a more in depth 
examination of chronic inflammation. 
Acute vs. Chronic inflammation: 
 Inflammation is the response mounted by the immune system characterized by the 
recruitment of leukocytes to areas of the body that have been damaged or infected by foreign 
pathogens 33. Initially, recognition of infection is modulated by tissue resident macrophages and 
mast cells. These immune cells secrete inflammatory cytokines, chemokines, and lipid molecules 
that dictate the inflammatory response.  Inflammatory cytokines act in countless ways 
throughout the body.  For example, during an acute infection, the inflammatory cytokines TNF-α 
and interleukin-1 (IL-1) work to increase the vascular permeability of the affected tissue and to 
increase the activation of vascular adhesion molecules, such as vascular cell adhesion molecule-1 
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(VCAM-1).  Circulating neutrophils and monocytes gain access to the inflamed tissue via 
interaction with their cell surface receptors for VCAM-1. Once inside the inflamed tissue these 
innate immune cells attempt to eliminate the foreign pathogen by their own effector function and 
in conjunction with the activation of the adaptive immune system 33 .  
 If the source of the inflammation (exogenous) is eliminated by an effective immune 
response then levels of inflammation will subside.  A classical inflammatory response is 
necessary for host defense. Physical injury of a tissue is also a potent activator of the 
inflammatory response and is necessary to initiate tissue repair. Prolonged periods of tissue 
dysfunction or stress also represent an inflammatory trigger.  This inflammatory response is the 
host’s response to restore the organ to balance 34. However, in chronic conditions such as obesity 
and T2D, the prolonged inflammation can eventually destroy normal physiological function of 
metabolically active tissues 1. 
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Pro- and Anti-inflammatory cytokines 
 Cytokines are soluble glycoproteins that aid in communication between both immune and 
non-immune cells and act to mediate inflammation 35. The benefits of regular exercise are 
believed to be modulated via the reduced production of inflammatory cytokines and or lowered 
expression of toll-like receptors (TLR) on monocytes and macrophages 36.  The pro- or anti-
inflammatory effects of a cytokine depend on the environment in which it is activated, the cell 
type from which secreted, and the specific cell-signaling cascade utilized 33,37,38.  
Tumor Necrosis Factor-Alpha (TNF-α)   
 Tumor necrosis factor-alpha TNF-α is a 212 amino acid cytokine produced as a 
transmembrane (mTNFα) and soluble (sTNF-α) factor mainly by monocytes and macrophages. 
TNF- α is considered a pro-inflammatory cytokine because it is released in response to 
lipopolysaccharide, which is the product of gram-negative bacteria in order to induce the acute 
phase response. TNF-α acts throughout the body in many different ways. During an 
inflammatory response the increased concentration of TNF-α acts to recruit additional monocytes 
and neutrophils to the affected area. TNF-α is associated with a number of acute and chronic 
conditions.  Septic shock is an acute life-threatening condition whereby mass amounts of TNF-α 
are released into the blood stream causing systemic vasodilation resulting in death. Chronically 
elevated levels of TNF-α is also associated with muscle wasting conditions 39. 
 Hotamasligil and colleges 6 were the first to report the metabolic link between obesity-
induced insulin resistance and TNF-α. This initial observation was followed by a series of 
experiments that demonstrated that adipose tissue of obese diabetic mice had increased 
expression of TNF- α 40,41.  The specific function of TNF-α was then studied by generating a 
TNF-α knockout mouse model (TNF-α-/-) that was fed a high fat diet (HFD) to induce obesity 
	 102	
and glucose intolerance 42,43. These high fat fed TNF-α-/- mice did not demonstrate the same 
degree of glucose intolerance when compared to obese wild type mice (with the intact TNF-α 
gene). The TNF-α-/-  animals were not protected from developing obesity and still demonstrated 
some glucose intolerance, albeit greater than wild type mice, suggesting that TNF-α is not solely 
responsible for the development of obesity-related insulin resistance.  
 In humans, serum concentrations of TNF-α and sTNF-α receptors levels have been 
shown to be elevated in obesity 44,45. These effects have also been observed within the adipose 
tissue itself.  For example, TNF-α mRNA content was measured in the adipose tissue of obese 
premenopausal women before and after weight loss 25. When compared to lean controls, obese 
women had significantly increased TNF-α mRNA and protein from adipose and secretion from 
adipose. Adipose tissue TNF-α mRNA was also significantly correlated with plasma insulin 
(r=0.82, P<0.001), glucose (r=0.031, P=0.06), and triglycerides (r=0.40, P=0.02). After diet 
induced weight loss both adipose tissue TNF-α mRNA and plasma insulin concentrations were 
reduced. However, the weight loss period failed to induce a significant reduction in the 
circulating levels of TNF-α 25. Consequently, some have suggested that TNF-α may act in a 
paracrine-autocrine manner, as opposed to an endocrine manner, on nearby by tissues.  
 In vitro and in vivo data suggest that TNF-α can induce insulin resistance by reducing the 
expression of key molecules involved in the insulin-signaling cascade 46,47. Specifically, obese 
mice with intact TNF-α signaling have decreased muscle glucose transporter type-4 (GLUT4), 
insulin receptor substrate-1 (IRS-1), and insulin receptor phosphorylation.  Insulin receptor 
phosphorylation is restored to significant degree when TNF-α function is ablated 42.  However, 
Stephens et al (1997) studied the effects of prolonged TNF-α exposure (96 hrs) on 3T3-L1 
adipocytes and demonstrated no impairment in GLUT4 translocation to the plasma membrane. 
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Rather, the transcriptional activity of GLUT4 and IRS-1 were inhibited which reduced the total 
available protein 47 .  Given these findings, it is apparent that TNF-α can induce insulin 
resistance by inhibiting the transcription factors responsible for the synthesis of insulin signaling 
intermediaries.  
 Although glucose transport into adipose is an important physiological phenomenon, it 
pales in comparison to the role that skeletal muscle plays in glucose disposal. In fact, there is a 
50% reduction in skeletal muscle glucose uptake during the last hour of insulin clamp studies in 
diabetic subjects 48.  Saghizadeh et al (1990) demonstrated that expression of TNF-α, in skeletal 
muscle, was increased by four fold in insulin resistant and diabetic subjects compared with 
insulin sensitive subjects 45. Using a hyperinsulinemic euglycemic clamp technique these 
researchers were able to show that, in insulin sensitive subjects, there was a significant inverse 
linear relationship between glucose disposal rate and muscle TNF-α 45.  
 The key substrates involved in the skeletal muscle insulin-signaling pathway appear to be 
altered by elevated TNF-α. In healthy humans, TNF-α infusion induces insulin resistance in 
skeletal muscle by increasing the phosphorylation of p70 S6 kinase, extracellular signal-related 
kines-1/2, and c-Jun NH2-terminal kinase in addition to increased serine and reduced tyrosine 
phosphorylation of IRS-1 46. TNF-α also promotes insulin resistance by altering skeletal muscle 
fatty acid oxidation by suppression of activated AMP-kinease (AMPK) activity through TNFR1 
signaling 49.  Suppression of fatty acid oxidation in skeletal muscle causes the accumulation of 
fatty acid intermediaries (DAG, acyl co-A, ceramides) 50,51. These bioactive molecules can 
activate the serine/threonine kinase cascade and lead to disruption of proper insulin signaling51-
54.  
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Interleukin-6 (IL-6) 
IL-6 is a pleiotropic cytokine, primarily synthesized by monocytes/macrophages, 
endothelial cells, and fibroblasts that serves both pro-and anti-inflammatory functions throughout 
the body and plays a significant role during infection or illness 55. IL-6 is pivotal in the synthesis 
of acute phase proteins that are released in an effort to restore homeostasis to the infected/injured 
tissue/organ 56. IL-6 also promotes inflammation through the proliferation and activation of T 
cells and the differentiation of B cells 33 .  
IL-6 signals through the IL-6 receptor complex consisting of IL-6R (80 kDa) and 130 
kDa glycoprotein gp130 which acts as a signal transducer 57. Once binding occurs between IL-6 
and gp130 a Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) 
signaling cascade is initiated 38,58. Additionally, IL-6 possesses a soluble receptor that binds to 
IL-6 in circulation to form an IL-6/sIL-6R complex extending the half-life of IL-6 59. This 
complex can activate the JAK/STAT pathway through membrane bound gp130. The improved 
stability and intact functional capability allows IL-6 to interact with many different cell types 59. 
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Elevated IL-6 concentrations are commonly associated with increased risk of T2D, 
obesity, atherosclerosis, hyperinsulinemia, and low HDL-Cholesterol 60-62. When dietary 
measures are taken to reduce body fat there is a reduction in circulating IL-6 63. Until recently, 
the mechanisms related to IL-6 production and the progression of obesity induced insulin 
resistance has been speculative and dependent on the tissue of study.  In vitro studies 
demonstrate that adipocytes 64,65 and hepatocytes 66become insulin resistance when cultured with 
IL-6. Additionally, Klover et al (2003) demonstrated that chronic infusion of IL-6 similar to 
levels observed during obesity induced hepatic insulin resistance in mice67.  
 Priceman et al (2013) recently determined that IL-6 signaling through STAT3 in the T 
helper 1 (TH1) and regulatory T cells (T regs) cells that reside within visceral adipose depots was 
essential in diet-induced obesity (DIO) induced insulin resistance.  The results of this study 
demonstrated that STAT3 was elevated in obese visceral adipose tissue (VAT) and in VAT T 
cells.  Ablation of STAT3 in T cells reduced VAT inflammation, DIO and improved insulin 
sensitive and glucose tolerance.  Interestingly, loss of STAT3 signaling shifted the VAT resident 
macrophage population from M1 classically activated to M2 alternatively activated 68.  
  Circulating concentrations of IL-6 are directly related to increased concentrations of 
CRP, which suggest its involvement in the acute phase response. During an infection IL-6, is 
released primarily from monocytes and macrophages to target hepatocytes to release CRP 56,69. 
CRP is one of the strongest predictors of cardiovascular events and is thought to play a direct 
role in the development of atherosclerotic lesions 70,71.  The relationship of IL-6 and CRP and the 
overwhelming evidence that increased adiposity contributes to elevated serum IL-6 demonstrate 
that metabolic dysregulation can perturb the immune system to cause chronic systemic 
inflammation.   
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Anti-inflammatory Cytokines:  
 During an inflammatory response, pro-inflammatory cytokines increase the circulating 
number of lymphocytes, monocytes, and granulocytes. Once the inflammatory cascade is set into 
motion the compensatory anti-inflammatory response is initiated via the production of anti-
inflammatory cytokines 37.  IL-10 is an anti-inflammatory cytokine produced by cells of both the 
innate and adaptive immune system 72. The primary producers of IL-10 are T helper 2 cells (TH2) 
cells and M2 macrophages. IL-10 acts to regulate and, in many cases, diminish the inflammatory 
response initiated by myeloid and lymphoid cells.  Genetic deficiencies in IL-10 are commonly 
associated inflammatory disease such as systemic lupus erythromatosis, inflammatory bowel 
disease and bechet’s disease73-75.   Additionally, IL-10 knockout mice reportedly demonstrate 
chronic enterocolitis 76. These data clearly demonstrate that IL-10 is necessary to promote 
tolerance meditated through an appropriate TH2 cell response 73-75,77.    
 Low circulating levels of IL-10 are associated with obesity and metabolic syndrome in 
humans 78.  The mechanism of IL-10 release from T cells and M2 macrophages works to 
downregulate the chronic inflammatory response that is potentiated by the adaptive immune 
system 77. IL-10 reduces the secretion of IL-12 and TNF-α from macrophages and dendritic cells 
in order to reduce inflammation.  Reductions in IL-12 cause the downregulation of MHC II-
peptide presentation on antigen presenting cells (APCs) and the reduction of the co-stimulatory 
molecules CD80 and CD86 79.   
In murine models muscle specific overexpression of IL-10 prevents lipid induced insulin 
resistance [80]. Increased IL-10 expression in skeletal muscle increases circulating systemic 
levels, but was not associated with decreased weight gain compared to wild type mice fed a 
HFD[81].  The overexpression of IL-10 significantly increases glucose infusion rate, whole-body 
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glucose turnover, and skeletal muscle glucose uptake in both chow and HFD fed animals 
compared to wild type.  Immunohistochemical analysis demonstrates that greater expression of 
IL-10 decreases the infiltration of CD68, F4/80, and total macrophage infiltration in skeletal 
muscle. Muscle IL-10 transgenic mice prevented macrophage infiltration by reducing the 
expression of macrophage recruiters CCR2 and MCP-1. It is apparent that IL-10 regulates the 
inflammatory response by modulating the intracellular signaling molecules of macrophages and 
resident tissues. 
 The nuclear factor kappa-B (NF-κB) pathway is an essential pathway that mediates 
inflammatory responses 80. IL-10 binding with its receptor (IL-10r) inhibits the NF-κB pathway 
in macrophages and that prevents release of interferon-Υ, (INF-γ), IL-2, interleukin-3 (IL-3), 
TNF-α and granulocyte macrophage colony stimulating factor (GM-CSF) 81,82.  The transcription 
regulation of IL-10 is controlled by the gene regulators GATA3, E4BP4, and to a lesser degree 
MAF 81. In a similar fashion to IL-6, IL-10 binds its receptor and initiating the JAK/STAT 
signaling pathway by phosphorylating the tyroinse kinases JAK2 and Tyk2, which then 
phosphorylate and activates STAT1, STAT2, STAT3, and STAT5 82.   
Interleukin-1 receptor antagonist (IL-1ra) is anti-inflammatory cytokine that binds IL-1 
and IL-1β receptors 83. As a result the activity of IL-1 and IL-1β are significantly reduced.  In 
terms of systemic chronic inflammation, IL-1ra appears to play a role in blocking IL-1β which 
plays a primary role in the inflammatory macrophage-adipocyte cross talk 84.  IL-1ra is often 
referred to as a soluble factor and not an active cytokine per se. IL-1ra was originally called IL-1 
inhibitor because it blocks the ability of IL-1 to stimulate synovial PGE2 inflammatory response 
85. In vitro, IL-1ra binds to T cells and fibroblast at the same infinity as IL-1. Remarkably, this 
binding does not induce any of the agonist activity of IL-186.  
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Many of the negative metabolic consequences that arise from systemic chronic 
inflammation are associated with elevated levels of TNF-α. TNF-α binding with its receptors 
TNF receptor I and II (TNFRI) works to increase the inflammatory response 41. Under certain 
circumstances the ectodomain of the 55-kda transmembrane TNFRI can be proteolytically 
cleaved or remain intact packed into exosomes to be released as a functioning soluble receptor 
(sTNFRI) 87.  Cells of the immune system will shed their TNF receptor to neutralize the function 
of TNF-α without provoking an inflammatory response 88. 
Sources of inflammation: 
Adipose Tissue:   
Adipose tissue is a complex tissue composed mainly of adipocytes.  However, other cells, 
such as pre-adipocytes, fibroblast, and endothelial cells comprise the stromal vascular fraction 
(SVF) are usually present.  Immune system cells also occupy the SVF of adipose primarily in the 
form of macrophages called adipose tissue macrophages (ATMs).  Adipose acts a major 
endocrine organ that regulates energy expenditure and food intake and secretes regulatory 
hormones like leptin, estrogen, and resistin.  Adipose tissue increases the expression and 
secretion of inflammatory cytokines, primarily IL-6, during the development of obesity.  These 
cytokines are primarily produced by ATMs, which comprise approximately 40% of the adipose 
tissue of obese individuals 2,89.  
Adipose tissue, as a whole, can be subdivided into subcutaneous adipose tissue (SAT) 
and visceral adipose tissue (VAT).  VAT, also referred to as abdominal fat, resides between 
abdominal organs.  VAT significantly increases during obesity and is positively associated with 
insulin resistance and T2D 62,90.  As is the case with all tissue, adipose contains a resident 
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population of immune system cells that provide surveillance against foreign microbes. Resident 
tissue macrophages in SAT and VAT are essential for the removal of apoptotic cells without 
increasing inflammation 91. However, if the stress is extreme or prolonged, as is the case in obese 
adipocytes, ATM may recruit addition immune system cells that promote inflammation. Kanada 
et al (2006) demonstrated that obese mice with malfunctioning adipocytes secrete monocyte 
chemoattractant protein-1 (MCP-1) to recruit additional macrophages into the adipose tissue 92. 
The physiological mechanism for this signal appears to be linked to tissue stress induced by 
hypoxic environment 93.   
Several animal and human studies demonstrate that as adipose tissue mass expands, there 
is decreased partial pressure of oxygen (PO2) to white adipocytes 94-97. In fact, in lean 
individuals, blood flow to the adipose is increased postprandially while there is no change in 
obese individuals 98,99. As adipocytes expand from energy imbalance, the diffusion of oxygen 
into the adipose becomes impaired, thereby lowering the O2 saturation of the tissue. This 
represents a fundamental physiological stress on adipose tissue.  The hypoxic environment of the 
adipocyte can trigger the regulator of cellular O2 homeostasis hypoxia inducible factor-1 (HIF-1). 
HIF-1 regulates the cells response to hypoxia by increasing chemoattractants (MCP-1 and 
CXCL12) to the stressed tissue 93.  Immunohistochemistry of the adipocytes of high fat fed 
C57/BL6 mice confirms that hypoxic areas had the greatest accumulation of macrophage and 
cytotoxic T cells 100.  
Excessive energy intake for prolonged periods of time without increases in energy 
expenditure tips the scale in favor of fat storage into adipocytes. As adipocytes reach their 
maximal storage capacity the cellular environment becomes stressed, which leads to the 
increased secretion of chemokines (MCP-1 and CCL5) and the cell surface expression of 
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adhesion molecules (α4β7) to recruit and navigate monocytes to the area.  Adipocytes that have 
been stressed in this manner can undergo apoptosis and their cellular contents (glycerol) spill 
into the interstitial space attracting more macrophages.  This cycle of tissue expansion, hypoxia, 
and metabolic stress work to overwhelm the resident tissue macrophage and activate the innate 
immune system in an attempt to restore homeostasis 34,93,96.   
Inflammatory Macrophages:  
Dendritic cells, granulocytes (neutrophils, basophils, eosinophils, mast cells), and 
macrophages comprise the three phagocytic cell classes of the innate immune system. Dendritic 
cells function primarily to ingest antigens and migrate to peripheral lymphoid tissues where they 
can present peptide to the cells of the adaptive immune system. Granulocytes are highly 
phagocytic cells that confer immediate short-live response to pathogens. Macrophages serve a 
primary role in immune surveillance and orchestrating the inflammatory response 33,101. 
Macrophages are long-lived cells that mature from circulating monocytes and populate 
tissues. Macrophages that encounter a pathogen or microbe are stimulated to release pro-
inflammatory cytokines.  During a classical, pathogen initiated immune response these cytokines 
promote increased blood flow, cell-adhesion molecules expression, and vascular permeability.  
The purpose of the inflammatory cascade is to increase the number of effector cells to the 
initiating site and to promote the destruction of the pathogen. The cytokine, macrophage colony-
stimulating factor (M-CSF) promotes the maturation of monocytes into macrophages that will 
continue to promote the inflammatory response or become tissue resident macrophages2.  
Tissue resident macrophages serve a central role in immune surveillance and the 
clearance of cellular debris from apoptotic cells.  An important aspect of immune surveillance is 
the “silent” removal of cellular debris that does not stimulate the release of inflammatory 
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cytokines or noxious substances. ATMs in lean mice (F4/80+) are considered to be “alternatively 
activated” (M2). This differs from classically activated macrophages (M1), which are induced by 
T helper 1 cell (TH1) cytokines INF-γ and TNF-α to initiate a classical inflammatory response. 
M2 macrophages, on the other hand, can be induced by TH2 cytokines IL-4 to secrete anti-
inflammatory cytokines.  
In mice, the development of obesity stimulates the recruitment and conversion of the 
ATM population to switch from M2 “anti-inflammatory” to M1 “pro-inflammatory” 
macrophages 102.  These M1 macrophages expressed the surface protein CD11c and have been 
shown to represent 90% of the ATM population in obese adipose tissue in mice 103. Humans do 
not demonstrate the same polarization in macrophage differentiation.  Human ATMs during 
obesity presents a mixed profile exhibiting variable qualities of both anti-and pro-inflammatory 
macrophages 24,104.  An analysis of ATMs from lean and obese individuals, utilizing flow 
cytometry, revealed that ATMs from obese humans produced pro-inflammatory cytokines (IL-6, 
TNF-α, IL-23, MCP-1, IL-8, and cyclooxygenase-2) and anti-inflammatory cytokines (IL-10, 
TGF-β, and cyclooxygenase-1)24.  
Human ATMs are considered to be positive for CD45, CD14, HLA-DR, CD31, and 
CD206 when analyzing cell surface markers 104. Within the population of ATMs there are 
markers for differentiation. For example, CD206, the manose receptor, is highly expressed on the 
surface of differentiated macrophages and, along with other scavenger receptors, promote a pro-
phagocytic phenotype. Additionally, the ATMs increase expression of matrix metalloproteinase-
9 (MMP-9), which is key protease involved in the breakdown of the extracellular matrix 
promoting angiogenesis 24,105. These studies demonstrate that human ATMs exhibit distinct 
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macrophage subpopulations that cannot be solely categorized on cell surface makers, but rather 
cellular behavior 24,104,105.  
Macrophages in vivo demonstrate high degrees of plasticity in their differing states of 
activation. This makes segregation of human ATMs into distinct classes and subsets unrealistic. 
In murine models of DIO adipose tissue there is a marked increase in the M1 macrophage that is 
temporally associated with insulin resistance. There is substantial evidence in favor of obese 
adipocytes undergoing apoptosis and recruiting monocytes from the circulation to be classically 
activated macrophages. MCP1-/- mice exhibit significantly less adipose tissue macrophage 
infiltration and subsequently have improved insulin sensitivity and hepatic steatosis when 
compared to wild type mice on HFD 106.  
Obesity can lead to the activation of the cytostolic multiprotein complex NLRP (NOD- 
LLR-and pyrin domain containing), adaptor molecule ASC, and caspase-1 effector molecule 
termed the inflammasome 91. The inflammasome can be activated in macrophages, and other 
cells of myeloid lineage, by pattern associated molecular patterns (PAMPs), reactive oxygen 
species (ROS), and endogenous ligands such bioactive lipid molecules (i.e. ceramides) 91,107.  
The result of activation of the inflammasome leads to the cleavage of pro-caspase-1 into caspase-
1, which then leads to processing and release IL-1β.  IL-β is considered a master inflammatory 
cytokine and a potential candidate for macrophage induced insulin resistance. Elevated levels of 
IL-1β and IL-6 are positively associated with increased risk of T2D. Gao et al (2014) found that 
IL-1β is a critical cytokine facilitating macrophage-adipocyte cross-talk, which detrimentally 
effects insulin signaling (i.e. significant reductions in GLUT4, IRS-1, IRS-2) 108. This study also 
demonstrates that inhibition of IL-1β results in increased protein expression insulin signaling 
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molecules GLUT4, IRS-1, PI3K p85α, and completely reverses the lipolysis initiated by the 
macrophage cytokine treated media.  
To summarize, ATMs represent a diverse subset of macrophages that may or may not 
represent a distinct lineage of circulating monocytes attracted to areas undergoing metabolic 
stress. The difference between human and murine ATM behavior may be representative of the 
models as a whole. The murine immune system has more distinct roles and relationships to 
certain cytokines, whereas the human immune system is clearly more pliable. Human ATMs are 
more hybrid macrophages that possess qualities of both pro-and anti-inflammatory (M1 and M2) 
macrophages.  Murine models of DIO elicits a clear transition in macrophage activation from 
“M2” alternatively activated macrophages that promote a toleragenic environment capable to 
quietly clearing cellular debris to a “M1” classically activated macrophage that secretes pro-
inflammatory cytokines. Considering these observations it is clear that macrophage infiltration 
into obese adipocytes promotes chronic inflammatory state 2,91,104.  
Human ATMs do not provide the same “smoking-gun” in their relationship to obesity 
related insulin resistance and chronic inflammation.  There is currently no consensus on all the 
cell surface markers to distinguish the activation state of human ATMs. However, in obese 
adipocytes, ATMs produce cytokines that promote insulin resistance, proteases that remodel the 
extracellular matrix, and induce adipocyte differentiation.  The ATMs in obese humans appear to 
promote inflammation in order to rebuild the adipocyte structure in order to store more lipids. 
Insulin resistance, due to the pro-inflammatory cytokines IL-6, TNF-α, and IL-1β, is potentially a 
adaptive response to limit the uptake of glucose into adipocytes that are overwhelmed 103,108 109.   
There is now little doubt that adipose tissue is the source of increased pro-inflammatory 
cytokines in circulation that defines obesity and chronic inflammation. Measurements of arterio-
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venous blood flow across subcutaneous adipose tissue beds demonstrate that approximately 30% 
of circulating IL-6 is produced by the adipose 89. While TNF-α is typically not detected in the 
serum of obese individuals, its protein expression is significantly increased in the adipose of the 
obese 89,110,111. This pro-inflammatory environment works not only to increase the recruitment of 
monocytes/macrophages, but also increases their phagocytic activity. Increased uptake of 
necrotic adipocytes and lipids by macrophages increases the presentation of those molecules by 
both major histocompatibility complex I and II (MHC I and MCH II) to cells of the adaptive 
immune system 89,110.  
Skeletal Muscle Inflammation: 
 Adipose tissue has been the primary focus of research in metabolically derived chronic 
inflammation. However, in recent years skeletal muscle has been receiving more interest as an 
affected tissue during chronic inflammation and as a potential contributor to inflammation.  
Indeed, there are many conditions under which skeletal muscle becomes inflamed. Duchene’s 
Muscle dystrophy and myasthenia graivs are characterized by an intense inflammatory response 
and repair process that promote fibrosis 112,113.  
 Activating inflammatory pathways within the skeletal muscle interferes with insulin 
signaling pathways and therefore insulin stimulated glucose uptake. Several in vitro studies 
demonstrate impaired glucose uptake when skeletal muscle cells are exposed to inflammatory 
cytokines 114-116.  However, these data do not fully support the role of inflammatory cytokines in 
the development of obesity.  For example, attempts to reverse insulin resistance by administering 
neutralizing antibodies against inflammatory cytokines has been largely unsuccessful 34. 
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Skeletal Muscle Macrophages 
The infiltration of inflammatory macrophages into expanding adipose tissue during 
obesity has been repeatedly demonstrated in both animal and human models and is positively 
associated with chronic inflammation 1,91.  The primary disease states associated with obesity are 
insulin resistance and frank T2D 21. T2D is largely considered a disease of the skeletal muscle 
due to the fact that the majority dietary glucose is disposed within skeletal muscle 48.  Therefore, 
it is logical to speculate that inflammatory macrophages may be increased in the skeletal muscle 
of obese individuals and type 2 diabetics.  
To address this, Fink et al (2013) obtained biopsies from lean normal glucose tolerant 
(NGT) individuals and overweight and obese individuals with and without T2D 117.  The results 
of this study demonstrate that CD11c+ macrophages are positively correlated with T2D in 
addition to HbA1c and fasting plasma glucose.  The genes for alternatively activated anti-
inflammatory macrophages (CLEC10A, MRC1, CD163) are inversely associated with the same 
parameters for T2D. The investigators of this study stated that when corrected for age these 
relationships did not reach significance 117. These results demonstrate that muscle-residing 
macrophages might play a role in the preserving or impairing insulin sensitivity.  
Limited methodological analysis of inflammatory macrophage infiltration in skeletal 
muscle has created a discrepancy in the theory that inflammatory macrophages infiltrate skeletal 
muscle and contribute to insulin resistance.  Several of these studies cite low relative number of 
macrophages in muscle when compared to adipose tissue 118-120. However, these studies failed to 
determine the inflammatory activity and polarization of macrophages in muscle in obesity. 
Studies by Varma et al (2009) and Fink et al (2014) utilize a multitude of techniques (flow 
cytometry, qPRC, and immunohistochemistry) to analyze the population and behavior of 
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macrophages in the muscle of mice fed a HFD and obese humans alike 26,121.  These data 
demonstrate a differential immune cell response in muscle in response to obesity.  In response to 
a HFD human and mouse muscle have proportionally fewer T cells than adipose tissue, but 
showed increased neutrophils. Importantly, MCP-1 (CCL2) increases in response to a HFD, in 
mice and humans, and is necessary to increase macrophage numbers within muscle 121. 
The cytokines and chemokines released by skeletal muscle macrophages and by the 
muscle fibers themselves appear to act synergistically to promote inflammation in response to 
HFD feeding in mice 5,26. In obese and type 2 diabetic humans, there is a similar response that 
up-regulates the expression of MCP-1 to recruit monocytes from circulation and populate the 
stressed muscle. This state of chronic inflammation initiates the cross-talk between skeletal 
muscle tissue and its resident immune cells that promotes insulin resistance and fibrosis 26,117,122.  
Chronic Inflammation and the Adaptive Immune System: 
 Innate immune system responses are mounted against extracellular and intracellular 
pathogens. As mentioned previously, monocytes are immature leukocytes that reside within the 
vascular endothelium and in circulation.  Monocytes, in the presence of inflammation due to 
infection or tissue injury, mature to become macrophages.  These phagocytic macrophages 
consume and lyse pathogens so that their peptide components can be “presented” on their surface 
by major histocompatibility complex class I and class II (MHC I and MHC II) 33.  
Vital to the survival of an organism is the ability to differentiate “self” from “not self”.  
Nearly all cells of the body display “self” peptides in conjunction of MHC I and II molecules. 
When an antigen-presenting cell has consumed and killed a pathogen by phagocytosis it will then 
present the pathogen to T cells and B cells that have specific receptors for that peptide-MHC 
complex.  Early in the development of human and mice there is an education of the immune 
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system, whereby the T cells and B cells undergo both positive and negative selection. T cells are 
a subset of lymphocyte that mature in the thymus. During that early maturation T cells that are 
auto-reactive or bind to strongly to “self” are deleted from population 33,123.  
The presentation of digested adipocytes and lipids through MHC I and MHC II molecules 
on the surface of macrophages functionally builds a bridge between the innate and adaptive 
immune system.  A major aspect the chronic inflammatory response is the persistent presentation 
of antigen via macrophages.  The T cell’s role in host protection is primarily in cellular defense, 
whereas, B cells contribute to humoral defense. Due to this fact T cells will be the primary focus 
of this portion of the review 124.  
T Cells 
T cells are CD3+, but also demonstrate other markers of differentiation such as CD8 and 
CD4. CD8+ T cells are called cytotoxic T cells that recognize antigen in the form of peptide-
MHC I and are major protectors against intracellular pathogens.  CD4+ T cells recognize antigen 
in the context of peptide-MHC II.  Upon recognition of the peptide-MHC complex T cells 
terminally differentiate into cytotoxic T lymphocytes (CTLs) and T helper cells (TH1, TH2, TH17, 
TH9) respectively.  It is at this point that T cells are capable of executing their effector function 33 
.  
A tolerogenic environment, in which the immune system does not attack its host, is 
fundamental to a healthy immune system.  The foreign microbes of the gastrointestinal tract do 
not cause an inflammatory response in healthy individuals. The explanation for this phenomenon 
stems from regulatory T cells (T regs) that promote tolerance by secreting anti-inflammatory 
cytokines IL-10 and TGF-β. T regs are positive for forkhead/winged-helix transcription factor 
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(FoxP3), CD25, and CD4.  FoxP3+ T regs occur commonly at sites of recently cleared infection 
to terminate the inflammatory response allowing the tissue to be restored to homeostasis.  
In C57BL/6 mice at 30 weeks of age approximately 50% of CD4+ T cells are CD25+ 
FoxP3+ T reg cells.  In vitro suppression assays demonstrate that T reg cell from the VAT of 
mice poorly suppress CD+ T cells with no deficiency in proliferation when compared to T regs 
taken from subcutaneous adipose125.  These VAT T regs had increased gene transcripts for 
chemokines that recruit leukocytes and promote extravasation (CCR1, CCR2, CCR9, CCL6, 
integrin αV, CXCL10, and CXCL2).  These cells also produce large of amounts of IL-10 and its 
receptor IL-10R.  Studying the function of the fat resident T reg cells has proven to be 
technically difficult. Therefore the precise role that these tolerogenic cells play in the 
development of obesity associated inflammation remains to be elucidated 126.  
The chronic inflammation that is associated with long-term obesity is sustained by the 
adaptive immune system. In support of this, CD3 gene transcripts have been shown to be 
elevated in humans VAT during obesity most of which are CD8+ and CD4+ 127.  The majority of 
T cells in VAT in obese individuals are effector memory CD8+ CD44+ CD62L-. These CD8 T 
cells, in contrast to naïve CD8+CD44-CD62L+T cells, are capable of promoting a long-term 
inflammatory response by recruiting and activating macrophages into the adipose tissue 128.   
Effector CD8+ T cells or CTLs release cytotoxic granules once binding with their cognate 
peptide-MHC complex. Cells that are exposed to cytotoxic granules will start to undergo 
program cell death called apoptosis 109.  
In adipose tissue, the CD4 T cell population is mainly comprised of TH1 and TH2 T cells 
128.  TH1 cells are primary producers of the pro-inflammatory cytokines INF-γ. INF-γ is a 
macrophage-activating factor that also stimulates the natural killers (NK) cell population.  
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However, it is the action of the macrophage that initially stimulates TH1 cells 127. The 
presentation of peptide-MHC II and release of IL-1 and IL-12 from macrophages that have 
encountered an extracellular pathogen stimulates TH1 cell activation.  TH1 cells are notably 
primary producers of INF-γ, which is a potent activator of macrophages in vivo and in vitro 
129,130.    
The recruitment of additional macrophages into the adipose tissue by INF-γ produced by 
TH1 cells is a potential mechanism for the role of the adaptive immune system in chronic 
inflammation.  In support of this, Rocha (2008) and Winer (2009) independently demonstrated 
that obese mice have greater total number of CD4+ and CD8+ T cells than when compared to 
lean controls131,132.  In vitro stimulation of T cells from obese mice produce significantly greater 
amounts of INF-γ and display a skewed TCR-Vα repertoire suggesting that expanding adipose 
tissue drives T cell biased towards adipose. These mice also show increased MHC II (I-Ab) 
presentation 131,132. These data support the theory that obesity elicits a specific T cells receptor 
repertoire response to adipose tissue that potentially displays self-epitopes.   
 The TH2 cytokines, IL-4 and IL-13, serve a role to promote the activation of anti-
inflammatory M2 macrophages 133.  As stated previously, M2 macrophages promote a 
tolerogenic environment via the production of anti-inflammatory cytokines and through the 
production of arginase-1101.  Arginine, the primary substrate for arginase-1, is necessary to 
sustain a CD4 T cell response.  The arginase-1 produced by M2 macrophages depletes arginine 
and is sufficient to reduce the CD4 T cell response 134. The potential protective role for a TH2 cell 
response in the protection of obesity induced inflammation and insulin resistance, however, is 
still up in question, as T reg cells also promote tolerance and reduce inflammation 135.  
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 It is important to note that many other cells of the immune system have been implicated 
in the pathogenesis of chronic inflammation. Eosinophils are granulocytes that are major 
producers of IL-4 and IL-13, which have been shown to promote M2 macrophages activation in 
VAT. Genetic deletion of eosinophils increased adiposity and insulin resistance in mice fed a 
HFD when compared to eosinophil intact mice 136.  Conversely, mast cell deficient mice were 
protected from DIO and insulin resistance when compared to wild type mice 137. However, the 
validity of mast cell deficient mice has been the subject of some scrutiny and care should be 
taken into consideration when interpreting the metabolic implications of mast cell deficient 
models 138.  
Anti-Inflammatory treatments to ameliorate metabolic disease: 
Evidence of increased acute phase proteins and inflammatory cytokines has linked 
metabolic dysfunction with the immune system response 27. The inflammation associated with 
these conditions is a low-grade subclinical level. It is not yet clear if inflammation is responsible 
for organ dysfunction or chronic over-nutrition and metabolic stress is the impetus for the 
inflammation of the organ. Much research has been dedicated to reversing the perceived harmful 
effects of inflammation on metabolically stressed organs by treating patients with anti-
inflammatory compounds (salsalate) and antibodies medications (infliximab, entanercept, 
tocilizumab)  139-142. The results of these trials have failed to demonstrate efficacy in improving 
glucose tolerance and insulin resistance 34.  
The shortcomings of anti-inflammatory therapies aimed to improve glucose homeostatsis 
emphasize the critical role that inflammation plays in the body’s response to metabolic stress. It 
is possible that the early response to nutritional overload and expanding adipose tissue is the 
increase in inflammation that acutely works to maintain energy homeostasis.  However, if the 
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stimuli for inflammation (over-nutrition, glucotoxicity, and physical inactivity) are not altered, 
than the inflammatory cycle promotes a negative adaptation that fundamentally alters the 
function of the organ 1. 
  Exercise is a potent anti-inflammatory therapy that reduces chronic inflammatory 
biomarkers associated with T2D and obesity 16,28-30,143. However, exercise, in particular 
resistance training, promotes a transient inflammatory response that increases the circulating 
levels of inflammatory cytokines (ex. IL-6).  This transient spike is followed by an increase in 
anti-inflammatory cytokines144.  The degree of improvement in the biomarkers for chronic 
inflammation (ex. CRP) are positively associated with the intensity of the exercise 17.  Muscle 
produced myokines present a novel a mechanistic explanation for the anti-inflammatory effects 
of exercise 145. The remainder of this review will focus on the various myokines and their 
relationship to exercise.   
  
Skeletal Muscle as a Mediator of Inflammation: 
IL-6 Myokine 
Regular exercise has been shown to reduce levels of chronic inflammation 146. The anti-
inflammatory mechanisms of exercise have focused on the production of pro-and anti-
inflammatory cytokines. Observations by Ostrowski et al (1998) first suggested that the elevation 
in IL-6 from prolonged running was a result of exercising muscle 147. Since that time extensive 
research has been conducted to confirm the muscle origins of increased IL-6 during exercise. 
This phenomenon of skeletal muscle production and release of myokines into circulation 
suggests that skeletal muscle itself may mediate the anti-inflammatory effects of exercise 146.  IL-
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6 is the most extensively studied myokine to date. Therefore IL-6 will provide the conceptual 
framework to understand how skeletal muscle can act as an anti-inflammatory endocrine organ.  
Northoff and Berg (1991) were amongst the first to identify the elevation in cytokines in 
response to strenuous exercise in humans148.  However, observations by Ostrowski and 
colleagues provided the bulk of the evidence for increased cytokines in circulation in response to 
prolonged running 147,149.  These early studies demonstrate that in marathon runners IL-6 levels 
peak immediately post-race and remain elevated for up to 4 hours. Work from this laboratory 
also demonstrates significantly increased circulating IL-6 levels at 30 minutes of treadmill 
running at 75% VO2max.  
Ostrowksi et al (1998) postulated that skeletal muscle is the primary producer of IL-6 
measured in circulation during exercise 149. To test this hypothesis, muscle biopsies and blood 
were collected before, immediately after, and two-hours post marathon.  Comparative 
polymerase chain reactions were conducted to detect the mRNA levels of IL-6 and other 
cytokines in skeletal muscle and blood mononuclear cells (BMNC). IL-6 mRNA was only 
detected immediately and 2hrs post-marathon in skeletal muscle sample and not PBMC 149.  
The primary source of IL-6 in circulation, during conditions like sepsis, is leukoycytes 
(monocytes).  Ostrowski et al (1998) provided indirect evidence to the contrary as it applies to 
increased IL-6 during strenuous exercise 149. Starkie et al (2000) utilized flow cytometry to rule 
out circulating monocytes as the producer of IL-6 150. Using a similar cohort and study design 
these researchers measured IL-6 and TNF-α levels and found no increase in the number of cells 
producing IL-6 or TNF-α or the fluorescent intensity of each cell. This study directly excluded 
PBCM as the producers of IL-6 during exercise150.  
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IL-6 production and release from skeletal muscle 
 In order to determine that skeletal muscle was in fact the source of IL-6 during exercise 
Steensberg et al (2000) measured IL-6 concentration during single leg extension exercise 151. In 
this landmark study, subjects completed 5 hrs of single leg extension exercise only against 
concentric resistance while blood flow was collected from catheters placed in the femoral artery 
of one leg and the femoral vein of both legs (arterio-venous difference method). IL-6 
concentrations only increased in the blood from the exercising limb with no release from resting 
muscle and the non-exercised leg. This is the first study to provide strong evidence for IL-6 as a 
contraction mediated myokine.  
 The criticism of a-v difference method is that it does not indicate if other cells residing 
within skeletal muscle (macrophages, fibroblast, endothelial cells, etc). To address this Jonsdottir 
et al (2000) showed that in rodent models, electrical stimulation of skeletal muscle increased IL-
6 mRNA as measured by quantitative-PCR 152. This effect could not be recapitulated by infusion 
of epinephrine at doses that reached peak exercise conditions 153,154. Together, these data indicate 
that contraction is an essential component of IL-6 release from the skeletal muscle and not the 
influence of circulating hormone on muscle.  
Utilizing immunohistochemistry and in situ hybridization IL-6 protein and mRNA 
respectively was detected in biopsies taken from male subjects before and after 120-minutes of 
continuous cycling at significantly higher levels post exercise compared to pre-exercise sections 
155. More recently, Lauritzen et al (2013) identified IL-6 containing vesicles in a mouse 
quadriceps muscle that was transfected with enhanced green fluorescent protein (EGFP), which 
was reduced upon muscle contractions 156.   
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 Initial observations from Brauusgaard (1997) indicate the IL-6 released from the skeletal 
muscle was due to damage that occurs during eccentric muscle contractions 149,157. This 
hypothesis was based from studies that compared the concentration of IL-6 in men after 
completing two separate exercise trials. In the first bout, 9 male subjects completed 30 minutes 
of concentric cycling at 65% of VO2 max. After two weeks the same group of men completed a 
bout of eccentric cycling that matched the workload achieved by the concentric cycling bout. As 
expected, the results of this study demonstrate that eccentric exercise significantly increases 
markers for muscle damage (ex. creatine kinase) when compared to concentric exercise157.  
These levels persist even up to 7 days after the exercise bout. IL-6 is significantly increased only 
after the eccentric training bout. The authors of this study concluded that IL-6 was likely 
increased due to exercise as a result of muscle damage and was linked the inflammatory 
response. However, there was no significant difference in the concentration of blood monocytes 
or the composition of leukocytes between exercise bouts. Taking this response into account, the 
authors suggest that the source of IL-6 was still completely unknown as it pertains to exercise 157.  
 Further work to demonstrate that muscle damage was a primary component for elevated 
IL-6 circulation during exercise does not support this hypothesis 158-160.  Coisier et al (1999) 
provides compelling evidence that muscle damage is not a necessary component for IL-6 
production during exercise 161. In this trial IL-6 and myoglobin were measured immediately after 
2 bouts of eccentric exercise, thereafter subjects completed 5 training sessions during a three-
week period. Subjects were then tested again to measure IL-6 and myoglobin.  The second 
testing bout at the end of the study was at the same workload as the pretest. Therefore the 
markers for muscle damage were reduced in the post-test. However, IL-6 levels from the pre-and 
post-test were similar.  
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IL-6 and glycogen 
 The highest measurements of circulating IL-6 during exercise have been recorded during 
prolonged running with elevations as high as 128-fold 144. These data shifted the focus from 
muscle damaging exercise to glycogen depletion as the mechanism for skeletal muscle IL-6 
production. Nehlsen-Cannrella et al (1997) made the observation that carbohydrate intake (6%) 
attenuated the IL-6 response to 2.5 hrs of running (~75% VO2max) when compared to placebo 
162. Previously mentioned work by Starkie et al (2000) demonstrated that carbohydrate intake 
influenced IL-6 release and that circulating monocytes were not the source of secretion 150. 
Bishop et al (2001) demonstrated that exercising in the glycogen-depleted state exacerbates the 
cytokine response 163. Due to the fact that carbohydrate intake during prolonged exercise 
preserves muscle glycogen 164 it is logical to speculate that IL-6 release from skeletal muscle is 
in some way modulated by those levels.  
 To test this hypothesis, Steensberg et al (2001) conducted a study on 7 recreationally 
active men to determine if pre-exercise glycogen levels influence the skeletal muscle mRNA and 
circulating IL-6 levels 165. Subject performed 2 hrs of single legged extensions for 1 hr followed 
by 1 hr of two-arm ergometery. The investigators stated that workload for single leg extension 
was sufficient to deplete muscle glycogen from the exercised leg and that upper body exercise 
prevented resynthesis in the depleted muscle from endogenous glucose production. Prior to 
exercise muscle glycogen was depleted 40% compared to control leg.  As measured by the a-v 
difference across the exercising limbs the circulating levels of IL-6 produced by the depleted leg 
were significantly greater at throughout the exercise bout and up to three hours post-exercise.  
Skeletal muscle IL-6 mRNA showed a similar significant relationship165.  
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 In a similar study Keller et al (2001) depleted muscle glycogen levels by having 6 male 
subjects undergo two identical 180-minute bouts of dynamic extension exercise 166. Subjects 
were glycogen depleted the night prior and given a high-carbohydrate or low-carbohydrate meal. 
When participants were given the low-carbohydrate meal muscle glycogen levels were depleted 
by 40% compared to the high-carbohydrate condition plasma IL-6 levels were significantly 
elevated during exercise at 120-and 180-minute time points. Measurement of isolated muscle 
nuclei IL-6 mRNA transcript also revealed significantly higher IL-6 expression in the low-
glycogen condition during exercise.  It is important to note that in both trials by Steensberg and 
Keller that pre-exercise IL-6 levels were not different between low-and normal glycogen levels.  
It was not until exercise commenced that the levels of IL-6 increased at the greater level in the 
glycogen-depleted condition.  This indicates a clear role for muscle contraction as a primary 
inducer of IL-6 transcription and protein release during exercise165,166.  
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 During intense or prolonged exercise hormonal factors are primary regulators of skeletal 
muscle glucose metabolism. Skeletal muscle expresses a large amount of β2-adergnic receptors 
to which epinephrine 167,168, norepinephrine, and cortisol 169 may bind and contribute to increased 
endogenous glucose production (EGP) during exercise and increase during intense or prolonged 
exercise. Interestingly, as glycogen levels decrease during exercise sympathoadrenal activity 
increases, as do circulating levels of IL-6.  Therefore, epinephrine induced increases in IL-6 is a 
factor that may confound the relationship between IL-6 and glycogen levels.  
 Ex vivo studies utilizing rat skeletal muscle have demonstrated that physiological doses of 
epinephrine (10-100 nmol) do not increase mRNA or protein release of IL-6 from incubated rat 
skeletal muscle 153. Only supraphysiological doses were shown to increase IL-6 mRNA into 
supernatant.  Infusions of physiological doses (8 ngkgmin-1) of epinephrine that mimic the 
levels experienced during exercise were shown to produce a 6-fold increase in plasma IL-6, 
whereas during exercise treadmill running for 2.5 hrs at 70% VO2max plasma IL-6 increased 29-
fold 154.  The authors of these studies conclude that epinephrine plays only a minor role in the 
production and release of IL-6 from skeletal muscle during exercise.  
IL-6 and Calcium (Ca2+) 
 During exercise the signal for muscle contraction is initiated by an abrupt increase in the 
release of Ca2+ from the sarcoplasmic reticulum (SR) 170.  Ca2+ is a second messenger that acts as 
a transcription factor that controls gene expression and cellular function and for that purpose 
intracellular Ca2+ levels are tightly regulated within all mammalian cells 171.  The Ca2+ ionophore, 
ionomycin, transports Ca2+ across the plasma membrane to raise intracellular Ca2+ concentrations 
172. Multiple studies have demonstrated that ionomycin is capable of increasing IL-6 gene 
expression in rat and human skeletal muscle 153,173,174.  
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The signaling pathways mediated by Ca2+ involve protein phosphatase calcineurin, which 
is activated during exercise 175 and electrical stimulation 176. Calcineurin is of interest because it 
dephosphorylates and therefore activates nuclear factor of activated T cells (NFAT). NFAT is 
involved in the integration of mechanical stress response from exercise and remodeling that 
occurs as a consequence, which may explain why NFAT levels are 10-times higher in myocytes 
when compared to other cell types 177,178.  Activation of NFAT induces its translocation to the 
nucleus where it increases transcription of cytokines most notably IL-6 and IL-2 33.  Muscle cells 
cultured with ionomycin and a selective inhibitor of calcineurin, cyclosporine A (CSA), 
significantly reduce IL-6 mRNA production when compared to ionomycin alone 174. The mRNA 
expression of TNF-α is not reduced, but rather increased in these conditions indicating the IL-6 
in skeletal muscle is linked to calcium/calcineurin signaling.   
Interestingly, NFAT can be retained in the cytosol by phosphorylation via 
serine/threonine kinases, such as glycogen synthase kinase 3 (GSK3) 33.  This supports the theory 
that skeletal muscle contraction, which increases the influx of calcium within the muscle cell, 
promotes mRNA transcription immediately upon exercise and that appreciable levels of IL-6 are 
detected in plasma as muscle glycogen levels are depleted. In addition to NFAT, p38 MAPK is a 
stress-activated protein kinase that is activated during muscle contractions 179,180. In order to link 
IL-6 to upstream transcription factors that correspond to glycogen level, Chan et al isolated 
nuclear fractions of muscle samples pre-and post-exercise in subject with normal and low-
glycogen levels 181. This important study demonstrates that low glycogen levels in exercising 
muscle cause increased phosphorylation of nuclear p38 MAPK and that IL-6 is likely induced by 
this phenomenon. L6 myotubes cultured with ionomycin phosphorylated nuclear p38 was 
increased significantly along with IL-6 mRNA.  P38 MAPK is significantly reduced in muscle 
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cells treated with ionomycin and the p38 MAPK inhibitor (SB203580) and IL-6 mRNA is nearly 
undetectable 181.  
Anti-inflammatory effects of IL-6 
 The beneficial anti-inflammatory response to exercise is multi-factorial.  Reduction in 
inflammatory visceral adipose tissue, inhibition of macrophage infiltration in adipose tissue, reduced 
expression of toll-like receptors, and increased catecholamine levels all in some way account for the anti-
inflammatory effects of exercise. However, skeletal muscle release of IL-6 plays an important biological 
role in the induction of the anti-inflammatory cytokine cascade.  
 During an acute infection TNF-α, IL-1β, and IL 6 are initially detected in that order followed by 
IL-1ra, sTNFR1 and IL-10.  Exercise, of a sufficient intensity, can induce 100-fold elevations in IL-6 
without increasing TNF-α levels significantly.  Muscle derived IL-6 induces the production of IL-10, IL-
1ra, and sTNFR1.  After marathon running IL-10 peaks immediately post exercise (27-fold), but unlike 
IL-6 declines rapidly post exercise 144. IL-1ra and sTNFR1 are increased 1.5 to 2.5 told, but peak 
approximately 1.5 hrs post exercise 145.  
 IL-6 functions as an anti-inflammatory myokine that not only stimulates the release of anti-
inflammatory cytokines, but also stimulates the release of cortisol.  To demonstrate the acute  
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anti-inflammatory effects of exercise Starkie et al (2003) injected LPS (0.6 ng/kg bw) into resting 
controls, exercising subjects (2.5 hrs treadmill running), and rhIL-6 infusion and measure TNF-α levels 
for up to 5.5 hrs 182.  Exercising subjects demonstrate a blunted TNF-α response to the endotoxin injection 
when compared to controls.  Importantly, rhIL-6 infusion mimics the effects of exercise by reducing the 
production of TNF-α in vivo 182.  These results demonstrate that muscle derived IL-6 promotes an anti-
inflammatory environment.  
 IL-6 is typically designated as an inflammatory cytokines often associated with a high prevalence 
of obesity and T2D.  This observation has led many researchers to believe that IL-6 is associated with 
negative metabolic consequences which potentially feedback to activate the immune response. However, 
this belief is not support by recent studies utilizing IL-6 knock out mice that develop late onset obesity 
and impaired glucose tolerance that is reversed when IL-6 is exogenously administered 183. Furthermore, 
clinic trials blocking IL-6 to treat chronic inflammation increase cholesterol and plasma glucose levels.  
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 The positive metabolic effects of IL-6 appear to be mediated by activated-AMP kinase (AMPK).  
AMPK is a metabolic energy sensing enzyme that regulates catabolic and anabolic signaling by detecting 
shifts in cellular AMP:ATP ratios. IL-6 signaling through its gp130 receptor transduces signaling that 
activates AMPK.  The metabolic consequences of this interaction affect both glucose and FA metabolism. 
IL-6 treated muscle cells have increased basal and insulin stimulated glucose uptake due to increased 
GLUT4 trafficking and insertion into the plasma membrane 184. In vivo work demonstrates that IL-6 
infusion increases glucose infusion rate without altering hepatic glucose responsiveness 185.  
 AMPK is also an important regulator of FA oxidation that may modulate IL-6 metabolic 
interactions 186. In fact, within skeletal muscle FA oxidation increases when infused with IL-6 (5000 
pg/ml) by 50%, whereas TNF-α infusion at the same concentration does not affect FA oxidation, but 
rather increases the uptake FA and increases the accumulation of DAG by 45% 187.  In vivo experiments 
demonstrate that IL-6 is also a potent inducer of whole-body lipolysis and FA oxidation even at low 
levels (140pg/ml) without any detectable increase in lipolytic hormones 187,188.  
 The relationship of IL-6 and AMPK activation is supported by research that demonstrates the 
robust lipolytic effects of IL-6 is reversed when AMPK function is ablated 185.  These finding demonstrate 
that IL-6 has potentially synergistic effects of exercise metabolism whereby substrates can be mobilized 
an oxidized at greater rates.   From an inflammatory standpoint there appears to be a significant benefit 
from regular exercise and regular exposure to elevated IL-6 levels. However, it is difficult to tease apart 
role of exercise in reducing inflammation that leads to improved metabolic health and vise versa.  
Irisin: A PGC1-α derived myokine 
 The transcriptional co-activator peroxisome proliferator-activated receptor (PPARΥ) 
coactivator-1α (PGC1-α) is a key regulator of mitochondrial biogenesis and fatty acid and 
glucose metabolism in skeletal muscle and adipose tissue 189,190. The use of transgeneic mice that 
overexpress PGC-1α promotes an oxidative skeletal muscle phenoytype (type I and type IIa) and 
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increases total muscle oxidative capacity 191.  These transgenic mice have also been shown to 
have improved insulin-sensitivity and resist age-related fat gain and muscle loss 192.    
 In wild type mice, cold exposure increases mRNA content of PGC1-α and robustly 
increases the transcriptional activity of PPAR-γ and the thyroid hormone receptor on the 
uncoupling protein (UCP-1) promoter193.  UCP-1 is involved in thermogenesis by directing 
protons back through the mitochondria to generate heat rather than promote ATP synthesis via 
ATP synthase 194.  UCP-1 content is significantly higher in brown fat than in white fat cells.  
Considering that brown fat contains significantly more mitochondria and less ATP synthase than 
white fat it represents an important metabolic depot 194,195.  
 Many of the beneficial effects of exercise appear to be mediated by the activation of 
PCG1-α in skeletal muscle 191,192. PGC1-α is increased acutely after exercise and chronically due 
to regular endurance exercise training.  A common adaptation to endurance exercise occurs in 
skeletal muscle, whereby muscle fibers undergo an observable shift to an oxidative profile 191. 
Generally, the health related benefits of exercise are associated with increased skeletal muscle 
oxidative metabolism. In resting skeletal muscle, levels of PGC1-α are elevated in type I and 
type IIA fibers compared to more glycolytic IIb/IIx fibers. Transgenic PGC1-α (PGC1-α +/+) 
mice demonstrate an oxidative muscle phenotype shift and increased endurance exercise capacity 
when compared to PGC1-α knockout mice (PGC1-α-/-), which demonstrate a more glycolytic 
shift and decreased exercise capacity compared to wild type mice.  
Fibronectin domain-containing protein 5 (FNDC5) is a membrane-bound protein that is 
highly expressed in skeletal muscle 196,197.  In an attempt to identify secreted muscle factors that 
increased due to PGC1-α Boström et al (2012) demonstrate that FNDC5 undergoes proteolytic 
cleavage and releases a peptide fragment named irisin 198.  Irisin represents the N-terminal 
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domain of FNDC5 that is released in response to exercise, into the extracellular matrix and can 
be detected in plasma, serum 199, urine, and saliva 200. FNDC5/irisin is 100% biologically 
identical between mice and humans 198. 
The application of nanomolar concentrations of irisin on white fat cells increases UCP1 
by 50-fold demonstrating a browning effect. Viral delivery of irisin stimulates a 3-fold increase 
in circulating levels; however, UCP1 level increase between 10-20 fold 198. Irisin administration 
was shown in this important study to improve glucose tolerance and increased energy 
expenditure in mice fed a HFD.  The authors of this study speculate that the levels of irisin, as 
stimulated by viral administration, which improve metabolic parameters, is similar to those 
measured during exercise and therefore irisin must be at least in part responsible for the 
beneficial effects of exercise 198. 
Irisin is considered a myokine that is secreted from the muscle by the cleavage of FNDC5 
after activation of PGC1-α198.  Lecker et al (2012) confirmed that FNDC5 mRNA increased in 
relation to the increase of PGC1-α mRNA in skeletal muscle of subjects with a high aerobic 
exercise capacity, but not in subjects considered to have a low exercise capacity 201.  Human 
studies demonstrate that acute exercise increases circulating irisin levels 199,200,202,203.  Recent 
studies of acute exercise demonstrate that plasma irisin peaks immediately post exercise and 
correspond to increased exercise workloads and return to baseline 10-20 minutes post exercise 
202,204.  
Irisin levels appear to be increased in response to acute exercise bouts, however, there is 
currently no consensus on irisin response to chronic exercise training 205.  Many studies that have 
demonstrated the acute increase in irisin failed to demonstrate a positive training response. 
Timmons et al (2012) demonstrated FNDC5 mRNA was not different between sedentary and 
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active subjects and that analysis of approximately 200 muscle biopsies revealed that only a high 
active cohort of elderly subjects has increase muscle FNDC5 mRNA 205,206.  Analysis of another 
relatively large cohort did not detect an increase in FNDC5 expression or serum irisin levels in 
response to chronic or acute exercise. 207 
Factors not related to exercise appear to also modulate the production of irisin in the 
human body. A significant positive relationship between body weight and plasma irisin has been 
reported on numerous occasions 199,206,208.  However, these studies do not provide direct evidence 
that increased muscle mass is responsible for increased irisin levels as adipose tissue can produce 
irisin as well 209.   
T2D is caused, in part, by impaired skeletal muscle glucose homeostasis 21 therefore the 
reported benefit on glucose tolerance of irisin on rats fed a HFD is of great interest 198.  In vivo 
measurement of irisin showed a significant negative correlation in relationship to 2 hr plasma 
glucose measured in newly diagnosed type 2 diabetics 210. In support of this several other studies 
have documented a similar relationship 211-213. However, some investigators have demonstrated a 
positive relationship with irisin levels and homeostatic model of insulin resistance (HOMA-IR) 
in obese humans 214. In this particular study, irisin levels were positively correlated with 
metabolic syndrome.  In calorie restricted rats that improved insulin sensitivity did so without 
any significant increase plasma FNDC5/irisin protein levels 215.  
In order to clarify the complexity that surrounds the relationship between irisin and T2D 
studies Kurdiova et al (2014) recently conducted a clinical study that measured circulating irisin 
levels across glycemic status 216. This study confirmed that type 2 diabetics have lower 
circulating irisin levels than non-diabetics. However, FNDC5 mRNA levels were increased 
significantly in prediabetic muscle compared to lean muscle, but not in T2D.  When muscle cells 
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from type 2 diabetics were cultured a decrease in irisin was not observed, rather FNDC5 gene 
expression and secreted irisin was increased. When cells were cultured with excess palmitate and 
glucose, the levels of irisin and FNDC5 were reduced. It is reasonable to speculate that factors 
involved in the in vivo diabetic environment contribute to the reduced irisin secretion 216,217. 
Myonectin/C1q Tumor Necrosis Factor-α Related Protein 15 (CTRP15) 
 Myonectin is characterized by an N-terminal peptide, a collagen repeat domain, and C 
terminal C1q-like globular domain. Some confusion exists regarding the classification of 
myonectin as a member of the C1q tnf-α family 218,219. Work by Park et al (2009) originally 
described a protein CTRP5 discovered during a search for nuclear genes that were differentially 
expressed as a result of altered mitochondrial DNA (mtDNA) content 220.  Marked reductions in 
mtDNA and PGC1-α have been measured in the insulin resistant offspring of T2D parents and is 
also associated with obesity 221.  Therefore the identification of factors that are associated with 
increased or decreased mtDNA are important to understand the mechanisms of metabolic 
dysfunction in T2D and obesity. CTPR5 is described in this study has having 40% sequence 
homology with adiponectin, an adipokine that improves insulin sensitivity.  
 In cell culture (L6 myotubes) CTRP5 activates energy utilization pathways by increasing 
phosphorylation of AMPK and acetyl-CoA carboxylase 220. Glucose uptake, measured by 2-
deoxyglucose (2-DG), uptake and FA oxidation, as measured by palmitate oxidation, is 
significantly increased in myocytes treated with myonectin. The increase in GLUT4 
translocation is accomplished without a measured increase in the phosphorylation of IRS-1 and 
AKT. Rather, GLUT4 translocation was related to an increase in AMPK, ACC, and p38 MAPK. 
AMPK phosphorylation of ACC is required for skeletal muscle FA oxidation and insulin 
sensitivity 222. These results indicate that CTRP5 functions in similar manner to 5-amino-4-
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imidazolecarboxamide ribonuleoside (AICAR) and adiponectin to increase FA oxidation and 
glucose uptake. However, it is important to note that ablation of the adiponectin receptors 
(AdipoR1 and AdipoR2) did not ameliorate the phosphorylation of myonectin treated cells.  This 
indicates that myonectin is a novel protein functioning through a novel receptor 220. 
 The loss of mtDNA and mitochondrial function is implicated in the etiology of insulin 
resistance 223-225.  The benefits derived from exercise are known to involve transcriptional factors 
and co-activators such as PGC1-α and PGC1-β that stimulate mitochondrial biogenesis 191,226.  
When a cell undergoes mitochondrial stress, such as reduced mtDNA, nuclear transcription 
factors are induced to aid in recovery 227.  It is believed that mitochondrial rescue is mediated 
through PGC1-α via calcium/calmodulin signaling pathways 228.  As previously mentioned Park 
et al (2009) demonstrated elevated circulating levels of CTRP5 in diabetic (db/db) obese rats 
(ob/ob) and mtDNA depleted rats (OLETF) rats 220.  A follow-up study in humans confirmed that 
circulating myonectin levels were positively correlated with HOMA-IR 229. Fifty-six women 
underwent 10-weeks of moderate intensity exercise (60% VO2max) for 1 hr three times a week, 
where after, significant increases in VO2max, mtDNA density, and adiponectin were observed. 
These improvements coincided with significant reductions in serum CTRP5 229.  
These the studies demonstrated that CTRP5 is related to insulin resistance and 
mitochondrial dysfunction. Lim et al (2012) erroneously designated CTRP5 “myonectin”, 
however, work by Seldin et al (2012) reported that CTRP15 is preferentially expressed in muscle 
and secreted by muscle, whereas CTRP5 is produced by predominantly adipocytes, suggesting 
that CTRP is a novel proprietary myokine 230. It is accepted that CTRP15 is now referred to as 
myonectin 231.  
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 Myonectin mRNA and protein secretion increases in cultured myotubes in response to the 
exercise memetics ionomycin, forskloin, and epinephrine, but not to insulin or AICAR in vitro. 
In mice, two weeks of wheel running significantly increased serum myonectin and mRNA in the 
plantaris and soleus muscles.  Remarkably, myonectin levels are suppressed in skeletal muscle 
and serum concentration during periods of fasting and drastically increase upon refeeding. This 
response was not preferentially induced by either glucose of emulsified intralipid gavage.  
Muscle cells were treated with glucose or palmitate also increase their expression of myonectin 
mRNA and secretion into media, which indicates that myonectin production is linked to nutrient 
flux though the cell230. 
 Injection of myonectin (sufficient to raise myonectin levels 60-70% above resting levels) 
does not lower blood glucose in mice, however, it was sufficient to reduce non-esterfied fatty 
acids (NEFA) by 30%.  Similar levels of myonectin cultured with 3T3-L1 adipocytes and H4EII 
hepatocytes increase FA uptake by 50% above non-treated cells and equal to 50nM insulin 
exposure. The measurements coincided with a significant increase in FA transporters CD36, 
FATP1, Cav1, and Fabp4. The level of FA uptake was in range with experiments that induce 
overexpression of currently measured FA transporters 232.  
 Myonectin is secreted in response to exercise and nutrient flux through the muscle cell 
via food intake. Recent work demonstrates that myonectin functions in an endocrine manner by 
activating mammalian target of rapamycin (mTOR) and AKT pathway to suppress liver 
autophagy in a similar manner to insulin 231.  Myonectin peaks approximately 3 hrs. after food 
intake or glucose gavage.  This suggests that myonectin provides a postprandial signal that acts 
long after the effects of insulin. These data provide evidence that myonectin is secreted in 
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response to nutrient flux through the muscle and released into the circulation to act in an 
endocrine manner by regulating autophagy in hepatocytes 231.  
Literature Review Summary 
 Chronic inflammation is a unique phenomenon that represents a disruption in metabolic 
homeostasis.  Adiposity due to poor diet and exercise habits can contribute to the induction of an 
immune system response. The fundamental function of the immune system is to protect the host 
from pathogens and noxious stimuli. In order to fulfill this responsibility, inflammation is a 
necessary component of the survival and repair of cells, tissues, and organ systems that have 
been affected.  Typical inducers of inflammation such as bacteria and viruses can elicit strong 
inflammatory response. However, metabolic dysfunction is also a strong inducer of inflammation 
 Obesity and T2D represent metabolic insults to adipose tissue and skeletal muscle.  These 
tissues demonstrate increased infiltration of inflammatory macrophages and T cells. These 
immune system cells receive signals from the cellular milieu to increase their secretion of 
inflammatory cytokines. Since obesity and T2D are chronic conditions, these conditions will 
likely continue unless considerable action is taken to restore the organism back to metabolic 
homeostasis. If this inflammatory environment persists, the physiological function of the tissue 
organ system can be damaged further. 
 Exercise has potent anti-inflammatory effects that are mediated through metabolic 
perturbations, which regulates the expression and behavior of the cells of the immune system. 
Physical inactivity is associated with numerous disease conditions such as obesity, T2D, 
Alzheimer’s disease, and some cancers.  Furthermore, prolonged bed rest has well characterized 
effects on muscle atrophy and the loss of type IIx muscle fibers. This functional decline in 
muscle mass coincides with a marked increase in insulin resistance. Inflammation has an 
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underappreciated role in this process.  Increased inflammatory cytokines (TNF-α, IL-6, IL-1β) as 
well as acute phase proteins (CRP) are significantly elevated during prolonged physical 
inactivity.  
 Muscle contractions are a fundamental component of exercise. Failure to adequately 
engage muscle fibers has serious deleterious effects on health and longevity. Therefore, the 
discovery of myokines provides reasonable speculative grounds that the beneficial effects of 
exercise are mediated through factors produced by the skeletal muscle during exercise (i.e. 
myokines).  Skeletal muscle has a well-understood role in metabolism during rest and exercise. 
However, the discovery that a classical cytokine, IL-6, is produced by and secreted from skeletal 
muscle forms a bridge between the metabolic and immune system.  
 The focus of this review was to establish the grounds for chronic inflammation that is 
induced by metabolic dysregulation and to provide a framework to understand the burgeoning 
field of “immunometabolsim”. The discovery and study of myokines has recently been dealt a 
considerable blow. Key researchers involved in myokine research have been convicted of fraud 
and several papers have been retracted.  Investigation into irisin has yielded few of the positive 
results first reported by Bostöm et al (2012) casting doubt on the importance of this novel 
myokine. However, several independent laboratories have reported the discovery of hundreds of 
currently unidentified myokines that appear to be regulated by muscle contraction.  
In conclusion, skeletal muscle represents a major target for the disposal of glucose during 
insulin-stimulated conditions.  Insulin resistance is considered to be the initial defect in the 
pathogenesis of T2D. Insulin sensitivity and chronic inflammation are inversely correlated in 
vivo whereas in vitro inflammatory cytokines have been shown to cause insulin resistance. 
Exercise that improves insulin sensitivity to the greatest degree also appears to have the greatest 
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impact on reducing chronic inflammation. Therefore, the study of myokines that are produced in 
relation to the improvements in insulin sensitivity would be of great importance.   
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1.2 Study Protocol 
 
Title of Study: THE IMMEDIATE AND EXTENDED EFFECTS OF HIGH INTENISTY INTERVAL 
EXERCISE ON METABOLIC FLEXIBILITY AND MITOCHONDRIAL FUNCTION 
 
Overview  
Metabolic flexibility is defined as the ability to switch from predominantly lipid oxidation and fatty acid 
uptake in the fasted state to insulin-stimulated suppression of lipid oxidation and high rates of muscle 
glucose uptake and glycogen synthesis that occurs in the postprandial state 233.  The inability to “shift” (Δ 
respiratory exchange ratio (RER)) metabolism from lipid to glucose oxidation, termed metabolic 
inflexibility, is a characteristic of obesity and T2D 234-236 and is implicated in the development of insulin 
resistance 233,237,238. However, metabolic inflexibility is present prior to the development of insulin 
resistance and fasting hyperglycemia in the offspring of T2D individuals 238-240 and remains in previously 
obese individuals after weight loss 236.  
 
Metabolically inflexibility is associated with impaired fasting lipid oxidation 235,237,241, which suggests that 
metabolic inflexibility is a reflection of the inability of the mitochondria to switch between fuels.234 Since 
lipid oxidation occurs in the mitochondria, it is logical to deduce that impairments in mitochondrial function 
could alter whole-body lipid oxidation.  Adding clarification to this issue, Ukropcova (2007) and van de 
Weijr (2013) have demonstrated that skeletal muscle mitochondrial function is reduced in metabolically 
inflexible individuals 240,242.  Recent evidence also suggests that the offspring of type 2 diabetics have 
impaired metabolic flexibility without the presence of other metabolic risk factors 239.  Moreover, 
individuals with a biological mother that has T2D are at greater risk of developing T2D, when compared 
with a father with a positive history 243,244.  
 
Continuous moderate to high intensity exercise training (6-12 weeks) has been shown to improve insulin 
sensitivity and metabolic flexibility in obese and type 2 diabetic patients, with greater improvements 
demonstrated with higher intensities 245,246. Interestingly, the time course of glucose tolerance and insulin 
action in response to a single bout of exercise reveals periods of increased insulin sensitivity (immediately 
post exercise to 3 days) and resistance (5 to 7 days post exercise) 247,248. Recent research suggests that 
2-6 weeks of high intensity interval training (HIIT) improves insulin sensitivity and skeletal muscle 
oxidative capacity 249,250.  However, data on the immediate and extended effects of a single bout of high 
intensity interval exercise area lacking. To date there are no studies investigating the time-course of 
metabolic flexibility in response to a single bout of high intensity interval exercise (HIIE). Characterizing 
the immediate and extended response of a single bout of HIIE could provide insight into the therapeutic 
applications of this exercise approach.    
 
Purpose and Procedures 
 
The purpose of this research is to determine the immediate and extended (48-hr) effects of a bout of high 
intensity interval exercise prior to a mixed meal on metabolic flexibility and mitochondrial function in men 
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and women with and without a family history of T2D. The offspring of type 2 diabetics without other risk 
factors (obesity, hyperglycemia, sedentary lifestyle) demonstrate the signs of metabolic inflexibility.  
  
Twenty apparently healthy, active, normal weight (BMI = 18 to 25 kg/m2) young (age 18 to 40 y) men and 
women with (n=10) and without (n=10) a positive family history of T2D will be recruited to participate in 
this study.  After an initial screening visit, graded exercise test, muscle oxidative capacity (OXPHOS), and 
mixed meal tolerance test (MMTT), participants will undergo 1 acute exercise session followed by a 
MMTT immediately after and 48 hours post exercise.  Results from the graded exercise test will be used 
to determine the peak power output at VO2maxto prescribe a practical low-volume, high intensity interval 
program.  Dietary intake will be recorded 24 hours before the initial MMTT and replicated 24 hours prior to 
the exercise session and the post-exercise MMTT.  The primary outcome of the study is the change in 
substrate oxidation (carbohydrate and fat) in response to the MMTT immediately and 48 hours post 
exercise. Secondary outcomes include measures of insulin action (plasma glucose, insulin, and free fatty 
acid responses).  Skeletal muscle OXPHOS, blood flow, on oxygen consumption using near infrared 
spectroscopy (NIRS) will also be measured.  
Inclusion/Exclusion Criteria:  The inclusion/exclusion criteria are summarized in Table 1.  Active, 
college-age men and women with a normal weight (BMI 18-25 kg/m2), with and without a family history of 
T2D will be recruited. Participants will be frequency matched to control for race. Women that are enrolled 
in the study will be tested at least 10 days after the last day of their menstrual cycle.  Individuals with 
known cardiovascular disease, T2D, and/or metabolic diseases will be excluded to reduce the likelihood 
of confounding circumstances regarding the exercise testing, acute aerobic exercise, and MMTT. 
 
 
 
Table 1.  Summary of the Inclusion/Exclusion Criteria 
Primary Outcomes – Shift in Substrate Metabolism and Insulin Action:  The primary outcome for this 
study is metabolic flexibility determined as ΔRER during an MMTT, which suggests a shift in substrate 
Inclusion Criteria  
Age 18-40 years 
Sex Men and Women 
Positive Family 
History of T2D Biological Mother with T2D or biological mother and father with T2D 
BMI 18-25 kg/m2 
Informed Consent The capability and willingness to give written informed consent, to understand the exclusion criteria, and to accept that the randomized group assignment is required 
Exclusion Criteria 
Significant CVD or 
disorders 
Including but not limited to serious arrhythmias, cardiomyopathy, congestive heart failure, 
stroke or transient ischemic attacks, peripheral vascular disease with intermittent 
claudication, acute, chronic or recurrent thrombophlebitis or myocardial infarction 
Physically Inactive Currently participating in aerobic exercise <20 minutes on <3 days per week and no resistance training. 
Diabetes Fasting glucose >125 mg/dL or 2 hour glucose of >200 mg/dL during MMTT 
Blood pressure Systolic blood pressure >130 and diastolic blood pressure >90.  
Other significant 
medical conditions 
Including but not limited to chronic or recurrent respiratory, gastrointestinal, neuromuscular, 
neurological, or psychiatric conditions. Hospitalization for mental illness within the past 5 
years or currently undergoing treatment for severe mental illness. Musculoskeletal problems 
interfering with exercise. Autoimmune or collagen vascular diseases. Any other medical 
condition or disease that is life-threatening or that can interfere or be aggravated by exercise 
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metabolism.  In addition, insulin action will be 
assessed by examining glucose, insulin and 
free-fatty acid responses during the MMTT.  
The MMTT will be conducted at baseline, 
immediately post-exercise and 48-hours after 
HIIE session (total of 3 MMTT; Figure 1). The 
ΔRER in response to a MTTT was selected for 
the following reason: the MMTT is a more cost-
effective and physiologically relevant stimulus 
for assessing metabolic flexibility compared to 
the gold-standard hyperinsulinemic-euglycemic 
clamp.  
Measurement of Metabolic Flexibility and Insulin Action:  Resting metabolic rate will be measured via 
indirect calorimetry while the subject is in the fasted state. An intravenous (IV) line will be placed in an 
antecubital vein for blood drawing purposes and will remain there throughout the testing. During each 
collection time point, 5 ml of blood (~1 teaspoon) will be drawn and stored for future analysis. A resting, 
fasting blood sample will be drawn after which the mixed meal will be prepared using a powered Ensure 
® and 250 ml of water measured to one-third the resting metabolic rate (RMR).  Additional blood samples 
will be drawn at  the 5, 10, 15, 20, 30, 60, 90, 120, 150, 180 minute time points after drinking the mixed 
meal. Blood samples obtained during the MMTT will be analyzed for plasma glucose, insulin, and free-
fatty acid concentrations using commercially available methods (Glucometer and/or Spectrophotometric 
assays and ELISA). 
Muscle Measurements:  NIR spectroscopy will be used to measure skeletal muscle OXPHOS at 
baseline. NIR spectroscopy will measure resting skeletal muscle oxygen consumption (mVO2) and blood 
flow before and during the MMTT.  The NIRS protocols developed and described by Kevin McCully’s 
Laboratory will be implemented with slight modifications as discussed below 251-253. 
High Intensity Interval Exercise Sessions:  The HIIE prescription will be based on the established 
practical low volume, high-intensity technique using a cycle ergometer (Velotron, Racermate, Inc., 
Seattle, WA) 249.  Prior to exercise, participants will complete a 5-minute warm-up at 50 watts. Based on 
the results of the VO2max test participants will engage in work intervals at 90% of the power output at 
VO2max for 60 seconds followed by rest intervals at 30 watts for 60 seconds. Participants will complete 10 
total intervals (~25 minutes).  
 
Resting Metabolic Rate during the MMTT:  Indirect calorimetry will be performed prior to and during 
each MMTT.  Resting energy expenditure and substrate utilization will be assessed using the 
ParvoMedics, TruOne 2400 metabolic cart (Sandy, UT) calibrated with standard gas mixtures.  A 
transparent plastic hood connected to the metabolic cart will be placed over the participant’s head and 
calculations of energy expenditure and carbohydrate and fat oxidation rates will be made from expiratory 
gases diluted to produce a constant fraction of expired carbon dioxide (~1.0%).  Resting metabolic 
measurements will be assessed before the MMTT and at 10 to 30, 40 to 60, 70 to 90, 100 to 120, 130 to 
150 and 160 to180 minutes after ingestion of the mixed meal.  The average of the 20minute 
measurement will be used to calculate resting metabolic rate and substrate oxidation using the equations 
of Jequier et al 254.  Participants will remain motionless and awake during the entire protocol. 
 
Visits and Timeline (Figure 1)  
Phone 
Screening 
Baseline 
MMTT 
Exercise 
MMTT, mVO2 
MMTT, mVO2 
(-1) (3) (1) 
Visit Schedule (Days) 
Baseline 
VO2max 
NIRS-OXPHOS, mVO2 
 
(-3) 
HIIE 48 hrs.  
Figure 1.  Visit schedule. *After confirmation of study eligibility participants will undergo a baseline VO2max and 
mitochondrial function test (OXPHOS). The following week  participants will complete a baseline mixed meal tolerance test 
(MMT) to determine metabolic flexibility. The next day participants will return to complete high intensity interval exercise 
(HIIE) followed by a MMTT with measures of mVO2. 48 hrs post exercise intervention MMTT and mVO2 will be repeated.  
________" "_Week"1 " "________" ________" "_Week"2 " "________"
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Recruitment and informed consent: Word of mouth, Facebook ®, and strategically placed fliers on the 
Louisiana State University campus will be utilized to recruit for this study.  Interested individuals will meet 
with study personnel and be provided a full description of study (structure of the study, study-related 
procedures, risks, benefits, etc).  Individuals who are still interested in participating in the study will be 
offered informed consent and the opportunity to ask questions.  If a participant chooses to sign the 
consent, he or she will continue on to study screening for inclusion/exclusion criteria including a medical 
history questionnaire, assessment of cardiovascular risk for exercise testing (PAR-Q), medication 
inventory, and anthropometric measures (height, weight, and resting blood pressure).  
VO2max testing:  If participants meet all inclusion/exclusion criteria during the screening visit, they will 
undergo a maximal cardiorespiratory test (VO2max) on a cycle ergometer (Velotron, Racermate, Inc., 
Seattle, WA).  Participants will ride at an initial workload of 25 Watts for 4 minutes.  The workload will be 
increased by 25 Watts every 4 minutes until respiratory exchange ratio reaches 1.05 after which, the 
workload will increase by 25 Watts every 2 minutes until volitional exhaustion.  Throughout the test, 
respiratory gases will be analyzed using a metabolic cart (ParvoMedics Inc., Sandy, UT) and fat oxidation 
rates will be determined using stoichiometric equations255..   
Mixed Meal Tolerance Test (MMTT):  The baseline MMTT will occur ~1 week after the screening visit 
and VO2max test.  Participants will record all food and beverages ingested and physical activity levels for 
the 24-hour period prior to the baseline MMTT. Participants will arrive fasted for at least 10 hours and 
refrained from moderate/vigorous exercise for at least 48 hours. mVO2 and muscle blood flow will be 
measured prior to and 1 and 2 hours post mixed meal (see NIRS Protocols for further details). The 
baseline MMTT will also complete the exclusion criteria for high fasting glucose (> 125 mg/dL) and 
abnormal 2-hour glucose (> 200 mg/dL).  Additional MMTTs will be conducted immediately (1 hour) post 
exercise and 48 hours after the HIIE session.  Prior to the post-exercise MMTTs, participants will replicate 
the 24-hour food and beverage diary recorded prior to the baseline MMTT.  In addition, both MMTTs, will 
be conducted in the morning hours after a 10 hour fast. 
NIRS Protocols to Measure Muscle Metabolism (e.g., NIRS mVO2, blood flow, and OXPHOS):  Subjects 
will rest in the supine position with knees slightly flexed.  The NIRS optode (Oxymon MKIII, Artinis 
Medical Sytsems) will be placed on the vastus lateralis just anterior to the iliotibial band and ~1/3 the 
distance between the top of the patella and the greater trochanter of the test leg.  The optode will be 
secured in place with adhesive tape and Velcro strap.  A blood pressure cuff (Hokanson, Bellevue WA) 
will be placed proximal to the optode, and connect the cuff to a rapid cuff inflation system (Hokanson E20, 
Bellevue WA) that will be controlled using an external controller and Labview 
Software.  We measure resting muscle blood flow in triplicate using venous 
occlusions by inflating the blood pressure cuff to (50-60 mmHg) for 20 seconds 
with at least 60 seconds between each measurement.  We will make 
measurements of resting muscle oxygen consumption (mVO2) in triplicate 
using arterial occlusions by inflating the blood pressure cuff to (250-300 
mmHg) for 20 seconds with at least 60 seconds between each measurement.  
For measurement of muscle oxidative capacity (NIRS-OXPHOS), subjects will 
complete a 20 second isometric contraction of the vastus lateralis (by knee extension) immediately 
followed by a series of 15-20 arterial occlusions (250-300 mmHg) to measure the rate of recovery of 
mVO2 as depicted in Table 1.  We will repeat this NIRS-OXPHOS protocol three times with ~5-10 min 
between each trial. Finally, we will perform an ischemic calibration procedure and calculate mVO2 
corrected for blood volume as previously described, which includes a 15-20 second isometric contraction 
of the vastus lateralis (by knee extension) immediately followed by ~5-6 minute arterial occlusion (250-
300 mmHg).  NIRS signals for oxygenated, deoxygenated, and total hemoglobin will be continuously 
monitored by NIRS.  Prior to testing, we will measure adipose tissue thickness by skin fold thickness 
and/or B-mode ultrasound (LOGIC e, GE) at the location of the optode.  Before and after the MMTT we 
Cuff	Occlusions	 On	 Off	
1-6	 5	 5	
7-10	 7	 7	
11-14	 10	 15	
15-20	 10	 20	
Table	1.	Arterial	Occlusion	Protocol	
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will measure resting blood flow and mVO2 as described above and at the time points indicated in the 
description of the MMTT.  
Continuous Glucose Monitoring: Participants will be given continuous glucose monitors (Dexcom G5, San 
Diego, CA). CGM use a sensor inserted under the skin by the participant to check glucose levels in the 
interstitial fluid. A transmitter sends sensor glucose readings to a display device.  The participant will be 
required calibrate the CGM with a finger stick reading from blood glucose monitor. Participants will be 
provided with two sensors (1 for the baseline visits and 1 for the week of the exercise bout and 48hr visit).  
Heart Rate Monitoring:  Heart rate will be monitored during the exercise bouts and oral glucose 
tolerance testing with a telemetric heart rate monitor (Bioharness, Annapolis, Maryland).  The monitor 
captures time intervals between R-R waves and can produce valid measures of heart rate variability. 
Statistical Analysis:  All statistics will be performed using JMP statistical software (SAS Institute Inc., 
Cary, NC).  Data analysis will generally follow CONSORT recommendations using General Linear Models 
and repeated measures analysis of variance (RM-ANOVA) co-varied as needed depending on normality 
distributions at baseline. An unpaired t-tests will be used to compare between group baseline 
characteristics. In addition, two way RM-ANOVA (exercise session x time point) will be used to determine 
differences in responses in both the primary and secondary outcome variables. A power analysis 
conducted indicated that to measure a difference RER of .04 would require 20 participants (α=.05, β=.80)  
Significant effects will be further evaluated using Tukey’s HSD post-hoc analyses were appropriate.  Data 
will be reported as mean±SD and differences declared at P<0.05. 
Expected Outcomes:  Based on previous work we expect that the offspring of type 2 diabetics will have 
impaired metabolic flexibility 239. We hypothesize that high intensity exercise will cause a greater shift in 
substrate metabolism in response to a mixed meal when compared to no prior exercise. We expect that 
high intensity interval exercise will result in a greater glucose tolerance and result in higher peak insulin 
levels, but lower area under the curve (AUC).  Additionally, we expect that greater mitochondrial function 
will be associated with greater fasting fat oxidation and lower AUC for the change in RER in response to a 
mixed meal. 
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1.4 Study Consent Form 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
INFORMED CONSENT 
 
Title of Study: THE IMMEDIATE AND EXTENDED EFFECTS OF HIGH INTENISTY 
INTERVAL EXERCISE ON METABOLIC FLEXIBILITY AND MITOCHONDRIAL 
FUNCTION 
 
We give you this consent form so that you may read about the purpose, risks and 
benefits of this research study. 
 
• The main goal of a research studies is to gain knowledge that may help future 
patients. 
• You have the right to refuse to take part, or agree to take part now and change 
your mind later on. 
• Please review this consent form carefully and ask any questions before you 
make a decision.  
• Your participation is voluntary.  
• By signing this consent form, you agree to participate in the study as it is 
described.  
 
1- Investigators: 
The following investigators will be available for questions about this study: 
  
 Principal Investigator:    Neil M. Johannsen, Ph.D. 
          Phone: 225-578-5314 
          Email:njohan1@lsu.edu 
 
 Co-Investigators:        Tim Allerton, MS 
          Phone: 504-919-3799 
          Email: taller2@lsu.edu 
      Brian Harrell, M.D.,  
      Phone: 337-292-0431,          
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      Email: brian.harrell@brgeneral.org 
      Brian Irving, PhD 
      Phone:225-578-7179,  
      Email: brianirving@lsu.edu 
     Guillaume Spielmann, PhD 
      Phone: 225-578-2926 gspielmann@lsu.edu 
 
Neil Johannsen, Ph.D. directs this study. We expect about 20 people from one site will 
be enrolled in this study.  The study will take place over a period of 4 visits and each 
participant will be enrolled for ~2 weeks. 
 
2- Performance Site: 
This study will take place at Louisiana State University-Baton Rouge Campus. 
 
3- Purpose of the Study: 
The purpose of this research is to determine the immediate and extended (48-hr) effects 
of a bout of high intensity interval exercise prior to a mixed meal on the ability to use 
nutrients after consuming a meal in men and women with and without a family history of 
T2D.  
4- Participant Inclusion: 
Study staff will discuss with you the requirements for participation in this study.  It is 
important that you are completely truthful with the staff about your health history.  You 
should not participate in this study if you do not meet all the qualifications.   
 
You are eligible for this study if you are: 
• Capable and willing to give written informed consent, understand exclusion 
criteria and accept the randomized assignment 
• Male or Female age 18-40 years  
• Have a biological mother with type 2 diabetes 
• Healthy (no uncontrolled disease) with a BMI between 18 and 25 kg/m2 and/or a 
waist circumference < 35 inches for women and < 40 inches for men.  
• Currently active (greater than 30 minutes/day, 3 or more days/week of moderate 
intensity, structured physical activity)  
	 181 
• Willing to record food intake and replicate for the 24 hours before each testing 
period. 
• Willing to participate in VO2max testing on a treadmill. 
• Willing to participate in an intense bout of interval based exercise (~20 minutes) 
• Willing to participate in 3 mixed meal tolerance tests with ingestion of 250-400 
calories 
• Willing to have blood drawn through an IV catheter and by finger stick 
• Willing to have a blood pressure cuff inflated (50-250 mm Hg) around your upper 
thigh  
• Willing to wear a continuous glucose monitor 
 
You are NOT eligible for this study if you have any of the following conditions: 
• HIV, Hepatitis B, or Hepatitis C 
• Uncontrolled CVD/ arrhythmia 
• COPD, Emphysema, Exercise Induced asthma/bronchospasm 
• Cerebral Palsy, Multiple Sclerosis, Amyotrophic lateral sclerosis, Cystic Fibrosis 
• Diabetes (Type 1 or 2); fasting glucose >125 mg/dL or 2 hour glucose >200 
mg/dL during the baseline mixed meal tolerance test 
• Systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 90 mmHg 
• Uncontrolled thyroid disorder (controlled = 6 months of medication) 
• Epilepsy 
• Osteo/Rheumatoid arthritis 
• Unresolved orthopedic injury of any kind 
• Any other medical, psychiatric or behavioral factors that in the judgment of the 
Principle Investigator that may interfere with study participation or the ability to 
follow the protocol 
 
 
Medications/Non-Drug Therapies: 
• Blood pressure medication 
• Diuretics 
• Beta-blocker 
• Anti-inflammatory drug (corticosteroid/anabolic steroid/NSAID) 
• Antipsychotic 
• Other medications that may affect glucose and or fat metabolism 
 
Lifestyle: 
• Consume > 3 drinks/day of any alcoholic beverage 
• Smoker (Former smokers must be smoke free for 12 months) 
• Donated blood within the past 6 weeks 
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5-Study Procedures: 
 
The study for which you are volunteering will take about 2 weeks to complete and will 
include 4 visits 
 
1. Screening Phase – 1 Screening Visit (Visit 1) 
2. Baseline Testing Phase – 1 Baseline Visits (Visit 2)  
3. Follow-up Phase – 2 Visits (3 and 4)  
 
Summary of Visit Schedule 
 
 Screening  
Baseline 
OXPHOS, 
VO2max 
 
Baseline  
Metabolic 
Flexibility 
Exercise 
Interventi
on 
48 
hours 
Post-
Exercis
e 
 Visit 1 Visit 2 Visit 3  Visit 4 
Procedure (Time) Day 0 Day 1 Day 2 Day  4 
Informed Consent X    
PARQ and Medical 
History 
X    
Height X    
Weight X    
Body Composition and 
skin folds 
X    
Vital Signs X X X X 
Medication Inventory X    
NIRS-blood flow and 
mVO2 
X X X X 
NIRS-OXPHOS X    
Questionnaires X  X X 
Food Recall  X X X X 
Physiological Monitors X X X  
VO2max test X    
Blood Samples  X X X 
Mixed Meal Tolerance 
Test 
 X X X 
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Substrate Metabolism  X X X 
 
 
Study Timeline 
	  
 
Screening Visit –(Phone or In-person)  
 
At this visit, the informed consent will be explained to you by our study staff and 
procedures are performed.  If you choose to sign the informed consent, the following 
tests and procedures will be performed to determine if you qualify to participate in this 
research study: 
 
• You will be asked questions about your: 
o Demographics 
o Medical history 
o Medication use 
 
• You will be asked to perform the following medical assessments: 
o Blood pressure and heart rate 
o Height and weight 
o Skin Folds for body composition 
 
Phone 
Screening 
Baseline 
MMTT 
Exercise 
MMTT, mVO2 
MMTT, mVO2 
(-1) (3) (1) 
Visit Schedule (Days) 
Baseline 
VO2max 
NIRS-OXPHOS, mVO2 
 
(-3) 
HIIE 48 hrs.  
Figure 1.  Visit schedule. *After confirmation of study eligibility participants will undergo a baseline VO2max and 
mitochondrial function test (OXPHOS). The following week  participants will complete a baseline mixed meal tolerance test 
(MMT) to determine metabolic flexibility. The next day participants will return to complete high intensity interval exercise 
(HIIE) followed by a MMTT with measures of mVO2. 48 hrs post exercise intervention MMTT and mVO2 will be repeated.  
________" "_Week"1 " "________" ________" "_Week"2 " "________"
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Volunteers who are meet the inclusion/exclusion criteria at the screening visit will be 
scheduled for baseline visits and intervention and follow-up visits.  
 
 
Baseline Visits: Visit will last approximately 1 ½  hour 
 
Baseline visit 1 (This visit may be divided into two separate days) :  
(Non-Fasting visit: Please refrain from caffeine for at least 5 hours prior to visit. )  
 
• You will be asked to return to the Clinical Exercise Testing Laboratory at LSU for 
Baseline Testing Visit 1.  For 24 hours prior to Baseline Visit 2, you will be asked 
to record your food and drink intake.  You will be asked to replicate this record 
before follow-up visit 1 and 2.  The following tests will be performed: 
o Blood pressure and heart rate – by a cuff placed around your arm and 
monitor worn around your chest 
o Weight 
o Resting Muscle Oxygen Consumption and Oxidative Function 
measurements (NIRS OXPHOS and NIRS mVO2) 
o Graded Exercise Test (VO2max) 
o Given continuous glucose monitor for self application 
 
The time involved with the VO2max test depends on your fitness level.  Your aerobic 
fitness will be assessed while you pedal on a cycle ergometer.  The workload of the 
ergometer will increase at regular increments (every 2 to 4 minutes) until you are unable 
to continue pedaling. Your tiredness will in most cases be due to your muscles 
becoming too tired to perform the work required of the stage and you may feel short of 
breath.  Both or a combination of both are normal responses to this type of test.  The 
purpose of this test is to determine your fitness level in order to prescribe the exercise 
intensities during the high intensity interval exercise bout (Visit 3). 
 
During the exercise test, the volume of oxygen and carbon dioxide you are breathing 
will be measured continuously using an instrument known as a metabolic cart.  The test 
requires that you breathe through a mouthpiece, similar to a snorkel, with a nose clip 
on.  The mouthpiece is attached to a long tube, which is then attached to the metabolic 
cart.  The breath gasses collected during the exercise test allow us to accurately 
measure your energy expenditure and type of fuel (carbohydrate or fat) you are using at 
each stage of the test.  Your heart rate will be monitored continuously through a 
wireless heart rate monitor (Bioharness 3.0).  At the end of each stage, you blood 
lactate levels will be measured by finger stick blood analysis.  
 
	 185 
In order to measure glucose levels throughout the study period you may or may not be 
asked to wear a continuous glucose monitor.  The monitor is self-applied by inserting 
the sensor under the skin by use of the sensor applicator. Instruction will be provided on 
site in addition to the manufactures guidebook.  
 
To measure muscle metabolism and blood flow, we will place a monitor on the upper 
leg secured with adhesive tape and a Velcro strap.  A blood pressure cuff will be placed 
above the monitor and connected to a rapid inflation device.  Triplicate measurements 
of resting muscle blood flow will be taken by inflating the blood pressure cuff to 50-60 
mm Hg (venous occlusion) for 20 seconds and releasing the pressure with at least 60 
seconds between each measurement.  Triplicate measurements of resting muscle 
oxygen consumption (mVO2) will be taken by inflating the blood pressure cuff for ~20 
seconds to ~250-300 mm Hg (arterial occlusion) and releasing the pressure with at least 
60 seconds between each measurement.  For muscle recovery measurements, you will 
complete ~20 second of maximum isometric knee extension exercise followed by 15-20 
arterial occlusions.  You will complete this muscle recovery protocol three times with ~5-
10 min between each trial.  You will also complete a 15-20 second maximum isometric 
knee extension exercise immediately followed by a ~5-6 minute arterial occlusion to 
calibrate the measurements.  Prior to testing, we will measure the fat tissue thickness 
under the monitor by skin fold thickness and/or ultrasound. 
 
Baseline Visit 2: Visit will last approximately 3 ½- 4 hours 
 
(Fasting Visit- Please arrive at 10 hours fasting and refrain from caffeine at least 5 
hours and refrain from vigorous exercise 48 hours prior to study visit) 
 
• You will be asked to return to the Clinical Exercise Testing Laboratory at LSU 
and the following tests will be performed: 
 
o Mixed meal tolerance test – ingestion of 250-400 calorie Ensure drink.  
o Blood samples – An IV catheter will be placed in your arm vein for blood 
draw purposes and will remain there throughout the testing period.  Blood 
will be drawn at specific times. About 5 teaspoons of blood will be 
collected each trial and measured for glucose, insulin, and free fatty-acids.  
The remaining blood will be stored for this study and for future research if 
you consent. 
o Respiratory measures - a plastic, transparent hood will be placed over 
your head before and periodically during the oral glucose tolerance test to 
measure resting energy expenditure and the type of fuel you are using 
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(carbohydrate or fat).  The hood will be attached to the metabolic cart 
similar to the exercise test. 
o Resting muscle oxygen consumption and blood flow measurements as 
described during testing visit 1 will be performed before and 1 and 2 hours 
after starting he mixed meal tolerance test. 
 
 
Exercise Intervention: Visit will last approximately 4 hours 
(Fasting visit – please refrain from eating 10 hours alcohol and exercise for 48 
hours and caffeine for 5 hours before this visit.) 
 
• You will be asked to return to the Clinical Exercise Testing Laboratory at LSU 
and the following tests will be performed: 
o Heart rate – by a cuff placed around your arm and monitor worn around 
your chest 
o Perform repeated bout of cycling lasting 1 minute followed by one minute 
of recovery for 20 minutes total.  
o Mixed meal tolerance test will be initiated 1 hour after the acute bout of 
exercise. 
o Resting muscle oxygen consumption and blood flow measurements as 
described during testing visit 1 will be performed before and 1 and 2 hours 
after starting he mixed meal tolerance test. 
 
Follow-up 48 hour Recovery Visit: Visit will last approximately 3.5- 4 hours 
 
(Fasting visit – please refrain from eating 10 hours alcohol and exercise for 48 
hours and caffeine for 5 hours before this visit.) 
 
• You will be asked to return to the Clinical Exercise Testing Laboratory at LSU 
and the following tests will be performed: 
 
o Mixed meal tolerance test – ingestion of 250-400 calorie Ensure drink.  
o Blood samples – An IV catheter will be placed in your arm vein for blood 
draw purposes and will remain there throughout the testing period.  Blood 
will be drawn at specific times. About 5 teaspoons of blood will be 
collected each trial and measured for glucose, insulin, and free fatty-acids.  
The remaining blood will be stored for this study and for future research if 
you consent. 
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o Respiratory measures - a plastic, transparent hood will be placed over 
your head before and periodically during the oral glucose tolerance test to 
measure resting energy expenditure and the type of fuel you are using 
(carbohydrate or fat).  The hood will be attached to the metabolic cart 
similar to the exercise test. 
o Resting muscle oxygen consumption and blood flow measurements as 
described during testing visit 1 will be performed before and 1 and 2 hours 
after starting he mixed meal tolerance test. 
  
6- Risks/Discomforts: 
 
VO2max and exercise testing:  All exercise testing is completed in accordance with the 
American College of Sports Medicine’s Guidelines for Exercise Testing and Prescription 
as well as the American Heart Association.  There is minimal risk of injury or a 
cardiovascular event during testing.  We believe the use of a highly trained staff, a 
pretest review of participant associated risk factors including the Physical Activity 
Readiness Questionnaire (PAR-Q) and medical screening by your doctor, and well-
defined emergency procedures minimize the risk of an event during testing.  During 
testing you may experience temporary discomfort during blood pressure recordings due 
to the pressure of the blood pressure cuff on the arm.  You may also experience muscle 
fatigue, weakness, soreness and/or muscle pulls or tears.  All tests are conducted in the 
presence of trained staff.  In addition, all staff are trained in BLS (basic life support-
CPR) and/or ACLS (advanced cardiac life support).  In the event of an emergency, you 
would be treated appropriately and transported to the nearest acute care medical-
surgical facility via Emergency Medical Services.  
 
IV procedure and blood draws:  There may be minimal discomfort and bruising and/or 
bleeding where the needle is inserted for finger prick blood sampling.  There is a 
possibility of pain, bruising, and/or infection at the site of the needle insertion for the IV 
line for mixed meal tolerance test.  Aseptic (sterile) technique and trained personnel 
minimize this risk. 
 
Body composition:  The measurement of skinfold thickness using skinfold calipers 
requires a firm squeezing and subsequent measurement of the skin.  This measurement 
may cause slight discomfort and possible bruising of the measured site.  However, if 
undue bruising, soreness, or if more than slight swelling occurs, please notify the 
Principal Investigator.  
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Metabolic testing:  It may be uncomfortable to have the plastic hood over your upper 
body during resting measurements if you are claustrophobic.  The hood is easily 
removed if you experience this symptom. 
 
Loss of Confidentiality:  Completing questionnaires may result in a breach in 
confidentiality of personal data.  Participants will be assigned ID numbers and 
information that could identify a participant will not appear in publications. 
 
Muscle Blood Flow and Metabolism Measurements:  Inflation of the blood pressure cuff 
around the leg may cause some discomfort and pain during the test.  The temporary 
numbness and tingling are similar to the sensation of having your foot “fall asleep”.  If 
the discomfort is too severe, you may stop the test by notifying the technician to stop 
and the test will be immediately terminated.  There is no known risk from the use of skin 
folds and/or ultrasound to measure your adipose tissue thickness. 
 
CGM Sensor Insertion: Inserting the sensor and wearing the adhesive patch might 
cause infection, skin irritation, bleeding, or pain. Sensors can be easily removed without 
discomfort.  
 
Unknown risks:  In addition to the risk listed above, you may experience a previously 
unknown risk or side effect. 
 
7- Benefits: 
We cannot promise any benefits from your being in the study.  However, possible 
benefits include: 
• Information about your general health 
• Knowledge of your cardiovascular fitness 
• An understanding of your exercise performance and physical activity 
 
8-Alternatives to Participation: 
There are no alternatives to the study described in this consent.  You have the choice at 
any time not to participate in this research study.  If you choose not to participate, any 
benefits to which you are entitled will not be affected in any way. 
 
9- Injury/Illness or Questions: 
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If you have any questions about your rights as a research volunteer, you should call 
Dennis Landin, Ph.D., Institutional Review Board Office at 225-578-8692.  If you have 
any questions about the research study or think you have a research-related injury or 
medical illness, contact Neil Johannsen, Ph.D. at 225-578-5314 during regular working 
hours.  
 
10-Privacy: 
Every effort will be made to maintain the confidentiality of your study records.  Results 
of the study may be published; however, we will keep your name and other identifying 
information private.  Other than as set forth above, your identity will remain confidential 
unless disclosure is required by law.  
 
11-Early Study Withdrawal: 
Neil Johannsen, Ph.D. can withdraw you from the study for any reason or for no reason.  
You may withdraw from the study at any time without penalty.  Possible reasons for 
withdrawal include injury, the presence of an old or existing injury that may be deemed 
risky, sufficient medical history deemed too risky for testing.   
 
12-Additional Information: 
During the course of this study there may be new findings from this or other research 
that may affect your willingness to continue participation.  Information concerning any 
such new findings will be provided to you.  
 
13-Charges for Participation: 
None 
 
14-Payments for Participation: 
Participants will receive $100.00 for completion of the study.  
 
15- Compensation for study-related injury or medical illness: 
No form of compensation for medical treatment or for other damages (i.e., lost wages, 
time lost from work, etc.) is available from Louisiana State University.  In the event of 
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injury or medical illness resulting from the research procedures in which you participate, 
you will be referred to a treatment facility.  Medical treatment may be provided at your 
own expense or at the expense of your health care insurer (e.g., Medicare, Medicaid, 
Blue Cross-Blue Shield, Dental Insurer, etc.) which may or may not provide coverage. 
 
16- Signatures:  
The study has been discussed with me and all my questions have been answered.  I 
understand that additional questions regarding the study should be directed to the study 
investigators.  I agree with the terms above and acknowledge that I have been given a 
copy of the consent form. 
 
 
       
Printed Name of Volunteer 
 
__________________________________                             _____________ 
Signature of Volunteer                Date 
                                                               
 
__________________________________ 
Date of Birth of Volunteer 
 
 
__________________________________________             _____________ 
Signature of Person Administering Informed Consent             Date                                                   
 
Neil M. Johannsen, Ph.D. 
Principal Investigator  
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18- Tissue/Specimen Storage for Future Research or Use 
 
Biospecimens for future research: 
You are being asked to allow some of your blood to be stored and used for research at 
a later time. These bodily materials are called biospecimens. The donation of 
biospecimens in this study is optional. No matter what you decide to do, it will not affect 
your study participation. You will still be allowed to take part in the study even if you 
don't want your specimens to be collected and used for future research. Some 
biospecimen samples will be stored and used for the study and other biospecimen 
samples will be stored for future studies. The collection of samples may give scientists 
valuable research material that can help them to develop new diagnostic tests, new 
treatments, and new ways to prevent diseases. If you agree to have your samples 
stored, you can change your mind up until the end of the study. 
 
The samples will be stored indefinitely. If you agree to donate your samples, they may 
be given to other investigators for future research as well. The future research may take 
place at Louisiana State University and may involve Louisiana State University 
Researchers in this study. The future research may not take place at Louisiana State 
University and may not be reviewed by Louisiana State University's Institutional Review 
Board. For privacy and confidentiality, your biospecimens will be labeled with a unique 
series of letters and numbers. Louisiana State University will store your biospecimens 
with this unique identifier and the minimum number of personal identifiers to meet 
laboratory standards. The research done with your specimens may help to develop new 
products in the future, or may be used to establish a cell line or test that could be 
patented or licensed. You will not receive any financial compensation for any patents, 
inventions or licenses developed from this research. 
 
Making your choice about future research:  
Please read about each biospecimen below. It is your choice which samples will be 
collected, stored and used for future research for this study or future studies. After 
reading about each I below, initial next to "Yes" or "No" to show your choice about the 
collections for this research study and for future research studies.  
 
Blood  
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If you give permission, approximately 1 tablespoon of blood will be stored by this study. 
Your stored samples may be tested at Louisiana State University or other locations 
used in future research.  
 
Do you give permission for your blood to be collected and used in future research by 
this study? 
 
Yes, I give permission  
                                                                             SIGNATURE 
 
 
No, I do not give permission 
                                                                             SIGNATURE 
If you decide you would like to withdraw your consent to use your samples, you will be 
able to do so until the study ends. After the study ends, you will not be able to withdraw 
your consent to use your samples because investigators will not know which one is 
yours. You must provide a written request to have your samples destroyed.  
 
For destruction of your samples, you can contact the Principal Investigator at: 
 
 
Neil Johannsen, PhD 
Louisiana State University 
112 Huey P. Long Fieldhouse 
Baton Rouge, LA 70803 
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